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Antigen-presenting cells (APCs), are crucial components of the immune system that are 
uniquely positioned at the interface between innate and adaptive immunity. In particular, 
a specialized subset of APCs, dendritic cells (DCs), play a pivotal role in initiating T and 
B cell responses. This thesis focuses on the initiation of T cell responses, a process that 
requires DCs to acquire antigens derived from infected or malignant cells and process 
them for presentation to T cells with appropriate antigen receptors. The DCs also have to 
receive distinct stimulatory signals in order to increase their expression of chemokines, 
adhesion molecules, co-stimulatory molecules and cytokines. These phenotypic changes, 
known as DC activation, facilitate interactions with antigen-specific T cells to promote 
their proliferation and differentiation into effector cells. Thus, compounds that enhance 
DC activation can be utilized as vaccine adjuvants; as such, they are highly sought after 
in the development of novel immunotherapies.  
 
Innate-like T cells express many of the features of conventional T cells but lack diversity 
in their antigen receptors, and exist poised in a semi-activated state, more like cells of the 
innate system. Of the different innate-like T cells subsets, CD1d-restricted natural killer 
T (NKT) cells are known to be potent sources of stimulatory signals that induce activation 
of DCs. Another innate-like T cell subset, mucosal-associated invariant T (MAIT) cells, 
have primarily been regarded as anti-bacterial effector T cells because they react to 
pyrimidines derived from bacterial riboflavin synthesis. However, because they share 
many phenotypic properties with NKT cells, it is possible that MAIT cells could also play 
a role in influencing adaptive immune responses by modifying the phenotype of DCs. 
Indeed, at the start of this thesis, a study was published showing that activated human 
MAIT cells could induce activation of monocyte-derived DCs in vitro. Importantly, 
MAIT cells are highly abundant in humans and are enriched at mucosal sites, potentially 
making them useful cells to exploit in vaccine designs that can be clinically translated. 
Therefore, this thesis sought to determine if agonists that activate MAIT cells could act 
as adjuvants by facilitating cellular interactions that modulate the functionality of DCs in 
vivo in order to augment priming of antigen-specific T cell responses. 
 
The MAIT cell agonist precursor, 5-amino-6-D-ribitylaminouracil (5-A-RU), forms 
pyrimidine intermediates with cellular by-products of metabolism that bind to the MHC 
I-related protein 1 (MR1) which engages and activates MAIT cells. For example, when 
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5-A-RU condenses with methylglyoxal (MG), the potent agonist 5-(2-
oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU) is formed. One major 
challenge in MAIT cell research is that 5-OP-RU is an unstable compound. To circumvent 
this problem, 5-A-RU was used as it is known to condense with endogenous metabolic 
by-products to form the agonists intracellularly for in vitro or in vivo studies. However, 
in this thesis, it is shown that 5-A-RU is also unstable, being labile to auto-oxidation 
resulting in the loss of biological activity. To overcome these challenges, a 5-A-RU 
prodrug was developed that impeded oxidative degradation and conferred enhanced 
MAIT cell-activating properties both in vitro and in vivo. Furthermore, this prodrug 
design also provided a scaffold for chemical conjugation of model antigens to 5-A-RU to 
facilitate co-localisation of both adjuvant and antigen within the same DC, a mechanism 
known to enhance T cell priming. In addressing the hypothesis that MAIT cells could 
help initiate T cells responses, it was initially shown that intravenous administration of 5-
A-RU in vivo resulted in DC activation, and when co-administered with soluble antigen, 
resulted in antigen-specific T cell immunity. Moreover, 5-A-RU-peptide conjugates 
showed enhanced DC functionality compared to 5-A-RU and drove effective anti-tumour 
activity. However, further analysis of these compounds revealed the presence of an 
unexpected, unknown microparticle that activated CD1d-restricted NKT cells, with the 
NKT cells being the source of the cellular adjuvant activity observed; this observation 
was shared by colleagues with 5-A-RU manufactured from a different laboratory. 
 
Elimination of the confounding NKT cell-activating microparticle by fractionation or 
filtration revealed that MAIT cells could still facilitate DC activation, but only when the 
filtered 5-A-RU was combined with MG to form 5-OP-RU immediately before use. 
Activation of DCs was only readily detected in the lungs and lung-draining lymph nodes, 
with MAIT activity potentially driving DC migration from the lung tissue to the lymph 
nodes. Interestingly, administration of antigen with 5-OP-RU formed from filtered 5-A-
RU failed to generate antigen-specific T cells. However, co-administration antigen with 
5-OP-RU and limited doses of a toll-like receptor (TLR) agonist provided additional 
stimulatory signals, enhanced DC activation and resulted in MR1-dependent expansion 
of antigen-specific T cells. 
 
In summary, this thesis presents evidence that MAIT cells can influence innate and 
adaptive immune responses. However, the activity of MAIT cells alone is insufficient to 
 v 
initiate T cell responses, as additional signals are required. Nonetheless, this feature of 
MAIT cell function could be incorporated into vaccine strategies in order to drive antigen-
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The generation of potent immune responses to pathogens or malignant tissues requires a 
concerted effort between numerous immune cell-types within the host through distinct 
molecular signalling pathways. To initiate this process, host immune cells specialised in 
sampling the local environment must acquire foreign or mutationally altered molecules 
known as antigens, and process them into structures that can be recognised and targeted 
by the other cells of the immune system1. These initiating cells, known as antigen 
presenting cells (APCs), are part of the innate immune system, and conduct their activities 
rapidly after they recognise molecules (or “patterns”) commonly associated with 
infection or cellular distress via innate pattern-recognition receptors (PRRs)2,3. 
Importantly, APCs are vital in driving the activation and differentiation of a specialised 
subset of lymphocytes, called T cells, which are the major topic of this thesis. The 
importance of T cells lies in their ability to clonally expand and penetrate infected or 
malignant tissues in large numbers in order to selectively eliminate cells that express the 
foreign or mutationally altered molecules they recognise. This high degree of selectivity 
to antigen, which takes several days to develop provides the precision required to 
eliminate infectious tissue with minimal danger to self-tissues (although this risk is not 
entirely removed) and is the basis of adaptive immunity4–6. Adaptive immunity also 
involves lymphocytes called B cells that release antibodies that can target the three-
dimensional structure of pathogen-derived antigens7. Though both T and B cell responses 
are critical determinants in sterilizing immunity in their own right, the focus of this thesis 
will focus on the development of T cell responses.  
 
Due to their pivotal role in T cell-based immunity, the molecular mechanisms that govern 
APC-T cell cross-talk have been of particular interest to immunologists, especially for 
the development of novel vaccine strategies and cancer immunotherapies. It has been well 
established that the presence of microbial or tumour-derived antigen alone is generally 
insufficient to drive sterilising or protective immunity8–10. Successful generation of 
antigen-specific immune responses requires auxiliary signals that drive the activation of 
the APC via PRRs. Where substances that stimulate this process have been added to 
vaccines to increase activity, the compounds involved are known as immune adjuvants. 
Adjuvants can also include compounds that help in the uptake and processing of antigens. 
The term adjuvant, in some cases, has become adapted to refer to the process of activating 
APCs, particularly when referring to third party cells that can be stimulated to perform 
this function, which is a primary topic of this thesis. These cells are sometimes, therefore, 
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referred to as “cellular adjuvants”, or as performing an “adjuvant function”. In microbial 
infection, common microbial signatures such as cellular structures like flagella, or nucleic 
acid structures such as unmethylated DNA or double-stranded RNA, provide these 
adjuvant signals and are recognised by APCs via PRRs2,3,11. Of these receptors, Toll-like 
receptors (TLRs) are perhaps the best-described. Recognition induces a signal cascade 
resulting in the activation of APCs, allowing them to effectively present antigen to T cells 
in a stimulatory context, prompting T cell activation. Use of synthetic TLR agonists has 
therefore been an attractive approach in vaccine development, especially for cancer 
immunotherapy as cancer cells do not naturally produce these APC maturing signals.  
 
However, APCs can also be matured through contact-dependent cellular signalling with 
other cells. The most well-recognised cell-types capable of this function are antigen-
specific CD4+ T cells, ultimately providing a positive feedback loop (or “help”) that co-
operates with pattern-recognition to improve APC function12–15. During antigen 
presentation to CD4+ or CD8+ T cells, processed peptide fragments are presented via 
major histocompatibility complex (MHC)-II or MHC-I molecules, respectively, on the 
APC surface to antigen receptors on the T cells (referred to as T cell receptors; TCR). In 
particular, during interactions with CD4+ T cells, APC maturation is enhanced through 
the provision of the ligand for CD40, a co-stimulatory molecule on APCs (whose 
expression, in turn, can be improved in response to pattern-recognition)15–17. This co-
stimulation is a critical step in initiating robust T cell responses, particularly those 
involving CD8+ T cells, which differentiate into cytotoxic T lymphocytes (CTL).  
 
Several animal models have shown that another T cell subtype, defined by their largely 
invariant TCR, referred to as type I NKT cells, are also poised to provide these ‘helper’ 
signals to APCs18–20. In vivo research utilising a synthetic agonist for NKT cells, α-
galactosylceramide (α-GalCer) has shown that NKT cells potently enhance the 
maturation of APCs through CD40/CD40L signalling. Due to this, α-GalCer has been 
used as a vaccine adjuvant, where co-administration with peptide or protein antigens 
induces the expansion of antigen-specific T cells. Perhaps surprisingly, this powerful 
response does not require any additional pattern recognition, although responses can be 
enhanced further if this is also supplied21. Specifically, the use of α-GalCer has shown 
promising results in cancer immunotherapy in various in vivo models, and use of α-
GalCer as an adjuvant in the clinical setting is currently under investigation. 
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Unfortunately, a clear limitation of NKT cell-based vaccine strategies is a significant 
difference in the frequency of these cells in humans compared to mice. Mice NKT cells 
outnumber those found in humans by up to 100-fold22; however, it is currently unknown 
whether this substantial reduction in numbers will hamper the quality of signalling 
provided to APCs within a human setting. Recently another T cell-subtype, MAIT cells, 
has been shown to not only be enriched in humans but also to display many functional 
similarities to the NKT cell phenotype23–25. Early reports suggest that MAIT cells may 
also be able to influence adaptive immune responses26–28. Critically, a recent publication 
has indicated that MAIT cells have the capacity to induce the maturation of APCs through 
CD40/CD40L when activated, in a similar manner to NKT cells29. However, the question 
remains whether MAIT cell-mediated APC maturation is sufficient to drive subsequent 
antigen-specific T cell responses. Therefore, this thesis aims to investigate the ability of 
MAIT cells to drive APC maturation in vivo to prime antigen-specific T cell responses. 
This introduction will review the background literature describing the generation of 
adaptive T cell responses as well as a summarise the evidence that MAIT cells may be 
able to augment this function for the development of novel immunotherapies. 
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 Initiation of the adaptive immune responses 
 
 Antigen processing and presentation 
The innate immune system consists of a plethora of cells that primarily act as an early 
barrier against infectious agents. Recognition of invading pathogens by the innate 
immune system is mediated by conserved germline-encoded PRRs which sense 
conserved microbial motifs that rapidly trigger a variety of anti-microbial immune 
responses30. The concerted action between cells of the innate immune system is efficient 
and fast-acting, however, lacks precise specificity. Another key feature of the innate 
immune response is the ability to provoke the activation of adaptive immune cells, i.e. T 
and B cells. These cells have randomly generated receptors specific for a given antigen 
and begin a process of clonal selection upon recognition of their cognate antigen. During 
this process, antigen recognition drives the selective expansion of reactive T or B cells 
clones, therefore providing pathogen-specific immunity. 
 
The focus of this thesis will be on the T cell-mediated arm of adaptive immunity which 
recognises antigen through randomly generated TCRs. To initiate T cell responses to a 
given pathogen, antigens must be loaded onto MHC molecules within APCs31. Once 
processed by an APC, these antigen (Ag)-MHC complexes are expressed on the cell 
surface where they can be recognised by T cells through their TCR to drive their 
activation. Two classical MHC molecules, MHC-I and MHC-II, are responsible for the 
presentation of short peptide fragments to engage with the TCR of CD8+ and CD4+ T 
cells, respectively. When T cells recognise these Ag-MHC complexes on APCs that have 
been activated by exposure to pathogen-derived (or other “danger-associated”) molecular 
structures, they undergo clonal proliferation and distinct phenotypic changes ultimately 
resulting in the capacity to clear pathogens or eliminate malignant tissue. 
 
1.1.1.1 Presentation of antigen on MHC class II molecules 
Initiation of the adaptive immune response first begins with recognition and uptake of 
extracellular bodies or proteins into APCs. Cell-associated antigens, such as whole 
bacteria or apoptotic bodies, are taken up into endocytic vesicles in a process known as 
phagocytosis32,33. These ‘phagosomes’ undergo a series of maturation events that includes 
fusion with acidified lysosomes. These lysosomes, containing host proteases, 
enzymatically digest proteins into antigenic peptide fragments34. Exocytic vesicles 
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derived from the endoplasmic reticulum (ER) contain MHC-II bound to an invariant chain 
(Ii), which inhibits premature binding of peptides to MHC-II. Exocytic vesicles then 
migrate through the trans-Golgi network and fuse with antigen containing phagosomes to 
form phagolysosomes32. Fusion with these exocytic vesicles brings processed antigen in 
contact with MHC-II molecules. Proteases such as Cathepsin S within the newly formed 
phagolysosome cleave Ii within the antigenic MHC-II binding groove, leaving behind a 
low-affinity Ii derived self-peptide (CLIP)35,36. The acidified environment within the 
phagolysosome now catalyzes the exchange of CLIP with the exogenously-derived 
antigenic peptides forming mature MHC-II-peptide complexes37. Finally, these 
complexes are transported to the cell surface where they can be recognised by cognate T-
cell receptor (TCRs) on CD4+ T cells initiating an adaptive immune response to 
extracellular pathogens.  
 
1.1.1.2 Presentation of antigen on MHC class I molecules 
For the host immune system to sense intracellular infection or formation of aberrant cells, 
cytosolic proteins are continually degraded by a collection of enzymes known as the 
proteasome38. Processed peptide fragments derived from the proteasome are then 
chaperoned via transporter associated with antigen processing (TAP) molecules into the 
lumen of the ER and loaded onto newly synthesised MHC-I molecules. Newly formed 
Ag-MHC-I complexes then translocate to the cell surface where they can engage with 
CD8+ T cells via a cognate T cell TCR interaction. Almost all nucleated cells possess the 
ability to present these endogenously-derived antigens on MHC-I39. Thus, providing an 
essential mechanism by which neoplastic cells that express aberrant proteins (such as in 
cancer), or cells infected by intracellular pathogens can become tagged for destruction by 
CD8+ T cells.  
  
MHC-I also plays a crucial role in the presentation of exogenous antigens derived from 
phagocytosed or endocytosed material in a process known as cross-presentation. 
Although many studies have described various methods in which exogenous antigens can 
become associated with MHC-I, in general, there are two main pathways of cross-
presentation: the cytosolic pathway or the vacuolar pathway. In the cytosolic pathway, a 
proportion of internalised material can ‘escape’ endosomes into the cytosol to be 
processed by the proteasome and amino- or carboxyl-terminal peptidases40,41. Antigen 
escape is enhanced in some DC subtypes, namely cDC-1s (discussed later), which in part 
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could be attributed to elevated levels of molecules such as NOX2 that prohibits rapid 
acidification of endosomes allowing prolonged antigen stability42,43. From here, the 
antigen enters the canonical pathway for MHC-I presentation via association with TAP 
followed by loading of MHC-I within the ER. In 1995, Kovacsovic et al. showed that 
cross-presentation could be abolished by blocking the transport of ER proteins to the 
Golgi with Brefeldin A or through the mutation of the TAP1/TAP2 genes44. However, 
subsequent studies showed cross-presentation could be achieved independent of both ER 
transport and TAP, suggesting a mechanism by which cross-presentation could occur 
outside the cytosolic pathway45,46. The model, termed the vacuolar pathway, was 
proposed after cross-presentation was demonstrated in a proteasome-independent but 
endosomal acidification-dependent manner47,48. In this way, in a similar manner to MHC-
II presentation, the endocytosed antigen is instead processed by endosomal proteases. 
Subsequently, antigenic peptides are loaded onto endosomal-associated MHC-I 
molecules. This was demonstrated in vivo in mice that lacked the endosomal cysteine 
protease, Cathepsins S, which showed reduced antigen generation when administered 
cell-associated antigen47.  
 
 Dendritic cells 
The ability of cells to capture and process antigen onto MHC molecules efficiently is 
critical in the generation of robust adaptive immunity. While a number of cells possess 
the capacity to capture and present antigens, including B cells and macrophages, DCs are 
considered the most proficient due to their heightened ability to uptake antigen and high 
expression of MHC and T cell co-stimulatory markers compared to other APCs1,49–51. 
Dendritic cells originate from the bone marrow from a common dendritic cell precursor 
(CDP) and are further delineated into two sub-categories; conventional DCs (cDC) or 
plasmacytoid DCs. Dendritic cells reside ubiquitously throughout the body within both 
secondary lymphoid organs and in peripheral tissues such as the skin, liver and mucosa52–
56. Additionally, under inflammatory conditions, Ly6Chi monocytes can also differentiate 
in situ into monocyte-derived DCs that migrate to secondary lymphoid organs and gain 
an increased capacity to present antigen57. As this thesis focuses on in vivo murine studies, 
the following section on DC subtypes will focus on literature from murine studies, 
particularly in reference to phenotypic surface markers. 
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1.1.2.1 Conventional DCs 
Conventional DCs are a diverse set of cells that act as the sentinels of the immune system, 
dedicated to sensing and sampling their local environment. Conventional DCs can be 
roughly divided into two subsets: resident cDC and migratory cDC. Resident cDCs, 
primarily populate secondary lymphoid organs and exhibit an ‘immature’ phenotype of 
low expression of MHC and T cell co-stimulatory markers: CD40, CD80 and CD8658. In 
contrast, migratory cDCs are located at peripheral tissues and constitutively circulate 
through the lymphatic system into draining lymph nodes59. During their circulation, even 
in the absence of microbes and microbial signalling, these DCs obtain increased levels of 
T cell co-stimulatory markers, enhancing engagement with naïve T cells within the lymph 
node60. This function highlights an important role for migratory DCs in the sampling of 
peripheral ‘self’ antigen to induce T cell tolerance – the process of inactivating or deleting 
autoreactive T cells. Conventional DCs can also be further delineated based on their 
ontogeny which dictates distinct functional differences; these are cDC-1 and cDC-2. 
 
The development of the cDC-1 population relies on the transcription factors Batf-3 and 
IRF861,62. Both lymphoid organ-resident and migratory populations of Batf-3 dependent 
cDC-1s exist, identifiable by their expression of CD8α and CD103, respectively. 
Importantly, cDC-1s have a critical role in cross-presentation and the stimulation of 
effector CD8+ T cells. While both cDC-1 and cDC-2 subsets show an equal capacity to 
capture antigen and present them on MHC-I and MHC-II molecules; it is generally 
regarded that cDC-1 are the most effective at cross-priming CD8+ T cell responses 63,64. 
This was demonstrated in vivo, where mice lacking Batf-3 lose their ability to cross-
present soluble or cell-derived antigens65. Their role as efficient cross presenters is also 
emphasised by their increased expression of molecules associated with antigen capture, 
i.e., c-type lectins DEC205, CD207 and Clec9A66–68, as well as higher expression of 
proteins involved in cross-presentation such as Tap and Sec61b69,70. Furthermore, 
constitutive expression of the chemokine receptor, XCR1, which binds to its cognate 
ligand XCL1 expressed by CD8+ T cells, is thought to facilitate the development of 
effector CD8+ T cells71. 
 
In contrast to the homogenous subset of cDC-1s, cDC-2s are a heterogenous population 
of DCs that differ in their transcription factor expression and development but can also 
be divided into resident and migratory populations. Several different transcription factors 
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are reported to be involved in the development of the cDC-2 subset including Notch2, 
KLF4 and IRF470,72,73. Notably IRF4 expression enhances MHC-II expression within the 
cDC-2 subset and drives migration from the periphery to secondary lymphoid organs74,75. 
In line with this, cDC-2s have been emphasised as key drivers in the activation and 
differentiation of CD4+ T cells76,77.  
 
1.1.2.2 Monocyte-derived DCs 
Monocyte-derived DCs (moDC) represent a highly plastic subtype of cells that share 
many functional similarities with the broader cDC subset. Rather than being a bona fide 
DC subtype of their own, under inflammatory settings, monocytes acquire functional 
capabilities reminiscent of cDC as well as increased levels of CD11c, MHC-II and T cell 
co-stimulatory markers, but can be differentiated from cDC based on the expression of 
the monocyte marker CD6478,79. In vivo studies demonstrate that during bacterial 
infection with pathogens such as Leishmania and Citrobacter rodentium, circulating 
monocytes are recruited to the site of infection where the inflammatory stimulus drives 
differentiation into moDCs57,80. Once differentiated, moDCs become active producers of 
the pro-inflammatory cytokine IL-12, supporting CD4+ T cells priming81.  
 
1.1.2.3 Plasmacytoid DCs 
Plasmacytoid DCs (pDC) are a distinctive subset of DCs found highly localised at steady 
state within secondary lymphoid organs,82–84 and show some capability to home to 
peripheral sites during inflammation85,86. As with other DC populations, pDCs are 
characterised by their expression of CD11c83. Although, in contrast to the other DC 
subsets, pDCs also resemble B cells in that they express high levels of the CD45 isoform, 
B220 (CD45R), as well as expression of the sialic acid-binding immunoglobulin-type 
lectin (Siglec)-H.  The primary role of pDCs is in recognition of viral-derived motifs, 
such as unmethylated CpG dinucleotides or double-stranded RNA, on intracellular 
sensing receptors - TLR7 and TLR9, respectively87,88. Upon activation, pDCs are avid 
producers of type-I interferons, IFNα and IFNβ, due to their constitutive expression of 
the transcription factor IRF-789. Activated pDCs also undergo distinct morphological and 
transcriptomic changes that are reminiscent of a matured cDC phenotype, upregulating 
MHC-I, MHC-II and T cell co-stimulation molecules CD40, CD80, and CD8690,91. In 
vitro and in vivo studies addressing the ability of pDCs to present antigen have revealed 
that whilst activated pDCs are able to process and present endogenous antigen on MHC-
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I or II, they lack the ability to effectively cross-present exogenous antigens onto MHC-I 
molecules92–94.  
 
 DC maturation  
At the cross-section between innate and adaptive immunity, DCs must undergo necessary 
phenotypic and morphological alterations to transition from an immature antigen-
capturing cell to a mature antigen-presenting cell, which allows them to prime naïve T 
cells. At the immature stage, DCs have high endocytic capacity enabling them to survey 
and capture antigens95. This stage is characterised by low expression of antigen-
presenting molecules, MHC-I and MHC-II as well as low levels of T cell co-stimulatory 
markers, CD86/80 and CD40. Therefore, immature DCs are poor stimulators of T cell 
responses. During maturation, DCs upregulate these co-stimulatory markers and also 
upregulate chemokines and adhesion molecules which facilitates recruitment and cell 
contact between naïve T cells and DCs96–98. However, merely acquiring antigen in 
isolation does not induce maturation of DCs. In fact, in steady-state, presentation of 
antigen to naïve T cells by immature DCs results in the induction of tolerance or 
generation of anti-inflammatory regulatory T cells8–10. Thus, to bypass promotion of 
tolerance, immature DCs must receive accessory signals in order to upregulate co-
stimulatory markers and expression of cytokines resulting in activation of naïve T cells.  
 
During  the course of an infection, germline-encoded PRRs,  
which include TLRs,  recognise extra- and intra-cellular microbial-based signatures. 
TLRs such as TLR1, TLR2, TLR4, TLR5, and TLR6 are expressed on the cell surface 
and recognise extracellular microbial motifs such as lipopeptides, flagellin and 
lipopolysaccharides (reviewed here99). Bacterial-derived unmethylated DNA can also be 
recognised intracellularly by TLR9, or virally infected cells can sense single or double-
stranded RNA on TLR3 and TLR7, respectively. Recognition of these signatures are not 
only key in the initiation of innate immunity by promoting inflammation, but also play a 
critical role in DC maturation11,99. TLR ligation in DCs results in a signal cascade 
mediated through adaptor molecules such as TIR domain-containing adapter inducing 
interferon β (TRIF) and Myeloid differentiation primary response 88 (MyD88), that 
results in expression of transcription factors such as Nuclear factor kappa light chain 
enhancer of activated B cells (NFκB) and various Interferon regulatory factors 
(IRFs)100,101. These activated DCs acquire the ability to migrate to local lymph nodes and 
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upregulate MHC molecules, which enhances DC-T cell interactions, as well as expression 
of co-stimulatory markers CD86/80, which bind to CD28 on T cells. Furthermore, 
activated DCs can now produce pro-inflammatory cytokines, such as IL-12, in a MyD88-
dependent fashion which augments T cell activation102. Due to their high capacity to 
induce the maturation of DCs, which in turn influences the development of T cell 
responses, synthetically derived TLR agonists have been extensively studied in order to 
adjuvant adaptive immune responses to exogenously delivered antigens, such as in 
immunotherapies or vaccination strategies.  
 
 Antigen-specific T cell responses 
 
T cells are the effector arm of the adaptive immune system responsible for the elimination 
of infected or neoplastic cells as well as augmenting other immune responses. T cells 
develop from lymphoid progenitors derived from the bone marrow that migrate to the 
thymus where they enter distinct phenotypic and morphological stages of development to 
form a naïve T cell103,104. During their development, the TCRα and TCRβ gene segments 
in lymphoid progenitors or ‘thymocytes’ undergo somatic recombination to develop 
randomly generated antigen receptors with unique specificities105. These TCRs then 
recognise self-antigens via Ag-MHC complexes on thymic cortical cells and undergo a 
process known as thymic selection. The intensity and manner in which these thymocytes 
recognise antigen on these complexes determines their survival and maturation. T cells 
with TCRs that bind Ag-MHC complexes with a moderate avidity receive survival signals 
and are positively selected. In contrast, if the TCR binds with too strong of an avidity 
then the T cell will undergo programmed cell death (apoptosis), therefore limiting 
generation of auto-reactive T cells. Additionally, the ability of a TCR to interact with 
antigen loaded onto MHC-I or MHC-II is crucial in influencing their CD4 or CD8 single-
positive commitment106,107. Following their maturation and selection, CD4+ and CD8+ T 
cells display distinct functional differences. CD8+ T cells contribute mainly to sterilising 
immunity through recognition of foreign or aberrantly expressed antigens on MHC-I, 
resulting in targeted destruction of infected or neoplastic cells by the CD8+ T cell108–110.  
 
In contrast to this, CD4+ T cells undergo context-dependent differentiation into several 
effector program states upon recognition of Ag-loaded MHC-II, and in turn influence 
pathogen-specific innate and adaptive immune responses111. Importantly, similarly to 
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TLR signalling, CD4+ T cells can also influence the state of APC maturation through the 
expression of co-stimulatory molecules which enhance the immunogenic presentation of 
antigen towards CD8+ T cells12,15,112,113. Moreover, this CD4+ T cell ‘help’ co-operates 
with TLR signalling synergistically to greatly improve the function of APCs21,114. The 
following sections will detail the importance of CD8+ T cells in sterilising immunity as 
well as emphasise the role of CD4+ T cells in augmenting these responses through their 
helper functions. 
 
 CD8+ T cells 
CD8+ T cells represent the cytotoxic arm of the adaptive immune system. Their main 
function is the recognition of viral or endogenously-derived antigens in the context of 
MHC-I. Alternatively, exogenous antigens may also be acquired during endocytosis or 
intracellular infection and provide MHC-I antigens through cross-presentation. Cognate 
interactions between the TCR and relevant antigen-loaded MHC-I, supplemented by co-
stimulatory molecules on the APC such as CD86/80 and cytokines like IL-12, result in 
the promotion of T cell cycle progression, survival and acquisition of effector 
functions115–118. Once activated, these primed cytotoxic lymphocytes (CTLs) lose 
expression of lymph node homing molecules CD62L and CCR7, and gain enhanced 
expression of CD44 and S1P1, which supports extravasation of CTLs into infected 
peripheral tissues119,120. CTLs activated through their TCR exert targeted destruction 
towards infected cells via the release of perforin and granzyme B, which results in the 
induction of programmed cell death121,122. They also express effector cytokines like IFNγ 
and TNFα that further contribute to the local inflammatory immune response to given 
infections through priming of other immune responses123.  
 
Following their proliferative burst and elimination of infection, the remaining CTLs 
undergo a contraction phase where the majority of cells will undergo programmed cell 
death to resolve inflammation124,125. The remaining cells may then undergo differentiation 
into memory cells that gain increased expression of markers such as IL-7 receptor-α 
(CD127), which promotes long-term survival124,126,127. These CD8+ memory T cells seed 
secondary lymphoid organs at low frequencies but are poised to recognise and expand 
upon re-encounter of relevant cognate antigen rapidly.  
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Owing to their highly specific and potent effector capacity, research into CD8+ T cells 
has highlighted their critical role in the control or resolution of numerous viral 
pathologies. Studies in mice infected with lymphocytic choriomeningitis virus (LCMV) 
show a substantial expansion of cytotoxic viral antigen-specific CD8+ T cells followed 
by generation of immunological memory128,129. Many other human viral infections show 
preferential expansion of CD8+ T cells such as Epstein-Barr virus, cytomegalovirus and 
hepatitis B virus130–132. Furthermore, in humans, non-progressing patients infected with 
human immunodeficiency virus (HIV) show a preferential expansion of HIV-specific 
CD8+ T cells that maintain perforin expression, highlighting the importance of CTLs in 
limiting viral replication133. CD8+ T cells also represent a highly significant subset in anti-
tumoural immunity. Numerous studies across a variety of cancer types including 
colorectal, ovarian and breast cancer in humans have shown the presence of CD8+ tumour 
infiltrating lymphocytes (TILs) as a prognostic factor for increased survival in patients134–
136. Moreover, a meta-analysis of over 50 research papers showed that CD8+ TILs were a 
positive prognosis factor with a hazard ratio (HR) of 0.71137.  
 
The overwhelming body of research details the imperative role that CD8+ T cells play in 
both viral and anti-tumoural immunity. Therefore, adjuvants that enhance APC function 
to allow the generation of potent antigen-specific CD8+ T cells are critically important 
and are desirable targets for the development of immunotherapies.  
 
 CD4+ T cells 
CD4+ T cells are specialised mediators of immunity against bacterial, fungal and parasitic 
infections. Upon recognition of exogenous antigen on MHC-II, CD4+ T cells may 
undergo further differentiation into T helper (Th) subsets identifiable by unique 
transcriptional and cytokine profiles. Importantly, this differentiation is determined by 
the local inflammatory environment with each subset providing tailored responses to the 
given pathogen. For example, during intracellular infection, activated APCs that produce 
IL-12 drive CD4+ T cell polarization to a ‘Th1’ phenotype. Downstream signalling 
through signal transducer and activator of transcription 1 (STAT1) and STAT4 results in 
expression of the T-box transcription factor (Tbet)113,138. This master regulator of the Th1 
response governs downstream expression of the inflammatory cytokine, IFNγ, which 
induces enhanced phagocytic functionality of phagocytes such as macrophages139. 
Therefore, Th1 cells represent an essential T cell subset in the elimination of intracellular 
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pathogens. In response to helminth infection, expression of the transcription factor GATA 
is induced in CD4+ T cells which governs the production of IL-4, IL-5, and IL-13. These 
‘Th2’ cells ultimately facilitate IgE production by B cells, eosinophil recruitment, and 
mucous production140. Responses involving Th2 cells are inappropriately initiated against 
otherwise innocuous antigens in allergy. Extracellular bacterial or fungal infections 
induce RORγt expression and differentiation into the Th17 phenotype, which through the 
production of IL-17, IL-6, IL-8, and TNF, mediate recruitment of neutrophils and 
monocytes141,142.  
 
1.2.2.1 CD4+ T cell help 
Amongst their immune-modulating effects, CD4+ T cells are also key in augmenting B 
cell responses. After activation, CD4+ T cells migrate to the edge of the B-cell follicle 
within lymph nodes where they may encounter and activate cognate antigen-presenting 
B cells to induce germinal centre formation13,17. The first evidence detailing the 
requirement of T cells in B cell activation were early cell transfer experiments in 
irradiated mice. These studies revealed that it was only when cells from both the thymus 
and bone marrow were simultaneously transferred back into mice that antibody responses 
could be generated after immunisation143,144. It was later found that efficient B cell 
activation required stimulation through both the B cell receptor (BCR) and CD40 (a 
member of the tumour necrosis factor family; TNF) driving germinal centre formation 
and promoting B cell proliferation and survival145. The ligand for CD40, CD40L, is 
expressed highly on activated CD4+ T cells146. Contact dependent co-stimulation of B 
cells through CD40L together with inducible T cell co-stimulator (ICOS) and SLAM-
associated protein (SAP) all contribute to providing help to B cells, as gene deletion of 
these proteins leads to severe defects in germinal centre formation and B cell 
memory17,147,148.  
 
Furthermore, humans who have X-linked hyper IgM syndrome contain mutations in 
CD40LG and cannot form germinal centres149. Upon ligation of CD40 to CD40L, several 
of TNF receptor-associated factors (TRAFs) induce signal transduction and downstream 
expression of transcription factors, such as NFκB, triggering B cell activation, survival, 
cytokine production, and class-switching of antibody150–154. In particular, a subset of 
CD4+ T cell, the T follicular helper (Tfh) cell are poised to provide help to B cells. These 
Tfh cells can migrate into the B cell zone due to increased expression of the chemokine 
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receptor chemokine (C-X-C motif) receptor 5 (CXCR5)155. Within early germinal 
centres, these cells provide signalling through their constitutive expression of CD40L and 
ICOS as well as expression of the cytokine IL-21156.  
 
Aside from B cells, CD40 is expressed on a number of other immune cells including 
monocytes, macrophages, and DCs where T cells are key providers of ‘help’ signal. In 
this way, CD4+ T cells are crucial in the activation and maturation of DCs and subsequent 
priming of potent CD8+ T cell responses. In a similar manner to CD40-CD40L signalling 
in B cell activation, this signal cascade in DCs leads to transcriptional changes resulting 
in the maturation of the DC. Recognition of cognate antigen between a CD4+ T cell and 
a DC leads to upregulation of co-stimulatory markers CD86/80 as well as heightened 
expression of IL-12 leading to enhanced interactions between CD8+ T cells and DCs14–16. 
Importantly, efficient CD4+-dependent priming of CD8+ T cells requires antigen to be 
recognised by both subtypes on the same APC15,157,158. Numerous early studies in vivo 
have highlighted the necessity of the presence of CD4+ T cells in priming antigen-specific 
CD8+ T cells158–160. Moreover, the formation and maintenance of immunological memory 
to infection requires the presence of CD4+ T cells112,161,162.  
 
It is now also clear from genomic and transcriptomic studies that CD4+ T cell help 
instructs CD8+ T cell fate through induction of differential transcriptional pathways. In 
an RNA-sequencing study, mice were vaccinated with one of two DNA vaccines. The 
first utilised the oncogenic human papillomavirus (HPV) E7 protein that encoded for the 
MHC-I peptide alone. The second utilised both the E7 protein and an unrelated HPV 
known MHC-II epitope, which would allow for expression and co-localisation of MHC-
I and II epitopes within a single APC12. The authors found that the CTLs generated in the 
presence of helper antigens had higher expression of TNF, IFNγ, FASL, and Granzyme 
A/B, which conferred higher cytotoxic qualities in further studies163. Furthermore, these 
CTLs showed higher expression of CXCR4, CX3C-chemokine receptor 1 (CX3CR1) 
promoting tumour extravasation. In contrast, CTLs that arose from no T cell help had 
higher expression of inhibitory proteins programmed cell death protein 1 (PD-1) and 
lymphocyte activation gene 3 protein (LAG3). These PD-1+ CTLs are reminiscent of 
those found in human cancers formed during early stages of effector differentiation and 
display an ‘exhausted’ dysfunctional phenotype which would suggest that exhausted 
CTLs may arise from lack of helper signals164.  
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These studies emphasised the biological impact of CD4+ T cell help, especially within the 
context of cancer. Importantly, this study highlighted the fact that CD4+ T cell epitopes 
did not need to be a tumour-specific antigen to elicit help. For this reason, many studies 
utilising MHC-I epitopes in vaccination studies often include MHC-II epitopes (reviewed 
here165). Alternatively, agonistic proteins to induce helper signalling has been used to 
bypass the requirement of antigen-specific CD4+ T cells. In a therapeutic cancer vaccine 
model, combination with agonistic CD40 antibody (αCD40) overcame peptide-induced 
tolerance and greatly enhanced anti-tumour activity166. Collectively, there is substantial 
evidence on the importance of CD40 signalling in the development of potent T cell 
responses, and accordingly, αCD40 has been employed as a combinatorial therapy in 
many cancer trials (reviewed here167).  
 
 NKT cell help 
Within a host’s diverse repertoire of T cells, with each cell population expressing multiple 
copies a single randomly generated TCR structure, there also exist subpopulations of T 
cells that display limited TCR diversity and therefore bind to a limited repertoire of 
antigens. These T cells generally have a “semi-activated” phenotype, and so respond very 
quickly (within hours) to exposure to antigen. They also commonly express markers 
typical of natural killer cells – fast-acting cytotoxic cells of the innate immune system. 
They have therefore been termed “innate-like” T cells. One such subset of innate-like T 
cells, NKT cells, have been extensively studied and have potent anti-tumour properties. 
NKT cells are selected in the thymus by an MHC class I-like molecule, CD1d168,169. This 
molecule presents an array of lipid antigens to NKT cells which are recognised by their 
invariant TCR (Vα14-Jα18 in mice and Vα24-Jα18 in humans). One of their most potent 
known agonists, α-GalCer, activates NKT cells and elicits rapid activation and production 
of an array of cytokines including large amounts of IFNγ and IL-4, key in driving Th 
responses. In fact, α-GalCer was originally discovered as an anti-tumour agent with 
potent single-agent effects. In vitro studies established that NKT cells themselves were 
capable of direct lysis of tumour cells when α-GalCer was loaded onto CD1d-expressing 
mouse or human tumour lines170,171. These findings were seemingly confirmed in vivo. 
However, further observations across models showed that the potency of α-GalCer was 
more related to activation and modulation of other arms of the immune system172,173. 
Indeed, α-GalCer-dependent tumour suppression was found to be dependent on IFNγ as 
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well as IL-12 producing DCs, an essential mechanism in the activation of natural killer 
(NK) cells and priming of CTLs174–176. Their pronounced ability to induce IL-12 secretion 
by DCs suggests that NKT cells could be acting as mediators of help, similar to CD4+ T 
cells. 
 
Further studies confirmed that mice injected with α-GalCer show strong activation of DC 
populations displaying increased levels of maturation markers CD86/80 and high levels 
of IL-1219,21. This effect was mainly mediated by contact-dependent stimulation through 
the CD40-CD40L axis. These immune-stimulating properties of activated NKT cells 
raised the possibility that α-GalCer could be used as an immune adjuvant to enhance 
priming of antigen-specific CTLs. This approach was attractive as NKT cells represent a 
highly frequent population of T cells, around 0.5% of circulating T cells in mice and can 
also be found highly enriched at secondary lymphoid tissues as well as distal tissues like 
the liver and lungs177. Indeed, co-administration of α-GalCer with model antigens showed 
that NKT cells could induce the proliferation of antigen-specific CTLs, which could 
confer significant protection against tumour challenge in a CD1d-dependent manner18–20.  
 
Moreover, the helper function of NKT cells has been highlighted across numerous disease 
settings. In murine models of malaria, administration of α-GalCer to mice was able to 
inhibit the development of the malarial parasites Plasmodium yoelii and Plasmodium 
berghei178. Intranasal administration of α-GalCer during murine influenza infection 
resulted in IL-4 dependent production of IgA179. Moreover, the role of NKT cells in anti-
viral immunity was confirmed in a porcine model of influenza where administration of 
α-GalCer resulted in inhibition of viral replication180. Importantly, NKT cells have also 
been shown to induce the expansion of CD8+ T cells specific for human tumour associated 
antigens in vivo when A2Kb transgenic mice were co-administered α-GalCer and NY-
ESO, highlighting the great therapeutic potential for clinical trials.181 
 
The anti-tumour benefits of NKT cell-based immunotherapies within the human setting 
remains unclear. A number of clinical trials across various cancers have been conducted 
where α-GalCer is either loaded onto autologous immature monocytes or mature DCs and 
infused back into the patient (reviewed here182). In many instances, NKT cells within the 
patients in these trials were found to be highly activated post-infusion, producing IFNγ 
and in some cases were accompanied by broad inflammatory responses including the 
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expansion and activation of T cells and NK cells. However, thus far, these NKT cell-
based therapies have shown little to no anti-tumour effects. Despite these numerous trials, 
little emphasis has been placed on the ability of NKT cells to adjuvant CD8+ T cell 
responses through CD40L-dependent help of DCs. However, one study found that 
infusion of patients with α-GalCer pulsed DCs resulted in the expansion of 
cytomegalovirus (CMV)-specific CD8+ T cells, providing evidence that NKT cell-based 
helper function could occur in the human setting183. A recently completed phase I clinical 
trial by our laboratory aimed to address this property of NKT cells further through the 
administration of autologous DCs loaded with α-GalCer and tumour-associated antigens;  
MELVAC study184. In this study, NKT cells in most patients were found to proliferate 
and produce pro-inflammatory cytokines post-vaccination. Moreover, seven out of eight 
patients showed an increase in polyfunctional antigen-specific T cells providing evidence 
that the NKT-helper function may indeed be conserved in humans.  However, more 
research is required to fully underpin the capacity of NKT cells to act as cellular adjuvants 
to improve the quality of anti-tumour responses. One possible limitation in NKT cell-
based immunotherapies, however, is the difference in frequency between mouse and 
humans. In contrast to mice, NKT cells in humans only represent up to 0.05% of 
circulating T cells22 which raises concern in the translation of NKT cell-based therapies 
in the clinic.  
 
 MAIT cells and their potential as immune adjuvants 
 
MAIT cells are another innate-like T cell group that are functionally reminiscent of NKT 
cells. They express an invariant TCR that recognises derivatives of the vitamin B2 
biosynthetic pathway produced by bacteria or fungi on an MHC I-like molecule, MHC I-
related gene 1 (MR1)185. Moreover, MAIT cells can react to viral infections and become 
activated in an MR1-independent manner through cytokines such as IFNα, IL-12 and IL-
18186. In contrast to NKT cells, MAIT cells are an abundant population of T cells in 
humans, representing 1-10% of circulating T cells23,25. They are enriched within 
secondary lymphoid organs, the liver, and at mucosal sites such as the lamina propria and 
the lungs. Since their discovery, MAIT cells have been highlighted as sensors of bacterial 
infection. Studies in MR1-/-, which lack MAIT cells, show defects in early protection 
against models of bacterial infection, however, do not seem to be essential for sterilizing 
immunity26,187. Amongst vertebrates, MAIT cells are highly conserved and therefore must 
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have essential and non-redundant functions aside from their anti-microbial properties that 
are yet to be described. Emerging evidence has indicated that MAIT cells also play a role 
in immune regulation and modulation27,29,188,189; however, the extent of this is not fully 
understood. This section will detail the current knowledge of MAIT cell biology, their 
known agonists, and explore their potential as immune adjuvants which may overcome 
the limitations of NKT cell research in humans. 
 
 MAIT cell development and phenotype 
Like conventional T cells, MAIT cells develop in the thymus from bone-marrow derived 
lymphoid progenitors. Once in the thymus, cells expressing the invariant MAIT TCR, 
Vα19-Jα33 in mice and Vα7.2-Jα12/20/33 in humans, are selected for by MR1 (ligand to 
be discussed later)190,191. They express limited Vβ chain diversity being mainly Vβ2 and 
Vβ13.2 in humans and Vβ6 or Vβ8 in mice23,192,193. In humans, the dominant population 
of MAIT cells are CD8+ but can be double negative (DN) for expression of CD8 and 
CD4, with a small population of CD4+ cells23,25. In contrast, the majority of murine MAIT 
cells are DN with small populations being CD8+ or CD4+23. During late stages of 
development, MAIT cells acquire expression of the transcription factor promyelocytic 
leukaemia zinc finger protein (PLZF), akin to other innate-like T cells, including NKT 
cells, Vγ9Vδ2 T cells, and innate lymphoid cells194–197. This transcription factor defines 
the innate-like T cell group as the expression of PLZF drives the acquisition of an effector 
phenotype through induction of lineage defining transcription factors such as T-bet, 
RORγt, and GATA3195. In the case of MAIT cells, the most commonly expressed factor 
is RORγt, making them phenotypically comparable to Th17 cells, especially within the 
lung, lamina propria and the skin with >80% being RORγt+ MAIT cells23,198. MAIT cells 
may also express T-bet, however, to a lesser extent than RORγt, only representing minor 
populations within the blood, spleen, lymph node, and liver. Interestingly, only a very 
small proportion of MAIT cells express GATA3, which are only detectable in B6-
MAITCAST mice. This strain on the C57BL/6 background harbours high MAIT numbers 
due to congenic expression of a genetic locus derived from CAST/EiJ mice that confers 
higher expression of the Vα19-Jα33 TCR arrangement198. For ease, RORγt+ MAIT cells 
and T-bet+ MAIT cells will be referred to as MAIT17 and MAIT1, respectively. Owing 
to the over-representation of MAIT17 cells, upon stimulation, the MAIT cell population 
produces high levels of IL-17 and low levels of IFNγ and IL-4, distinctive from NKT 
cells23,25. Analogous to CTLs, MAIT cells also produce perforin and granzyme B during 
 20 
activation. Upon recognition of antigen-loaded MR1 on infected cells MAIT cells rapidly 
degranulate and release these effector molecules to induce apoptosis199. Although human 
and mouse MAIT cells highly overlap in their phenotype and functionality, one striking 
difference is that human MAIT cells can represent up to 10% of circulating T cells, as 
well as 45% of T cells within the liver25,200. In contrast, in mice, MAIT cells are far less 
represented at these locations. In mice, MAIT cells account for less than 0.1% of 
circulating T cells and reach up to 1% of T cells within the lungs. As MAIT cells react to 
bacteria-derived metabolites, and most laboratory mice are specific-pathogen free (SPF), 
this may be a consequence of evolutionary negative selection pressure against the need 
for high frequencies of MAIT cells. 
 
 MAIT ligands and MR1  
The MHC I-related  molecule, MR1, is notably one of the most conserved MHC-I proteins 
across mammals with 90% sequence homology between the α1 and α2 domains within 
the murine and human Mr1 genes201,202. As a comparison, between murine and human 
CD1d, the selecting and presenting molecule for NKT cells, only shares about 60% 
sequence homology. In a similar manner to classical MHC-I molecules, MR1 is 
ubiquitously expressed amongst tissues and is synthesised and localised within the ER 
where it associates with β2-microglobulin (β2m)203. In contrast to MHC-I molecules, 
MR1 does not bind to peptide antigens, evident by the lack of commonly conserved 
residues found in MHC-I molecules involved in peptide anchoring203. Instead, MR1 binds 
to small pyrimidine intermediates that are formed as a by-product of microbial riboflavin 
(vitamin B2) synthesis185. Specifically, the intermediate 5-A-RU, which was found to 
activate MAIT cells, does not directly bind to MR1 itself but instead undergoes enzymatic 
condensation with α-dicarbonyl species. Methyglyoxal, glyoxal and butane-2,3-dione 
react with 5-A-RU to form the ligands 5-OP-RU, 5-(2-oxoethylideneamino)-6-D-
ribitylaminouracil (5-OE-RU) and 5-(1-methyl-2-oxopropylideneamino)-6-D-
ribitylaminouracil (5-MOP-RU), respectively185,204. For simplicity, studies on 5-OP-RU 
will be the main focus of discussion here. During intracellular infection or phagocytosis 
of bacteria, it is thought that 5-A-RU condenses with methylgloxal, which is produced as 
a product of cellular metabolism in order to form 5-OP-RU. This molecule then 
covalently bonds to ER-localised MR1 through Schiff base formation via a lysine residue 
(K43) located within the antigen-binding groove185. Binding of 5-OP-RU to MR1 induces 
conformational change and subsequent translocation to the cell surface for presentation 
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to MAIT cells205. Activation of MAIT cells is then induced through direct hydrogen bond 
interactions between the CDR3α loop on the MAIT cell TCR and the ribityl moiety on 5-
OP-RU206. It is important to note that MR1 does show some level of versatility in the 
antigens that it binds. For instance, a screen of small molecules showed that MR1 could 
bind drug-like molecules and metabolites, which can activate MAIT cells207,208.  
 
The vitamin B9 metabolite, 6-formylpterin (6-FP), is another ligand that is able to form 
a Schiff base with MR1, induce conformational change and egress to the cell 
surface206,209. However, in contrast to 5-OP-RU, 6-FP lacks the necessary moieties to 
contact the MAIT TCR and therefore, acts as an antagonistic ligand by sequestering MR1 
molecules and inhibiting binding with other activatory ligands. Thus, 6-FP and its 
synthetic derivative, acetyl-6-formylpterin (Ac-6-FP), are useful tools in studying the 




















Figure 1.1. Formation of MR1 ligands to activate MAIT cells. (1) During microbial 
riboflavin synthesis, 5-A-RU undergoes condensation with dicarbonyl adducts such as 
MG to form 5-OP-RU. (2) This pyrimidine intermediate forms a Schiff base with K43 on 
MR1 and is then presented to the MAIT cell TCR, inducing activation. (3) However, 5-
OP-RU is also susceptible to cyclisation into 7-methyl-8-D-ribityllumazine which is a 
weak MR1 ligand. 
 
1.3.2.1 MAIT agonist instability 
One of the limitations of research utilising MAIT agonists is their propensity to rapidly 
cyclise into inactive lumazines (Figure 1.1)185,204. The formyl group located on 5-OP-RU 
is a crucial binding site for covalent bonding to MR1. Thus, cyclisation of this group in 
the formation of lumazines precludes this site from bonding to MR1, making it a poor 
activator of MAIT cells. Moreover, in aqueous solution at 15oC, 5-OP-RU has a half-life 
of 14 h (pH 6.8), 5-OE-RU 18 min, and 5-MOP-RU 14 h, both at pH 8210. The formation 
of 5-OP-RU is normally achieved by adding MG to 5-A-RU prior to use. However, in 
aqueous solution, this has been reported to be highly inefficient, with only around 1% 
conversion to 5-OP-RU, and rapid degradation with a half-life of 12 min. These issues 
have been overcome when 5-A-RU was reacted with MG in DMSO and under argon, 
which displaces air and prevents oxidation, enhancing 5-OP-RU conversion and 
stability210. In the same study, the authors also attempted to chemically modify 5-OP-RU 
in order to impede lumazine formation. Unfortunately, this was not highly successful as 
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the chemical variants of 5-OP-RU were drastically reduced in their ability to activate 
MAIT cells, possibly due to altered MR1 presentation. The precursor 5-A-RU has also 
been reported to succumb rapidly to degradation upon exposure to light or air, although 
these degradation products and their ability to activate MAIT cells have not been 
explored211, which is a topic of this thesis. In this degradation study, 5-A-RU could be 
stabilised through the preparation of 5-A-RU as an HCl salt which protected the 
compound from degradation at room temperature for a maximum of 37 d in solid form 
when protected from light. However, it was unclear from the results of this study, whether 
stabilisation of 5-A-RU was able to confer reproducible and enhanced activation of MAIT 
cells compared to native 5-A-RU.  
 
While these studies successfully provided methods to stabilise MAIT cell antigens for 
storage and use in vitro, no data has yet been published that detail modifications which 
result in the enhancement of MAIT cell activation in vitro or in vivo. During bacterial 
infection, 5-A-RU is produced in situ by bacteria present within the cell and therefore in 
close proximity to MR1. As of yet, it is unclear if the integrity of MAIT antigens is 
compromised by proteins or metabolites present in vitro within cell cultures, or in vivo 
within serum or extracellular spaces prior to uptake by APCs. Therefore, the generation 
of a modified 5-A-RU that both increases stability and prevents the formation of putative 
degradation products prior to cellular uptake would be a welcome advance within the 
MAIT cell field in order to explore this possibility. This is another topic of this thesis. 
 
1.3.2.2 The mode of MR1 presentation 
The canonical mode of MR1 presentation occurs in a similar manner to most MHC-I 
molecules and requires association with β2m to form stable complexes212. In a TAP-
independent manner, MR1 is loaded with 5-OP-RU within the ER, which results in 
trafficking to the cell surface. After contact with the MAIT cell TCR to prime activation, 
MR1 becomes internalised within endosomes that consequently enter the degradation 
pathway through fusion with lysosomes. However, a proportion of these MR1 molecules 
are also able to enter the recycling pathway205,213. In this way, endosomes containing MR1 
can acquire antigens by fusion with incoming endocytic vesicles containing phagocytosed 
bacteria. Evidence for the requirement of such pathways were detailed in studies 
comparing MR1 presentation between mycobacterial supernatant, containing exogenous 
soluble MAIT cell antigens, and whole mycobacteria, which provide 
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intracellular/endogenous sources of MAIT cell antigens. In these studies, cells loaded 
with the MR1 ligand 6-FP, blocked MR1 presentation and MAIT cell activation by 
mycobacterial supernatant but not when whole mycobacteria were used214,215. Genetic 
silencing of pathways involved in ER-Golgi organisation and endosomal trafficking 
revealed different requirements for exogenously provided soluble antigen versus 
endogenous bacterial derived antigen. Additionally, access of recycled MR1 molecules 
by soluble MAIT antigens was confirmed in a 2016 study. Here the authors showed that 
once MR1 was allowed to accumulate on the cell surface by incubation of cells with 6FP, 
blocking egress of ER-derived MR1 with brefeldin did not completely inhibit loading of 
MR1 when the cells were loaded with 5-OP-RU205. However, the biological implications 



























 Role of MAIT cells as anti-microbial effectors 
Evidenced by the high evolutionary conservation of MR1 across mammalian species and 
its propensity to bind by-products of bacterial riboflavin synthesis produced by bacteria 
and some yeasts, MR1-restricted MAIT cells are a significant subset of T cells poised to 
react to bacterial infection. Early research has shown in vitro that MAIT cells can directly 
react to and lyse bacterially infected cells, as well as some yeasts species199,216,217. The 
ability to control bacterial infection is also reflected in in vivo studies. Mice deficient for 
MR1, and therefore lacking MAIT cells, succumb to disseminated infection by Klebsiella 
pneumoniae following intraperitoneal challenge compared to WT controls187. Similarly, 
sublethal intranasal infection with Francisella tularenis, resulted in preferential 
Figure 1.2 Mode of MR1 presentation. (1) Loading of an unknown endogenous or 
exogenously provided soluble antigens occurs in the ER where formation of a Schiff base 
with K43 in the MR1 binding groove induces translocation of MR1 through the trans-
Golgi network to the cell surface for presentation. (2) Bacterially derived MAIT antigens 
can also provide ligands to ER-localised MR1. (3) However, MR1 can also enter 
recycling endosomes after presentation on the cell surface, which could potentially fuse 
with incoming endocytic vesicles containing bacteria, thus providing a separate loading 
mechanism for exogenous antigens. 
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expansion of MAIT cells in the lungs during early and intermediate stages of infection. 
MR1 deficient mice showed significant decreases in levels of pro-inflammatory cytokine 
within the lungs such as IFNγ, TNF, and IL-17 and failed to control bacterial growth 
resulting in delayed clearance of disease26. Additionally, this study showed MR1 deficient 
mice had reduced levels of activated CD8+ and CD4+ T cells infiltrating the lungs during 
infection compared to wild type, inferring that MAIT cells may also play a role in the 
modulation of other adaptive immune responses. Another study in MR1 deficient mice 
infected with Bacille de Calmette et Guérin (BCG) showed higher bacterial loads at early 
stages of disease compared to wild type218. Moreover, MAIT cells were shown to directly 
and potently inhibit intracellular growth of BCG-derived bacteria within macrophages. 
These studies show a role for MAIT cells in potentiating inflammatory immune responses 
in vivo for the control of bacterial disease. 
 
In humans, reduced numbers of MAIT cells were commonly correlated with active 
diseases such as in patients with Pseudomonas aeruginosa infection (cystic fibrosis), 
tuberculosis and septic shock216,217,219,220. Moreover, patients whose MAIT cells remained 
at low frequencies after infection were more susceptible to subsequent hospital-acquired 
infections. Studies in mice showing an accumulation of MAIT cells within tissues during 
active infection suggest that this reduction in circulation is caused by direct recruitment 
of MAIT cells towards infected tissues from the periphery. However, more definitive 
research comparing MAIT cells from the tissue and peripheral blood is required in order 
to assess the role of MAIT cells in bacterial infections directly, and whether they are 
indeed homing to sites of infection.  
 
 MAIT cells as modulators of adaptive immune responses 
The growing body of literature describes MAIT cells as potent effectors against bacterial 
infection, in which MAIT cells are able to accumulate within infected tissues where their 
primary function is assumed to be the control of bacterial growth through direct lysis of 
infected cells. However, as briefly described above, MAIT cells are producers of pro-
inflammatory cytokines and are involved in the recruitment of activated T cells into the 
lung during pulmonary infection, suggesting that MAIT cells may be involved in 
modulating adaptive immune responses. The evidence for MAIT cells being involved in 
these responses are studies detailing their ability to interact with DCs. In one study, 
human MAIT cells were shown to drive the maturation of moDCs in vitro. In this study, 
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co-culture of MAIT cells and monocytes resulted in CD40L-dependent increased 
expression of the co-stimulatory markers CD80 and CD83 as well as the production of 
IFNγ and IL-12p4029. Moreover, MAIT cells were also able to activate primary DCs 
isolated from human blood, showing that they have the ability to interact with multiple 
subtypes of DC. Furthermore, in an in vivo study of mice infected with F. tularensis, 
MAIT cells could directly produce GM-CSF, an essential cytokine for DC development26. 
In this study, the production of GM-CSF by MAIT cells was key during infection to 
induce the recruitment and differentiation of monocytes into moDCs. Critically, MR1 
deficient mice showed not only reduced recruitment of these moDCs but also a reduction 
in the number of CD4+ T cells coming into the lung, which could be rescued by adoptive 
transfer of MAIT cells. It is likely that moDCs are acting as APCs in this model, priming 
the expansion of CD4+ T cells. In another study, mice infected with Legionella 
longbeachae showed heightened expression of the co-stimulatory molecule, ICOS, on 
MAIT cells221. In this model, ICOS stimulation by MAIT cells induced the production of 
IL-23 (assumed to be from APCs) which drove the expansion of lung resident MAIT cells 
and subsequently conferred protection against infection.  
 
The interactions between MAIT cells and B cells have not been explored in great detail. 
The first indication of MAIT-B cell interactions occurring was shown in mice that lack 
the immunoglobulin heavy-chain joining region (JH-/-). These mice were deficient for 
MAIT cells showing that B cells were important for MAIT cell development222. In a 
recent study, MAIT cells were shown to be able to influence B cell responses in a murine 
model of lupus189. In the mouse strain FcγRIIb−/−Yaa, B cells spontaneously develop 
autoantibodies to nuclear antigens leading to inflammation across a variety of organs. In 
this study, when FcγRIIb−/−Yaa were crossed with MR1-/-, there was a marked reduction 
in autoantibody production and concurrent reduction in germinal centre responses. In 
vitro co-culture of MAIT cells with B cells and LPS lead to autoantibody production 
dependent on the presence of MAIT cells. Importantly, blockade of CD40L abrogated 
autoantibody production. This recent data reveals that MAIT cells are also able to provide 
CD40L signalling to B cells and may be a useful avenue to explore MAIT cells as cellular 
adjuvants towards generation of B cell responses, however, this possibility will not be 
explored in this thesis. 
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Overall the collected evidence presented here suggests that MAIT cells have the potential 
to modulate adaptive immune responses, which is likely to be relevant in disease 
pathogenesis and potentially provides an opportunity to develop novel immunotherapies. 
For this reason, the interaction of MAIT cells with APCs, and downstream effects on T 






 Rationale and aims 
 
There is now growing evidence that MAIT cells are able to not only directly lyse 
bacterially infected cells but also influence the activation state of APCs. Moreover, the 
recent revelation that MAIT cells can provide co-stimulation to DCs through CD40-
CD40L signalling indicates that, similar to NKT cells, activated MAIT cells may be 
harnessed therapeutically in vaccination strategies in combination with peptides.  
 
At the initiation of this thesis, the ability of synthetic MAIT agonists to drive DC 
maturation, and potentially influence adaptive immunity, had not been explored in any 
great detail. During the course of the study, it was reported that MAIT cells activated by 
bacteria could induce DC activation in mice27. Also, when 5-A-RU is combined with MG 
to form 5-OP-RU, and then administered to mice intranasally, MAIT cells within the lung 
become activated204. Linking these observations together, it was hypothesised here that 
activation of MAIT cells in mice with synthetic cell agonists could be sufficient to lead 
to DC maturation. Furthermore, this process could potentially help drive T cell responses 
to co-administered antigens. If this hypothesis were correct, this information would 
provide supporting evidence that MAIT cell activities can shape T cell responses in 
disease, and could potentially be exploited in immunotherapy.  
 
One of the limitations of research utilising these synthetic MAIT agonists is their poor 
stability and propensity to rapidly cyclise into inactive lumazines. Moreover, the 
degradation products of the precursor MAIT agonist, 5-A-RU, and their effects on MAIT 
cell activation have not been fully explored. Therefore, at the start of this thesis, these 
degradation processes were characterised, and an attempt was made to synthesise a stable 
version of 5-A-RU. Later in the thesis, the impact of activating MAIT cells in vivo with 
synthetic agonists was explored.    
 
The specific aims of this thesis were to: 
• Assess the degradation pathway of 5-A-RU when diluted in aqueous solution in 
preparation for biological use. 
• Develop a stable “prodrug” form of 5-A-RU and assess the mode of release and 
presentation of this compound to MAIT cells 
 30 
• Investigate whether activation of MAIT cells in vivo with synthetic ligands leads 
to enhanced activation status of DCs 
• Examine whether co-administering or conjugating antigens with synthetic MAIT 































Chapter 2:Materials and Methods  
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 Buffers and solutions 
 
Alsever’s solution 
Distilled H2O with 20.5mgmL-1 dextrose, 4.2mgmL-1 sodium chloride and 8.0mgmL-1 
sodium citrate (all BDH Laboratory Supplies, UK) adjusted to pH 6.1. Buffer was stored 
at 4oC until use. 
 
Fluorescent Activated Cell Sorting (FACS) buffer 
Non-sterile PBS with 10mM ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich, 
MO, USA), 1% foetal calf serum (FCS; Gibco, ThermoFisher, MA, USA) and 0.01% 
sodium azide. Buffer was stored at 4oC until use.  
 
Iscove’s Modified Dulbecco’s Medium – human complete (huIMDM-5) 
Gibco™ IMDM supplemented with 5% Human AB serum (Sigma-Aldrich, MO, USA), 
2mM GlutaMAX™ (Gibco), 1% penicillin/streptomycin (Gibco) and 55µM 2-
mercaptoethanol (ThermoFisher). Buffer was stored at 4oC until use. 
 
Iscove’s Modified Dulbecco’s Medium – murine complete (muIMDM-5) 
Gibco™ IMDM supplemented with 5% FCS, penicillin/streptomycin and 55µM 2-
mercaptoethanol. Buffer was stored at 4oC until use. 
 
Percoll gradient solution 
Non-sterile PBS with 33% Percoll (GE Healthcare Bio-Sciences AB, Sweden) and 2.2% 
Alseiver’s solution. Buffer was stored at 4oC until use. 
 
Roswell Park Memorial Institute 1640 – complete (RPMI-5) 
Gibco™ RPMI 1640 supplemented with 5% human serum, 1% penicillin/streptomycin, 
2mM GlutaMAX™, 2mM non-essential amino acids (NEAA; Gibco), 55µM 2-
mercaptoethanol and 1000U/mL IL-2 (derived from in-house hybridoma). Buffer was 
stored at 4oC until use. 
 
Würzburger buffer 
Sterile PBS with 1% FCS, 5mM EDTA and 0.1% DNase I (Sigma-Aldrich). Buffer was 




 Maintenance and Ethics approval 
All mice were bred and housed at the Malaghan Institute of Medical Research and used 
from 6 weeks of age. Animal protocols were approved by the Victoria University Animal 
Ethics Committee and performed according to institutional guidelines. 
 
 Mouse strains 
C57Bl/6J mice were derived from breeding pairs purchased from Jackson Laboratories 
(Bar Habor, ME, USA). Stock no. 000664. 
 
MR1-/- mice lack the α1 and α2 domain for the Mr1 gene and thus do not produce 
functional MR1 proteins. As a consequence, MR1-/- lack MR1-restricted T cells including 
(Vα19-Jα133) MAIT cells. Breeding pairs for this strain were kindly provided by 
Vincenzo Cerundolo (WIMM, Oxford, UK). 
 
CD1-/- mice have their Cd1d1 and CD1d2 loci replaced by a neomycin cassette and thus 
do not produce functional CD1d proteins. These mice lack CD1d-restricted T cells 
including (Vα14-Jα18) iNKT cells. Breeding pairs for this strain were purchased from 
Jackson Laboratories. Stock no. 008881. 
 
Jα18-/- mice have the Traj18 exons replaced by a neomycin cassette and thus lack 
functional Jα18 proteins. These mice cannot form a functional variable region within the 
iNKT cell T cell receptor and therefore lack iNKT cells. Breeding pairs for this strain 
were purchased from Jackson Laboratories. Stock no. 0030524. 
 
CD11c-DTReGFP mice express a CD11c transgene containing an insertion of the human 
diphtheria toxin receptor (DTR) sequence and enhanced green fluorescent protein (eGFP) 
under the control of the CD11c promoter (Itgax). Administration of DT i.p to these mice 
results in selective depletion of CD11c expressing cells223. Breeding pairs for this strain 
were purchased from Jackson Laboratories. Stock no. 004509. 
 
Clec9A-DTR mice express a contain an insertion of the human DTR sequence replacing 
the exon 1 of Clec9A. Administration of DT i.p to these mice results in selective depletion 
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of Clec9A expressing cells. Breeding pairs for this strain on a BALB/cByJ background 
were originally sourced from Dr Cristiane Ruedl (Nanyang Technological University, 
Singapore)224. Mice were then bred as heterozygotes with C57Bl/6J mice for experiments.  
 
IL-12p40eYFP mice have an internal ribosomal entry site containing an enhanced yellow 
fluorescent protein (eYFP) downstream of the IL-12p40 (Il12b) endogenous stop codon. 
This allows for visualization of IL-12p40 in myeloid cell populations during activation. 
Breeding pairs for this strain were purchased from Jackson Laboratories. Stock no. 
006412. 
 
 Generation of CD11c-DTReGFP bone marrow chimeras 
Mice older than 8 weeks of age were fasted for 24 h prior to exposure to radiation. Using 
a Gammacell® 3000 Elan irradiator (Best® Theratronics, Canada), mice were irradiated 
by exposure of 500cGy radiation twice, 3 h apart then transferred into ventilated cages. 
After 24 h, mice were given an intravenous (i.v.) injection of 1x107 bone marrow cells 
from donor CD11c-DTR mice. Mice were maintained on drinking water containing 
2mgmL-1 of neomycin trisulphate (Sigma-Aldrich) for three weeks and rested for a further 
five weeks prior to use in experiments.  
 
 In vivo depletion 
DT derived from Corynebacterium diptheriae (Sigma-Aldrich) was reconstituted at 
1mgmL-1 in distilled H2O. Administration to mice was given at a dose of 15ng per gram 
of body weight and administered i.p. as indicated by each experiment.  
 
 Tissue extraction and processing 
 
 Blood 
2.3.1.1 Peripheral white blood cells 
Blood was extracted from mice older than six weeks of age via submandibular bleeding 
with a 4mm lancet. Approximately 100µL of blood was collected into a 1.5mL Eppendorf 
tube containing 200µL of PBS (+10mM EDTA). One mL of red blood cell (RBC) lysis 
buffer solution (Qiagen, Hilden, Germany) was added to each tube before incubating at 
37oC for 30 min. Tubes were centrifuged at 1500 x g for 4 min to pellet white blood cells. 
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Supernatant was discarded and the cell pellet was resuspended in 200µL of FACs buffer 
prior to staining for flow cytometry. 
 
2.3.1.2 Serum 
Blood was extracted from mice older than six weeks of age via submandibular bleeding 
with a 4mm lancet. Approximately 150µL of blood was collected into a 1.5mL Eppendorf 
tube. Blood was allowed to coagulate at room temperature for 3 h before centrifugation 
at 21,000 x g in order to separate red blood cells from serum. Serum was collected into a 
new 1.5mL tube and stored at -20oC until application. 
 
 Bone Marrow 
Mice were culled by CO2 asphyxiation, followed by cervical dislocation and legs were 
removed. Skin, tissue and muscle were removed from each leg and the tibia and fibula 
were collected into ice cold IMDM. Bones were cleaned first in 70% ethanol then IMDM 
to remove residual tissue. To extract bone marrow, the ends of the bones were cut off and 
flushed through with a 24-gauge needle containing IMDM. Bone marrow was 
mechanically processed through a 70µM filter (Becton Dickinson, NJ, USA) and washed 
through with IMDM into a 50mL Falcon tube (ThermoFisher). Cells were pelleted by 
centrifugation at 250 x g for 10 min. Cells were resuspended in unsupplemented IMDM 
at 5x107 cells/mL prior to i.v. administration to irradiated mice.  
 
 Liver 
Mice were culled by CO2 asphyxiation, followed by cervical dislocation. Using an 18-
gauge needle, 10mL of ice-cold PBS was injected through the left ventricle of the mouse 
in order to perfuse the liver, removing circulating red and white blood cells. Livers were 
harvested into ice-cold PBS then mechanically processed and washed through a 70µM 
filter into a 50mL Falcon tube. Cells were pelleted by centrifugation at 572 x g for 4 min. 
Supernatants were removed and resuspended in 50mL of 33% Percoll gradient solution. 
Cells were pelleted by centrifugation at 322 x g for 10 min with the brake off. Supernatant, 
including the top layer of hepatocytes, was removed and cells were resuspended in 2mL 
of RBC lysis solution for 5 min at 37oC. Cells were pelleted by centrifugation at 572 x g, 




Mice were culled by CO2 asphyxiation, followed by cervical dislocation. Using an 18-
gauge needle, 10mL of ice-cold PBS was injected through the left ventricle of the mouse 
in order to perfuse the lung, removing circulating red and white blood cells. Lungs were 
harvested into 1mL of IMDM containing 5mgmL-1 of Collagenase I (Gibco) and 
0.25mgmL-1 of DNase I (Sigma-Aldrich) before cutting the tissue into small pieces and 
incubating at 37oC for 30 min. Lung tissue was mechanically processed and washed 
through a 70µM filter into a 50mL Falcon tube. Cells were pelleted by centrifugation in 
at 572 x g for 4 min. Supernatants was discarded then cells were resuspended in 2mL of 
RBC lysis solution and incubated for 5 min at 37OC. Cells were pelleted by centrifugation 
at 572 x g, supernatant discarded and resuspended in 1000µL of FACS buffer prior to 
staining for flow cytometry. 
 
 Lymph nodes 
Mice were culled by CO2 asphyxiation, followed by cervical dislocation. The mediastinal 
lymph node (mLN) was isolated and placed 500µL of IMDM containing 100µgmL-1 of 
Liberase™ TL (Sigma-Aldrich) and 100µgmL-1 of DNase I.  Lymph nodes were broken 
up using a 25-gauge needle and then incubated for 30 min at 37oC. After 25 min of 
incubation, EDTA was added to the digestion media at a final concentration of 10mM. 
Cells were collected and filtered through a 70µM filter into a 1.5mL Eppendorf tube. 
Cells were pelleted by centrifugation at 1500 x g for 4 min. Supernatant was discarded 




Mice were culled by CO2 asphyxiation, followed by cervical dislocation. Spleens were 
harvested into 1mL of ice-cold IMDM prior to processing. Spleens were mechanically 
processed and washed through a 70µM filter into a 50mL Falcon tube. Cells were pelleted 
by centrifugation at 572 x g for 4 min. Supernatants were discarded then cells were 
resuspended in 2mL of RBC lysis solution and incubated for 5 min at 37oC. Cells were 
pelleted by centrifugation at 572 x g, supernatant discarded and resuspended in 1000µL 
of FACS buffer prior to staining for flow cytometry. 
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 Cell viability 
Cells were diluted in Trypan Blue dye (Gibco) and placed onto a haemocytometer. Viable 
cells were counted as those cells which had excluded the dye (white). Total cell number 
was determined as: 
 
Total live cells = (Average cell count per area) x (dilution factor) x (104) x (total volume 
of cells) 
 
 Vaccine compounds 
 
 Generation of 5-A-RU 
5-A-RU was synthesised and kindly provided as an aqueous solution from Prof. Gavin 
Painter (Ferrier Research Institute, Wellington, New Zealand) and stored at -80oC. 5-A-
RU was diluted in PBS and kept on ice for immediate use to allow minimal auto-oxidation 
of 5-A-RU. For in vivo use, 5-A-RU was used at 180nmol per mouse unless stated 
otherwise. Where stated, methylglyoxal (MG) was added to diluted 5-A-RU at 10x the 
molar concentration and mixed for approximately 1 min before immediate administration 
to the mouse.  
 
 Generation of 5-A-RU prodrugs and conjugates 
The 5-A-RU prodrugs and conjugates were synthesised and kindly provided by Prof. 
Gavin Painter (Ferrier Research Institute, Wellington, New Zealand) as a lyophilised 
powder. To solubilise the compounds, DMSO was added drop-wise up to 10mgmL-1 then 
diluted further to 1mgmL-1 in PBS. Stock solutions were aliquoted and stored at -20oC. 
For in vivo use 5-A-RU prodrugs or conjugates were used at 5nmol per mouse unless 
otherwise stated. 
 
 Filtration of 5-A-RU 
Where stated, 5-A-RU was filtered using Ultrafree®-MC filter tube (Merck KGaA, 
Darmstadt, Germany) according to manufacturers’ instructions. Briefly, up to 500µl of 
stock 5-A-RU was pipetted into the tube into the filtered chamber and capped. The tube 
was added to a centrifuge and spun for 1 minute at 12,000 x g. Filtered 5-A-RU was 
collected from the tube for experimental use or frozen at -80oC for later use. 
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 In vivo treatments 
 
 Intravenous vaccination 
Each compound was prepared at the indicated concentrations per experiment in a total of 
200µL of PBS. Mice were warmed under a heat lamp, placed in a restrainer then 
administered 200µL of the indicated compound into the lateral tail vein. 
 
 Intraperitoneal antibody blockade 
CD40L blockade 
Mice were administered 500µg of anti-mouse CD40L (CD154) (clone MR-1; BioXCell, 
NH, USA) via intraperitoneal injection (i.p.) on d -1. On d0, mice were administered anti-
CD40L i.p again and then administered 5-A-RU or 5-A-RU + MG via i.v. Control mice 
received the same dose of Armenian Hamster IgG (BioXCell). 
 
TNFα blockade 
Mice were administered 500µg of Etanercept (Enbrel®; Amgen, CA, USA) via 
intraperitoneal injection (i.p.) on d -1. On d0, mice were administered Etanercept i.p again 
and then administered 5-A-RU or 5-A-RU + MG via i.v. Control mice received the same 
dose of Human IgG (Privigen; CSL Behring, PA, USA). 
 
IFNγ blockade 
Mice were administered 500µg of anti-mouse IFNγ (clone XMG1.2; BioXCell, NH, 
USA) via intraperitoneal injection (i.p.) on d -1. On d0, mice were administered anti- 
IFNγ i.p again and then administered 5-A-RU or 5-A-RU + MG via i.v. Control mice 
received the same dose of Rat IgG (BioXCell). 
 
IFNAR blockade 
Mice were administered 200µg of anti-mouse IFNAR (clone MAR1-5A3; BioXCell, NH, 
USA) via intraperitoneal injection (i.p.) on d -1. On d0, mice were administered anti- 
IFNAR i.p again prior to i.v. with 5-A-RU or 5-A-RU + MG. Control mice received the 
same dose of Mouse IgG (BioXCell). 
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 Adoptive transfer antigen specific T cells 
 
 Dynabead enrichment 
Spleens were harvested from OT-I and OT-II mice and processed to a single cell 
suspension as described in section 2.3.6. Cells were washed with and resuspended in 
Würzburger buffer at 1x108 cells/mL. Isolation of OT-I and OT-II cells was done with 
DynabeadsTM FlowCompTM mouse CD8 or CD4 kit, respectively (ThermoFisher), 
according to manufacturer’s instructions. To OT-I and OT-II cells respectively, 50µL of 
FlowComp CD8 or CD4 antibody was added per 1x108 cells and incubated at 4oC for 10 
min. Cells were washed by adding 2mL of Würzburger buffer, pelleting cells by 
centrifugation at 572 x g for 4 min then resuspended in 1mL of Würzburger buffer. 
FlowComp Dynabeads was added to either cell population at 150µL per 1x108 cells then 
incubated at 4oC for 15 min, mixing cells well every 5 min to ensure maximum binding 
of Dynabeads. Cells were then placed in a magnetic column for 1 min and the negative 
fraction was removed. Cells were removed from the magnet and washed in 1mL of 
Würzburger buffer then placed in the magnet for another min and the negative fraction 
removed. The bead-bound cells were resuspended in 1mL of FlowComp release buffer 
and incubated at room temperature for 10 min. Cells were placed in the column for 1 min 
to separate the now unbound Dynabeads from the positive cell fraction. The positive 
fraction was transferred to a new tube and washed in 10mL of PBS prior to adoptive 
transfer. 
 
 Adoptive T cell transfer  
OT-I and OT-II cells were prepared as stated in 2.6.1. Viable cell count was performed 
as in section 2.3.7. OT-I and OT-II cells were resuspended in PBS at 1x105 cells/mL and 
5x106 cells respectively. Equal volumes of OT-I and OT-II cells were combined and 
200µl of the final mixture was injected intravenously into each mouse. The final 
concentration each mouse received was 1x104 OT-I cells and 5x105 OT-II cells.  
 
 Tumour cell culture and challenge 
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 B16-OVA cell culture 
B16-OVA tumour cells (kindly provided by Dr Dick Dutton, Trudeau Institute, NY, 
USA) (were cultured in Nunc™ EasYFlask™ Cell Culture Flasks (ThermoFisher) in 
muIMDM-5. Cell cultures were also supplemented with 1% 500µg/mL Geneticin (Gibco) 
to select for OVA expressing B16-OVA cells until ~70% confluence was reached. 
Adherent cells were harvested by incubation with TrypLE (Gibco) for 2 min at 37oC. 
Cells were then washed twice with IMDM to remove FCS before tumour challenge.  
 
 TC-1 cell culture 
TC-1 tumour cells (kindly provided by Dr. Wu from John Hopkins University, MD, USA) 
were cultured in Nunc™ EasYFlask™ Cell Culture Flasks (ThermoFisher) in RPMI-5. 
Cell cultures were  grown until ~70% confluence was reached. Adherent cells were 
harvested by incubation with TrypLE (Gibco) for 2 min at 37oC. Cells were then washed 
twice with RPMI to remove FCS before tumour challenge.  
 
 Tumour challenge 
Tumour cells were harvested as described in 2.7.1 or 2.7.2 and viable cell count 
performed. B16-OVA cells were resuspended in IMDM at a final concentration of 5x106 
cells/mL and TC-1 cells were resuspended in RPMI at a final concentration of 1x106 
cells/mL. Cells were filtered through a 70uM filter to remove cell aggregates. Each mouse 
was administered 100µL of the final suspension subcutaneously into the left flank. 
Tumours were measured and monitored over time until a maximal limit of 200mm2 was 
reached. Mice were culled by cervical dislocation or CO2 asphyxiation if mice showed 
any illness of reached the maximum tumour size. 
 
 Flow cytometry 
 
 Cell surface staining 
Cells were obtained from the protocols outlined in previous sections and aliquoted into a 
96-well plate. Cells were pelleted by centrifugation at 1000 x g for 2 min and the 
supernatant discarded. Prior to staining for flow cytometry, all human cells were pre-
treated with 50µL of FACS buffer containing 1% Human IgG (Privigen, PA, USA) for 5 
min at 4oC to block non-specific FcR-mediated antibody staining. For mouse cells, 50µL 
 41 
of FACS buffer containing 1% anti-CD16/32 Ab (24G2; prepared from hybridoma 
supernatant) was used. Cells were washed by pelleting the cells by centrifugation, 
resuspending in 200µL of FACS buffer, pelleting again and discarding the supernatant, 
all consequent wash steps were done this way. In some experiments, 1µL of the H-
2Kb/SIINFEKL Pro5™ MHC  Pentamer (ProImmune, , Oxford, UK) was added directly 
to the pellet, the plate vortexed vigorously and incubated for 10 min in the dark at room 
temperature. Without washing the cells, 50µL of PBS containing 1:1000 Zombie NIR™ 
was added to the cell pellet and incubated for 20 min in the dark at room temperature. 
Cells were washed once prior to addition of the cell surface antibody mix. Antibody mixes 
containing the appropriate cell surface markers were added to FACS buffer according to 
their pre-determined concentration then added to the cell pellet and incubated at 4oC for 
20 min. Cells were washed a twice then resuspended in 200µL of FACS buffer for flow 
cytometry. Flow cytometry was performed on the either the BD LSRII SORP (Becton 
Dickinson) or the Cytek Aurora (Cytek Biosciences; CA, USA) and data was analysed 
using FlowJo software (TreeStar; OR, USA). 
 
Table 1. List of mouse fluorescently labelled antibodies 
Target Fluorophore Clone Supplier Concentration 
CD3ε BV510 17A2 Biolegend 1:100 
CD4 APC-H7 GK1.5 BD Pharmigen 1:600 
CD8α BV421 52-6.7 Biolegend 1:1000 
CD11b BV650 M1/70 Biolegend 1:900 
CD11c PE-Cy7 HL3 BD Pharmigen 1:200 
CD25 PE/Dazzle™ 594 3C7 Biolegend 1:400 
CD40 FITC 3/23 Biolegend 1:200 
CD44 BV711 IM7 Biolegend 1:1000 
CD45.1 FITC A20 Biolegend 1:1000 
CD45.2 APC-Fire 750 104 Biolegend 1:600 
CD64 
 
Alexa Fluor 647 X54-5/7.1 Biolegend 1:200 
CD69 Super Bright 600 H1.2F3 eBioscience 1:300 
CD80 BV421 16-10A1 Biolegend 1:400 
CD86 APC R700 GL1 BD Biosciences 1:800 
CD170 (Siglec F) Alexa FluorTM 700 1RNM44N eBioscience 1:200 
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CD274 (PD-L1) PE-Dazzle™ 594 10F.9G2 Biolegend 1:600 
CD279 (PD1) PE-Cy7 RMP1.30 Biolegend 1:600 
CD317 (BST2) PE 927 Biolegend 1:1000 
CD326 (EpCAM) BV605 G8.8 Biolegend 1:1000 
Ly6C BV570 HK1.4 Biolegend 1:300 
Ly6G BV711 1A8 BD Biosciences 1:600 
MHCII eFluor 450 M5/114.15.2 Invitrogen 1:300 
NK1.1 BV650 PK136 Biolegend 1:600 
Siglec H PerCP-eFluor710 eBio440c eBioscience 1:200 
TCRβ APC H57-597 Biolegend 1:200 
Vα2 PE B20.1 eBioscience 1:1000 
XCR1 PerCP-Cy5.5 ZET Biolegend 1:200 
Zombie NIR™   Biolegend 1:1000 
CD1d-α-GalCer 
tetramer 
PE - NIH tetramer core 1µl per pellet 
MR1-5-OP-RU 
tetramer 
BV421 - NIH tetramer core 1:200 
H-2Kb-SIINFEKL 
pentamer 
PE - ProImmune 0.5µl per pellet 
 
Table 2 List of human fluorescently labelled antibodies 
Target Fluorophore Clone Supplier Concentration 
CD3 BV510 UCHT1 Biolegend 1:100 
CD19 APC-Cy7 HIB-19 Biolegend 1:100 
CD137 BV421 4B4-1 Biolegend 1:1000 
CD161 APC HP-3G10 Biolegend 1:100 
Vα7.2 PE-DazzleTM 594 3C10 Biolegend 1:100 
 
 Fluorescence-activated cell sorting 
Fluorescence-activated cell sorting (FACS) sorting was carried out on a Sony SH800S 
Cell Sorter to purify populations of MAIT cells from human PBMCs. Human PBMCs 
were purified according to the protocol in 2.9.1. To stain for MAIT cells, the antibodies 
Vα7.2 and CD161 were added directly to the cell pellet in a 50mL Falcon tube and 
incubated on ice for 20 min, mixing every 5 min to ensure even staining. Cells were 
washed then resuspended in FACS buffer at a final concentration of approximately 1x108 
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cells/mL Once sorted, cells were washed in RPMI-5 before cell culture as detailed in 
2.9.2. 
 
 VITAL assay 
In order to study the ability of a given vaccine to induce cytotoxic antigen-specific 
immune responses, the VITAL assay was used as previously described225. Briefly, 
spleens from C57Bl/6J mice were harvested and processed into a single cell suspension 
as described in 2.3.6. Cells were divided equally into four tubes. All cells were pelleted 
by centrifugation at 572 x g and supernatant was discarded. 
 
CellTrace™ CFSE labelled & SIINFEKL loaded cells 
Three of the tubes were resuspended in 2mL of muIMDM-5 containing SIINFEKL 
(OVA257-264) at one of the final concentrations: 50nM, 5nM or 0.5nM. All cells were 
allowed to incubate for 2 h at 37oC, vortexing the tubes every 30 min to ensure 
homogenous uptake of the SIINFEKL. Tubes were pelleted by centrifugation and washed 
in excess IMDM two times and once in PBS. The 50nM, 5nM and 0.5nM SIINFEKL 
loaded cells were resuspended in PBS containing 2.5µM, 0.5µM and 0.1µM of 
CellTrace™ carboxyfluorescein succinimidyl ester (CFSE; ThermoFisher), respectively. 
Cells were incubated at room temperature in the dark for exactly 7 min at which point 
10mL of FBS was added to each tube to quench any extracellular dye. Cells were washed 
twice in muIMDM-5 then once in IMDM before a cell viability count was performed. 
Each of the cell populations were resuspended in a final concentration of 3x107 cells/mL 
and kept on ice until further application. 
 
CellTracker™ Orange peptide-negative cells 
One tube of splenocytes was resuspended in pre-warmed muIMDM-5 containing a final 
concentration of 5µM chloro-methyl-benzoyl-aminotetramethyl-rhodamine 
(CellTracker™ Orange; ThermoFisher) and incubated at 37oC for 15 min. Cells were 
pelleted by centrifugation and resuspended in pre-warmed muIMDM-5 then incubated a 
further 20 min at 37oC. Cells were pelleted by centrifugation and washed twice in 
muIMDM-5 and once in IMDM. The labelled splenocytes were resuspended in a final 
concentration of 3x107 cells/mL and combined with each of the CFSE-labelled 
splenocytes at equal volumes. Cells were mixed well and 200µL of the final cell mix was 
injected i.v. into C57Bl/6J mice (6x106 cells of each population per mouse). 
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Peripheral white blood cells were collected from the mice via submandibular bleeding as 
described in 2.3.1.1, 18 h post i.v. injection. Populations of CTO and CFSE labelled cells 
were analysed by flow cytometry. To calculate the cytotoxicity of a given vaccine, a ratio 
was calculated between the total number of CFSE labelled (antigen-positive) cells and 
the total number of CTO labelled (antigen-negative cells). The CFSE/CTO ratio in treated 
mice was then normalized to that of naïve mice. Cytotoxicity was expressed as a 
percentage of specific lysis using the following equation: 
 
 % = 100 – ((“Treated mice ratio” / “Naïve mice ratio”) x100) 
 
 Human in vitro cell culture 
 
 Human ethics 
Human peripheral blood mononuclear cells (PBMCs) were obtained from healthy 
volunteers who have given written consent. This study was approved by the Otago 
University Ethics Committee reference number H15/114 and all experiments were 
performed with relevant guidelines and regulations. The research advisory group for 
Māori (RAG-M) was also consulted in consideration for potential Māori participants to 
ensure cultural requirements. The consent form, patient information sheet and RAG-M 
approval can be found in Appendix E. 
 
 Isolation of peripheral blood mononuclear cells 
Human PBMCs were obtained through density centrifugation (Lymphoprep; Axis-Shield, 
Oslo, Norway) of heparinised venous blood as follows. In a 50mL Falcon tube 35mL of 
blood was carefully layered onto 12mL of Lymphoprep. Cells were centrifuged at 800 x 
g for 20 min at room temperature with no brake. The mononuclear interphase located 
between the top plasma layer and above the Lymphoprep layer was collected with a 
Pasteur pipette into a new tube containing RPMI. Cells were pelleted by centrifugation 
then washed twice with RPMI prior to use. For applications beyond the day of collection 
PBMCS were pelleted and resuspended in a mix of 10% DMSO (Sigma-Aldrich, MO, 
USA) and 90% FCS (Gibco) at a final concentration of 2x107 cells/mL, and cryopreserved 
in liquid nitrogen until required. To assess activation of MAIT cells, PBMCs were thawed 
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by diluting in pre-warmed RPMI, cells were then pelleted by centrifugation and 
resuspended in huIMDM-5 medium.  
 
 Activation of human MAIT cells 
Human PBMCs were isolated as in 2.9.2 then cultured at 5x105 cells/well in a Nunc™ 
MicroWell™ 96-well microplate (ThermoFisher). The MAIT agonists were added at 
concentrations specified in the text. Where stated, some cultures were pre-incubated with 
1µM of Ac-6-FP (Cayman Chemical, MI, USA) for 2 h before adding the agonists. After 
18 h, cell cultures were analysed by flow cytometry to assess MAIT cell activation.  
 
 Generation and culture of THP-1 mutant cell lines 
The THP-1 mutant cell lines: THP-MR1, THP-GPI and THP-K43A were generated and 
kindly provided by Vincenzo Cerundolo (Oxford, UK). Briefly, to generate THP-1 
mutant cell lines the endogenous MR1 locus was first deleted in THP-1 cell lines by 
CRISPR-Cas as previously described226. These MR1 depleted THP-1 cells were 
transduced with lentiviral particles generated in 293T cells transfected with lentiviral 
vectors encoding for full length human MR1 (GenBank AJ249778.1), MR1 K43A227 or 
GPI-linked MR1228. THP-1 cell lines and variants were maintained in 6-well Nunc™ 
Cell-Culture plates (ThermoFisher) in RPMI-10. 
 
 MAIT cell agonist presentation 
Human MAIT cells were isolated by FACS according to the protocol in 2.8.2 on PBMCs 
isolated from buffy coats purchased from Oxford Blood Donor Centre (Oxford, UK). 
Cultures of purified human MAIT cells were maintained in 6-well plates for up to 30 days 
in RPMI-5 at 37oC with 5% CO2. To assess presentation, 2x104 MAIT cells were co-
cultured with 5x104 THP-1, THP-MR1, THP-GPI or THP-K43A in a 96-well plate at a 
final volume of 100µL combined. Where stated, increasing doses of Bafilomycin A1 
(Sigma-Aldrich) was added to cultures for 2 h prior to the addition of 100µL containing 
the indicated MAIT cell agonists. After 24 h, supernatants were harvested and assessed 
for IFN-γ production via enzyme-linked immunosorbent assay detailed in 2.9.5. 
 
 46 
 Enzyme-linked immunosorbent assay (ELISA) 
To assess IFNγ production from cell supernatants, enzyme-linked immunosorbent assay 
(ELISA) was performed as follows. To a 96-well ELISA Microplate (Greiner Bio-one, 
Austria) 25µL of ELISA coating buffer containing 0.4% anti- IFNγ capture antibody (BD 
biosciences) was added and incubated overnight at 4oC. The capture antibody was 
removed and the plate washed six times in ELISA wash buffer. The plate was then 
blocked with 25µL of PBS containing 10% FBS and incubated at room temperature for 
2 h to saturate non-specific binding sites. Blocking buffer was removed by flicking and 
titrating amounts of IFNγ standard (BD biosciences) were added in duplicate across the 
plate starting at 10ngml-1 final concentration in assay diluent (PBS + 10% FBS) and 
titrating down 2-fold each time until 10 titrations were made. Supernatant samples were 
added directly to the remaining wells and the plate was incubated overnight at 4oC. The 
plate was washed six times in ELISA wash buffer before the addition of assay diluent 
0.2% biotinylated anti-IFNγ detection antibody (BD biosciences) then allowed to 
incubate at room temperature for 2 h in the dark. The plate was washed eight times in 
ELISA wash buffer then assay diluent with 0.25% avidin-peroxidase (BD biosciences) 
was added to the plate and allowed to incubate at room temperature for 45 min in the dark. 
The plate was washed a final eight times with ELISA wash buffer before the addition of 
developing substrate containing 1mgmL-1 of O-Phenylenediamine Dihydrochloride 
(Sigma-Aldrich) and 0.4% H2O2. The ELISA plate was allowed to develop and then 
stopped by adding 2M H2SO4 when the top four standards became visible. Absorbance 
was read on a microplate reader at 450nm. 
 
 Serum cytokines 
 
Serum was collected at the indicated times within the text according to 2.3.1.2. Cytokines 
were measured in the serum using a Bio-Plex Pro™ Mouse Cytokine 23-plex Assay 
(BioRad Laboratories, CA, USA). To generate the Bio-Plex standard, 128µL of the 
reconstituted standard was mixed in a tube containing 72µL of Bio-Plex sample diluent 
by vortexing. To generate a 4-fold dilutions series, 50µL was taken from the stock tube 
and mixed in a new tube containing 150µL of sample diluent by vortexing. This process 
was repeated until a total of eight dilutions was reached. For a full 96-well plate, the 10x 
coupled beads were vortexed for 30 seconds then diluted to 1x in Bio-Plex assay buffer 
by taking 575µL of beads mixing with 5175µL of Bio-Plex assay buffer. The filter plate 
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was first prewet with 100µL Bio-Plex assay buffer then 50µL of well vortexed 1x beads 
was added to each well. The plate was washed two times by adding 100µL of Bio-Plex 
wash buffer before adding 50µL of standards or samples (diluted 1:4 with assay diluent) 
to each well. The plate was sealed and placed on shaking incubator at 850rpm for 30 min, 
protected from the light. After 20 min of incubation, the 10x detection antibody was 
vortexed vigorously then diluted to 1x by taking 300µL of detection antibody and diluting 
in 2700µL of detection antibody diluent. After the 30 min incubation, the plate was 
washed three times with 100µL of wash buffer before the addition of 25µL of 1x detection 
antibody to each well. The plate was sealed and placed on shaking incubator at 850rpm 
for 30 min, protected from the light. After 20 min of incubation the 100x SA-PE was 
vortexed briefly then diluted to 1x by taking 60µL of SA-PE and diluting in 5940µL of 
assay buffer. The plate was washed three times with 100µL of wash buffer before the 
addition of 50µL of the 1x SA-PE to each well. The plate was sealed and placed on 
shaking incubator at 850rpm for 30 min, protected from the light. The plate was washed 
three times with 100µL of wash buffer then the beads were resuspended in 125µL of 
assay buffer. The plate was sealed and placed on shaking incubator at 850rpm for 30 
seconds. To read the plate, the seal was removed and read on the Luminex 200 array 
reader (Merck Millipore, MA, USA) on low PMT, RP1 setting. Serum cytokine 
concentrations were determined by the in-built software (Bio-Plex manager – Luminex 
xPONENT) against commercial standards (Bio-Rad laboratories) and lower limit of 
detections were set according to the appropriate lot numbers. 
 
 Statistical analysis 
 
For biological studies, statistical analysis was performed on GraphPad Prism version 
8.1.1 software (CA, USA). When comparing two groups a t-test was performed. When 
comparing multiple samples greater than two, a one-way ANOVA with a Tukey’s 
multiple comparisons test was carried out where P<0.05 was considered significant. 
When using two parameters with multiple groups, two-way ANOVA with a Tukey’s 
multiple comparisons test was used where P<0.05 was considered significant. 
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Chapter 3:  The chemical synthesis, stability and 
activity of MAIT cell prodrug agonists that access 





The MAIT cell activatory ligands 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-
OP-RU), 5-(2-oxoethylideneamino)-6-D-ribitylaminouracil (5-OP-RE) and 5-(methyl-2-
oxopropylideneamino)-6-D-ribitylaminouracil (5-MOP-RU), are pyrimidines formed 
endogenously, via the non-enzymatic condensation of α-dicarbonyl glycolysis products 
with the riboflavin precursor 5-amino-6-D-ribitylaminouracil (5-A-RU, structure shown 
in Fig 3.1, and labelled “1”)185. Within the endoplasmic reticulum, these carbonyl species 
form a covalent Schiff base with lysine 43 (K43) within the A’ pocket of MR1, stabilising 
the MR1-antigen complex and triggering the trafficking to the plasma membrane for 
presentation to MAIT cells205. After cell surface expression, MR1 is internalised and, like 
other MHC-I molecules, is either targeted for degradation or may enter the recycling 
pathway where antigen exchange may occur with endosomal MAIT antigens such as 
those derived from endocytosed bacteria205,213.  
 
Unfortunately, research into MAIT cell immunology can be confounded by the instability 
of the most commonly prepared agonists 5-OP-RU, 5-OE-RU and 5-MOP-RU. In 
aqueous solution at 15oC, 5-OP-RU has a half-life of 14 h (pH 6.8), 5-OE-RU 18 min and 
5-MOP-RU 14 h both at pH 8204,229. For biological studies, 5-OP-RU is most commonly 
used and is typically prepared in situ by the addition of an excess of MG to 5-amino-6-
ribitylamino uracil (5-A-RU, 1) immediately prior to use. However, formation of 5-OP-
RU (and other analogues) have been shown to rapidly cyclise into lumazines rendering 
them dramatically less potent due to their inability to bind to MR1 efficiently229. In vitro 
studies have demonstrated that 5-A-RU itself can activate MAIT cells within human 
PBMCs even without added glyoxal or MG (albeit, less efficiently than 5-OP-RU)204. 
This suggests that eukaryotic cells may provide a sufficient concentration of endogenous 
aldehyde metabolites that condense with 5-A-RU to provide a functional MR1 ligand. 
This indicates that 5-A-RU could be used without prior addition with MG in order to 
study the effects of MAIT cell activation both in vitro and in vivo.  This approach would 
bypass the need for the prior synthesis of 5-OP-RU, which is subject to cyclisation to 
lumazines. However, as has been noted anecdotally by various groups230,231, 5-A-RU is 
itself rather unstable.  
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In this chapter, the stability of 5-A-RU was definitively characterised, including 
assessment of ability to drive MAIT cell activation, following its exposure to storage 
conditions that would typically be used in biological studies. It was then investigated 
whether stabilisation could be achieved by modification of the 5-amino group with a 
cathepsin-cleavable valine-citrulline-p-aminobenzyl carbamate (VC-PAB). This well-
established chemical modification232,233 would not only allow stabilisation of the labile 
parent molecule, but also enforce an additional processing step to release the 5-A-RU 
structure, which would only occur in the presence of the proteolytic activity of cathepsins, 
found in high concentrations within APCs234,235. It was hypothesised that this step may, 
in turn, enhance localization of 5-A-RU with MR1, and therefore improve MAIT cell 
activation. Overall, the intention was that this chemical modification would lead to the 
development of stable and potent MAIT agonist precursors that would improve the 





A significant challenge in MAIT cell research is that both the agonist 5-OP-RU, and the 
MAIT agonist precursor, 5-A-RU, are chemically unstable. At the outset of the studies 
described below, it was speculated that 5-A-RU was labile to auto-oxidation, which may 
lead to loss in biological activity. Therefore, the overall aim of this chapter was to 
establish the extent and nature of the instability of 5-A-RU and then to develop a prodrug 
form of 5-A-RU to overcome stability issues. It was anticipated that, when combined with 
cells in vitro or in vivo, sufficient MG would be available intracellularly to permit 
condensation to form the MAIT cell agonist 5-OP-RU. Given that such a prodrug would 
require enzymatic processing, it was also anticipated that the route to the presentation of 
5-A-RU on MR1 might be altered. This possibility was also investigated.  
 
Specific aims covered: 
• Assessment of auto-oxidation of 5-A-RU generated by two synthesis methods, 
infer decomposition products and determine their capacity to activate MAIT cells 
in vitro. 
• Generation of stable 5-A-RU prodrugs and comparison of activatory potential 
versus native 5-A-RU in vitro and in vivo. 
• Determination of the mode of presentation of the prodrug versus 5-A-RU using 
antigen-presenting cells that have been genetically modified to alter distribution 





 Instability of 5-A-RU 
It has been reported that 5-A-RU is unstable, decomposing to a “multitude of products”236. 
To investigate this formally, 5-A-RU was prepared for stability studies. To achieve this, 
5-A-RU (Fig 3.1, labelled “1”) was prepared by palladium (Pd)-catalysed hydrogenolysis 
of 5-nitrosouracil 2. Preparations of 5-A-RU usually are highly concentrated and require 
dilution in PBS or water for biological application. Thus, to mimic conditions in which 
5-A-RU would be used for experiments, a freshly prepared batch was diluted in water 
and gently agitated while exposed to air at room temperature at various lengths of time in 
order to generate any natural degradation species. To characterise the products of this 
aeration, liquid chromatography mass spectrometry (LCMS) was performed by Dr Regan 
J. Anderson (Ferrier Research Institute). All chemical synthesis and chemical 
characterisation studies were performed by R.J.A and will be specified accordingly within. 
Methodology for the chemical analysis of the compounds in this chapter can be found in 
Appendix F. 
 
During this process, the various reaction mixtures were eluted through a reverse-phase 
silica column, separating chemical species based on their charge, which alters the time of 
elution. These products were then viewed as separate species on a chromatogram based 
on the time of elution from the column. Once separated, these chemical species were 
identified through mass spectrometry. Through this process, each elution peak was 
identified based on their mass (m) and charge (z) to give a mass to charge ratio (m/z) 
which infers directly to its molecular weight. 
 
LCMS analysis (with care to avoid air exposure) showed one major peak, corresponding 
to 5-A-RU (Fig 3.2a, peak a, m/z: 277 = M+H). Exposure of this dilute sample (0.1 
mg/mL) to air for 8 min led to the disappearance of this peak over 40 min, with the 
concomitant appearance of two new peaks b (m/z: 275) and c (m/z: 294). Peak b was 
short-lived, while peak c diminished more slowly and after one day was replaced by a 
new peak d with the same mass (m/z: 294). These results suggest the degradation of 5-A-
RU proceeds with loss of dihydrogen to generate azaquinone species 3 (Fig 3.2b), 
corresponding to peak b. Hydrolysis gives intermediate 4 (not observed) which exists as 
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its hydrate 5 (peak c). A slow attack of water leads to the rearranged end-product 6 (peak 
d), analogous to the reported rearrangement of alloxan to alloxanic acid237 
 
As an alternative synthetic route, generation of 5-A-RU reported for use within biological 
studies has been accomplished by sodium dithionite reduction of nitrosouracil 2.185 When 
a fresh sample of 5-A-RU prepared in this manner was briefly exposed to air, the 
formation of two earlier-eluting peaks was observed (Fig 3.3a, peaks e and f). As shown 
in Fig 3.3b, an initial dehydrogenation step was proposed to produce azaquinone 3, which 
is rapidly attacked by sulfite (present as a by-product of dithionite oxidation) to give 7. 
Sulfonate 7 may rearrange to give 8 and/or 9 which regenerates the uracil core in its 
original oxidation state.  
 
To determine the potential of any downstream decomposition products to activate MAIT 
cells, the 5-A-RU preparations (from either method) were exposed to and allowed to stand 
for 5 h. In the case of the Pd-catalysed hydrogenolysis reaction product, samples were 
aged for either 5 h or 29 h, to give solutions enriched in peak c and peak d, respectively 
(Fig 3.2). These aged samples, together with fresh 5-A-RU samples prepared by both 
methods, were then assessed in vitro for their ability to activate MAIT cells in cultures of 
PBMCs. MAIT cells are highly represented in human PBMCs, and therefore easily 
identifiable by flow cytometry. Following exclusion of dead cells and B cells (the latter 
based on expression of CD19), MAIT cells were gated based on expression of their 
invariant TCRα variable fragment arrangement, Vα7.2, and high expression of the C-type 
lectin receptor CD161. During activation, T cells downregulate their TCR in response to 
interaction with their respective ligands. This process is typically followed by 
upregulation of 4-1BB (CD137), a member of the TNF receptor superfamily. It was 
therefore possible to assess MAIT cell activation using flow cytometry and a gating 
strategy that allowed for downregulation of the TCR, and then determining the percentage 
of CD137+ MAIT cells in the cultures (Fig 3.4a). Upon stimulation of PBMC cultures 
with freshly prepared 5-A-RU for 18 h, MAIT cells readily down regulated their TCR 
and upregulated CD137. Indeed, 5-A-RU prepared by either method activated MAIT cells 
in a dose dependent manner to a similar degree (Fig 3.4b, c). This confirms previous 
findings227 that in the absence of exogenously added MG the intracellular concentration 
of dicarbonyls is sufficiently high to react with 5-A-RU to generate MR1 binding ligands 
such as 5-OP-RU or 5-OP-RE. Weak MAIT cell activation was observed for the aged 5-
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A-RU sample obtained from dithionite reduction (Fig 3.4b), while neither of the samples 
obtained from the hydrogenolysis reaction activated MAIT cells (Fig 3.4c). Combined 
with the observation that 5-A-RU is similarly active when carefully prepared by either 
method, this effectively rules out the downstream oxidised products 3 - 9 as contributors 





                      





Figure 3.2. Auto-oxidation of 5-A-RU prepared by Pd/H2 catalysis. (a) LCMS 
analysis (254 nm) of 5-A-RU (1) freshly prepared using Pd/H2 (top trace), and 5-A-RU 
exposed to air (8 min) by gentle agitation followed by standing for the indicated times 
(see supporting information for details); B. Inferred oxidative decomposition of 5-A-RU 
(1) in dilute aqueous solution. Other tautomeric forms may be considered. Experiment 




Figure 3.3 Auto-oxidation of 5-A-RU prepared by sodium dithionite reduction. (a) 
LCMS analysis (254 nm) of 5-A-RU (1) freshly prepared using sodium dithionite (top 
trace), and dithionite-produced 5-A-RU exposed to air (3 min) followed by standing for 
the indicated times.(b) Inferred oxidative decomposition of 5-A-RU (1) in aqueous 




Figure 3.4. Oxidized 5-A-RU preparations fail to activate MAIT cells. (a) Gating 
strategy for MAIT cells, defined as CD19- CD161hi Vα7.2+ cells, depicting TCR 
downregulation during activation with 5-A-RU. Human PBMCs from a single donor were 
incubated for 18 h with titrating amounts of the indicated 5-A-RU preparations (1x106 
cells per preparation). (b) 5-A-RU was prepared from the reduction of nitrosouracil 2 with 
sodium dithionite; 5-A-RU-ox was prepared by the same method but aerated for 5 h (c) 
5-A-RU was prepared from the reduction of nitrosouracil 2 by Pd-catalysed 
hydrogenolysis; 5-A-RU-ox1 and -ox2 were prepared by the same method but aerated for 
5 h and 19 h, respectively. Activation of MAIT cells is depicted as percentage of MAIT 
cells positive for CD137 at the end of the culture period. Data representative of two 
separate experiments. 
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 Synthesis of 5-A-RU prodrugs 
The propensity of 5-A-RU to autoxidation necessitated careful handling and storage for 
biological studies. Even with such precautions, degradation could not be avoided in our 
experience, especially in dilute solutions in which oxygen diffusion is a more significant 
issue. Additionally, in vivo, dissolved oxygen in blood or tissues may lead to significant 
losses in potency. Therefore, the ability to generate a stable MAIT cell agonist without 
specialist chemistry skills would be a welcome advance and potentially facilitate more 
consistent results. The uracil core of 5-A-RU is electron-rich, contributed partly by the 5-
amino group, making it labile to attack by electrophilic oxygen molecules, leading to 
oxidation. It was posited that generation of a prodrug by modification of the 5-amino 
group with a (cleavable) electron-withdrawing group would temper the electron-rich 
uracil core, stabilising 5-A-RU against oxidation. Upon enzymatic cleavage of the 
prodrug, 5-A-RU may be released intracellularly. Here, 5-A-RU could combine with 
endogenous dicarbonyls (that are present as metabolic products in higher concentrations 
inside cells) to provide a functional MR1 ligand with agonism for MAIT cells. 
 
Synthesis of compound 10 was, therefore, the primary focus to test this hypothesis (Fig 
3.5). The VC-PAB linker present in 10 is widely used as a cleavable linker in antibody-
drug conjugates232. Cleavage by cathepsin B at the citrulline carboxyl side, gives an 
aniline intermediate which spontaneously collapses with loss of CO2 to release the drug-
amine (in this case, 5-A-RU)233. Cathepsins and other proteases are highly expressed in 
APCs and are key enzymes involved in protein degradation as well as processing long 
antigenic peptides into oligomeric fragments to be loaded onto MHC molecules234,235. In 
this way, chemical conjugation of 5-A-RU to a VC-PAB linker should mediate the release 
of 5-A-RU preferentially within APCs, and also potentially protect the reactive 5-amino 
group of 5-A-RU until it is in close proximity to MR1 molecules. To investigate the 
importance of cathepsin-mediated cleavage of the linker in 10, a stereoisomer was also 
prepared, which contains D-citrulline at the cleavage position (compound 11). The use of 
the stereoisomer would act as a retardant against cleavage by cathepsin by disallowing 
enzymatic access. Thus, evaluation of the capacity of compound 11 to stimulate MAIT 
cells would test whether release of 5-A-RU was indeed mediated by cathepsin cleavage 
at the VC sequence. A third prodrug was developed as a simple carbamate derivative, 12 
(Fig 3.5). This analogue lacks any cleavage site for cathepsin and simply acts as a 
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stabilising terminal group, which was assessed to again emphasise the importance of an 
intact and accessible VC sequence.  
 
To examine the stability of these modified 5-A-RU-derivatives, aqueous solutions of 12 
and 10 were exposed to air and agitated on a mechanical shaker at ambient temperature 
for 24 h. The samples were subsequently analysed by LCMS at various time points. As 
shown in Fig 3.6, minimal degradation was observed in both samples over 21 d, 
demonstrating that, even with deliberate over-exposure to air, these modified 5-A-RU-
derivatives were much more stable than the parent molecule, and that no special care in 
handling these compounds is required.   
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Figure 3.5. Chemical structure of 5-A-RU prodrugs. 
 
 






T = 7 d 
T = 1 d  
T = 21 d 
T = 0 
min 
a b 
Figure 3.6. Stability of 5-A-RU prodrugs. Stability as determined by LCMS of (a) 12 
in water, and (b) 10 in 1:4 DMSO:water at room temperature, including 24 h exposure 
to air. Experiment performed by R.J.A. 
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 5-A-RU prodrugs can activate human MAIT cells.  
To compare the ability of 5-A-RU and its prodrugs to activate MAIT cells, the compounds 
were diluted in PBS with or without MG. In the case of 5-A-RU itself, it was anticipated 
that this would allow condensation to 5-OP-RU before incubation with human PBMCs 
(although, as noted in the introduction, this is not a practical process to give reproducible 
biological results, due the instability issues described here). With the prodrug design, it 
was anticipated that preincubation with MG was unnecessary, as MG would be supplied 
intracellularly. Significantly, prodrug 10 started activating MAIT cells at ~10-fold lower 
doses than 5-A-RU without MG (Fig 3.7a), highlighting the increased potency of the 
stabilised MAIT agonist precursor. As expected, the presence of MG did not alter the 
activity of 10 confirming the protection of the 5-amino group prior to intracellular 
cleavage of the linker. After preincubation with exogenous MG, 5-A-RU was expected 
to be converted to 5-OP-RU, which in turn was more potent than 10, perhaps suggesting 
that supply of intracellular dicarbonyls ultimately limited the activity of 10. Compounds 
11 and 12 were assessed similarly alongside 10. The simple carbamate 12, lacking a 
cleavage sequence, did not show any activity, even at the highest concentration examined 
(Fig 3.7b). As the carbamate structures in 12 and 10 are electronically and sterically 
similar, these results suggest that enzymatic cleavage is important in releasing an active 
agonist (in the case of 10). This was further supported by the observation that replacing 
L-citrulline with D-citrulline in the cathepsin cleavage site (compound 11) resulted in 
much reduced activity. It is likely that the weak activity observed for this epimer was due 
to residual natural L,L-isomer (i.e., 10) contaminating the material (~0.6% as determined 
by HPLC analysis, data not shown). 
 
Although a range of proteases are found in the late endosomes and lysosomes and could 
be involved in processing of the Val-Cit dipeptide linkers, cathepsin B is believed to play 
the most prominent role233. Therefore, in vitro susceptibility to cathepsin B cleavage may 
serve as an indicator of a prodrug or conjugate’s in vivo propensity to cleavage. Prodrugs 
10 and 11 were incubated with human liver cathepsin B and progression of cleavage was 
followed by LCMS. After 4 h, around 75% of 10 had been consumed while in the same 
time frame 11 remained intact (Fig 3.8). No cleavage of 10 was observed in the absence 
of enzyme (data not shown). These results corroborate those from the MAIT cell 
activation experiments and together point to the importance of cathepsin B or functionally 







Figure 3.7 Activation of human MAIT cells with 5-A-RU prodrugs. Human PBMCs 
were incubated for 18 h with different concentrations of the indicated compounds, and 
then the percentage of activated MAIT cells in the cultures determined by flow cytometry. 
(a) 5-A-RU, 5-A-RU + MG, 10 or 10 + MG; (b) 5-A-RU carbamate derivatives 10, 11 
and 12. Activation of MAIT cells is depicted as percentage of MAIT cells positive for 
CD137 at the end of the culture period combined from three separate donors. MAIT cells 
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Figure 3.8. Cathepsin mediated cleavage of 5-A-RU prodrugs. LCMS analysis of in 
vitro cathepsin B-mediated cleavage of (A) 10, and (B) 11. Samples were incubated at 
37 °C with or without cathepsin B and analysed after 30 min and 4 h. Detection is by MS 
[combined extracted ion chromatograms for prodrug, expected cleavage product and 
internal standard (IS)]. Experiment performed by R.J.A. 
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 5-A-RU prodrugs access the recycling endosome 
Similar to MHC class Ia molecules, MR1 is predominantly loaded with soluble antigens 
within the ER. However, after presentation on the cell surface, MR1 is internalised, and 
a proportion of molecules are able to sample and exchange antigens within the recycling 
endosome205,214. Interestingly, it has been shown that MAIT cell activation by 
mycobacterial supernatant containing soluble MAIT antigens could be blocked by pre-
saturation with the soluble MR1 antagonist, acetyl-6-formylpterin (Ac-6-FP), whereas 
stimulation with whole mycobacteria was not affected by blocking with Ac-6-FP205. This 
suggests separate loading compartments, with MAIT antigens derived from intracellular 
infection potentially entering a distinct pathway that does not involve the ER, and may 
therefore require access to MR1 in recycling endosomes that fuse with the incoming 
phagocytic vesicle.  
 
As the 5-A-RU prodrug 10 requires protease cleavage before the release of 5-A-RU, and 
these enzymes are rich in endolysosomal compartments, it was possible that the 5-A-RU 
released from 10 can similarly access MR1 molecules from the recycling pathway. To 
test this hypothesis, PBMCs were pre-incubated with Ac-6-FP prior to incubation with 5-
A-RU or 10. As expected, activation of MAIT cells with 5-A-RU was inhibited by Ac-6-
FP, indicating presentation of 5-A-RU was effectively blocked. In contrast, the 
presentation of MAIT cells agonists from the processing of 10 was largely unaffected, 
suggesting that loading of the released ligand onto MR1 occurs predominantly in a 
different compartment (Fig 3.9a). To test the requirement of acidified compartments such 
as recycling endosomes in the release of 5-A-RU molecules from 10, cells from the 
immortalised monocyte-like cell line, THP-1, were incubated with bafilomycin A1, an 
inhibitor of the vacuolar ATPases required to lower the pH, before being exposed to 5-
A-RU or 10 and then incubated with human MAIT cells. To increase the sensitivity of 
the assay, MAIT cells were purified from PBMCs by fluorescence-activated cell sorting 
(FACS) before analysis was conducted. The readout of activity was release of IFN-γ into 
the supernatant once MAIT cells were stimulated, which was determined by enzyme-
linked immunosorbent assay (ELISA). As hypothesised, inhibition of endosomal 
acidification with bafilomycin abrogated MAIT cell activation by 10, but not 5-A-RU. In 
fact, bafilomycin A1 actually increased presentation of 5-A-RU, an outcome that has been 
previously reported238 (Figure 3.9b).  
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To examine presentation of 10 further, studies were conducted with MR1-KO THP-1 
cells226 that were then modified to overexpress either full-length MR1, or MR1 with a 
glycosylphosphatidylinositol (GPI) linker that covalently links it to the outer leaflet of 
the plasma membrane to prevent internalisation into recycling endosomes. While the 
presence of the GPI anchor did not affect the ability of 5-A-RU to be presented to purified 
human MAIT cells (again as defined by IFN-γ release), the presentation from 10 was 
substantially reduced (Fig 3.9c and d). It is therefore highly likely that MR1-loading from 
the prodrug occurs through access to MR1 in recycling endosomes. In addition, the 
agonist released from 10 required bonding to a K43 on MR1, located within the binding 
groove of MR1, which is typical of the known derivatives of 5-A-RU, as no MAIT cell 
activation could be induced when incubated with THP-1 cells overexpressing MR1 with 








Figure 3.9. 5-A-RU prodrug is processed and presented via the recycling endosome. 
(a) Human PBMCs were incubated with Ac-6-FP or media for 2 h prior to addition of 5-
A-RU or compound 10. Cells were incubated for 18 h and MAIT cell activation was 
assessed via flow cytometry. (b) The modified THP-1 cells were pre-incubated with 
increasing amounts of bafilomycin A1 for 2 h, 5-A-RU or 10 was added and then cultured 
for a further 18 h before co-culture with human MAIT cells. Supernatant was taken after 
24 h and IFNγ was measured. Data representative of two separate experiments. (c) 
Purified human MAIT cells were incubated with either THP-MR1, THP-GPI or THP-
K43A cell lines loaded with titrating amounts of 5-A-RU or 10. After 24 h, IFNγ 
production by MAIT cells was measured in the supernatant. Data representative of three 
separate experiments. (d) Combined data from three separate human donor MAIT cells 
co-cultured with THP-MR1 or THP-MR1 cells lines incubated with equivalent 5-A-RU 
or 10. Activation of MAIT cells for (a) is depicted as percentage of MAIT cells positive 
for CD137 at the end of the culture period. MAIT cells were identified as CD19-
CD3+Vα7.2+CD161hi cells. Graphs are depicted with the mean ± SEM. Statistical 




 5-A-RU prodrug activates MAIT cells in vivo 
To determine whether prodrug 10 could activate MAIT cells in vivo, and perhaps show a 
benefit over 5-A-RU, studies were conducted in mice, which as noted in the Introduction, 
harbour MAIT cells with similar TCR structures, although cell numbers are reduced 
compared to humans. The compounds were administered intravenously, and assessment 
of MAIT cell activation was conducted in lungs, where measurable populations of MAIT 
cells are known to exist23. After 18 h, activation of MAIT cells in the lungs of mice was 
assessed by flow cytometry using fluorescent 5-OP-RU-loaded MR1 tetramers and 
expression of the TCR β chain to identify the MAIT cell population (Appendix B). As 
shown (Fig 3.10), both 5-A-RU and 10 were capable of activating MAIT cells at a high 
dose (180 nmol) as indicated by expression of the early activation marker CD69, and the 
IL-2 receptor CD25. However, at a lower dose of 5 nmol, 5-A-RU did not induce any 
obvious activation of MAIT cells, while, compared to untreated controls, prodrug 10 
increased expression of these activation markers, indicative of in vivo activation. Thus, 
not only does the prodrug have the advantage of being significantly more stable than 5-





Figure 3.10. 5-A-RU prodrug induces activation of murine MAIT cells in vivo. Mice 
(n=5) were administered intravenously PBS, 180 nmol (high dose) or 5nmol (low dose) 
5-A-RU or 10. After 18 h, lungs were harvested and stained for flow cytometry. MAIT 
cells were defined as CD45+B220-CD11b- and 5-OP-RU tetramer+. Median fluorescence 
index (MFI) was calculated for the markers CD69 and CD25 on MAIT cells. Graphs are 
depicted with the mean ± SEM. Statistical significance was determined by a One-Way 




The instability of the MAIT cell agonist precursor, 5-A-RU, has been reported 
anecdotally previously230,231, but no formal stability study had been published at the outset 
of this study. Given that this material is used many biological studies, it was necessary to 
characterise the extent and nature of degradation when exposed to oxygen, which could 
occur in the storage solutions used by many researchers. In this chapter, it was shown 
that, indeed, when 5-A-RU was diluted in aqueous solutions, it was immediately 
susceptible to oxidation. Auto-oxidation was apparent in 5-A-RU samples derived from 
synthesis via both sodium dithionite reduction or Pd/H2 hydrogenolysis of nitrouracil, 
with the appearance of alternative eluting peaks seen by LCMS as early as a few minutes. 
This instability was perhaps unsurprising since the lone pair of electrons located on the 
5-amino nitrogen make it particularly susceptible to electrophilic attack. This chapter 
provides the first theoretical schematic of the species formed after 5-A-RU  is exposed to 
air. Oxidation of the uracil ring at the 5-amino position followed by deamination (Fig 
3.2b) or N-sulfation (Fig 3.3b) is of particular importance as this amine is the site of 
condensation with dicarbonyls which converts 5-A-RU into 5-OP/OE/MOP-RU. The 
newly formed formyl group at this position is responsible in the formation of a Schiff 
base with the K43 residue on MR1, inducing conformational stabilisation, translocation 
to the cell surface and consequently TCR-mediated activation of MAIT cells204. 
Therefore, oxidation of the parent molecule 5-A-RU at the 5-amino position would 
obstruct dicarbonyl condensation and thus preclude bond formation with K43 on MR1, 
impeding MAIT cell activation. These results emphasise the limitations of using 5-A-RU 
in biological studies or drug development, with the high susceptibility to oxidation likely 
to pose a significant problem with respect to the reproducibility of experimental 
procedures or treatments.  
 
To address this problem, the instability of 5-A-RU was overcome by the synthesis of a 
stable prodrug that can be cleaved intracellularly to provide active MAIT cell agonist 
precursor(s). Importantly, when added to cultures containing MAIT cells, prodrug 10 
induced MAIT cell activation at lower doses than 5-A-RU alone, emphasising the 
increased potency of the stabilised MAIT agonist precursor. While this may be explained 
to some extent by the enhanced stability, it is also possible that the altered mode of 
presentation of the prodrug is a contributing factor. Unlike 5-A-RU, prodrug 10 was still 
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able to induce MAIT cell activation in the presence of Ac-6-FP, which blocks 5-A-RU 
mediated activation and therefore suggests an alternative loading mechanism. However, 
the capacity of prodrug 10 to stimulate MAIT cell activity was blocked by inhibiting 
acidification of endosomes with bafilomycin A1, presumably because cathepsins within 
these vesicles require low pH to drive enzymatic cleavage at the VC sequence in the 
prodrug linker. Previous studies have highlighted the importance of acidified endosomes 
in the presentation of MAIT cell antigens, specifically those derived from whole bacteria. 
In vitro studies show reduced activation of MAIT cells when they were co-incubated with 
Escherichia coli-loaded bone marrow-derived DCs that had been treated with 
chloroquine, another inhibitor of endosomal acidification199. Similarly, another study 
showed that THP-1 cells loaded with whole bacteria, but not bacterial supernatant, had 
reduced capacity to activate MAIT cells when treated with bafilomycin A1238. It is 
unknown yet if agonists from the bacteria are loaded onto endosomal MR1 molecules, or 
if the localisation of bacteria within these compartments provides a highly concentrated 
pool of agonists that then traffic to the ER for presentation. Interestingly, 5-A-RU actually 
induced higher levels of MAIT cell activity in the presence of increasing bafilomycin A1 
dose. One explanation for this is that 5-A-RU is becoming sequestered and trapped within 
lysosomes inhibiting access to MR1 molecules and thus lowering MAIT cell activation. 
Therefore, when lysosomal acidification is neutralized by bafilomycin, 5-A-RU may be 
released back into the cytosol in order to access MR1. As 5-A-RU contains a weak amine 
group, it is possible that it exhibits some degree of tropism for lysosomes. In this manner, 
the net neutrality and low molecular weight of 5-A-RU would support passive diffusion 
down its concentration gradient through the lipid bilayer of lysosomes. The free amine 
base on 5-A-RU would then become protonated due to the low pH of the endosome. This 
protonation creates a concentration gradient where the levels of native 5-A-RU within the 
cytosol now exceeds 5-A-RU within the lysosome therefore driving the accumulation of 
more 5-A-RU into the lysosome by diffusion in a process known as pH partitioning239.  
Protonation of the 5-amino group would also result in electrostatic repulsion of 5-A-RU 
molecules from the hydrophobic lipid bilayer; thus, inhibiting translocation out of the 
lysosome towards ER-localised MR1. Bafilomycin is an inhibitor of V-ATPases. 
Therefore, incubation with cells would result in increased pH levels within the lysosomal 
compartment. This neutralisation would then facilitate escape and lead to the increased 
availability of 5-A-RU and therefore increased levels of MAIT cell activation. As an 
additional explanation, 5-OP-RU molecules have been reported to have substantially 
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lower half-life at lower pHs going from 12 h at pH 6.8 to 44 min at pH 5.4229. Matured 
endosomes typically reach a pH of ~5. Therefore, neutralisation of endosomes may 
simply promote stabilisation of 5-A-RU once it has condensed with dicarbonyls. 
 
While the experiments with bafilomycin A1 shows the requirement of acidified 
endosomes for the presentation of MAIT ligands derived from the prodrug, bafilomycin 
A1 is known to have some additional effects on cells at high concentrations such as cell 
cycle arrest and Bax-dependent apoptosis240,241. Therefore, the use of THP-1 cells that 
express MR1 with a GPI anchor allowed for the direct assessment on the presentation of 
prodrug 10 vs 5-A-RU when MR1 could not internalise into recycling endosomes without 
affecting other cellular processes. Indeed, the presentation of agonists derived from 
prodrug 10 was drastically inhibited in THP-GPI cells compared to THP-MR1, whereas 
5-A-RU was not. This study, therefore, provides definitive evidence that MAIT agonists 
can indeed be loaded onto recycling MR1 molecules which occurs after internalisation of 
MR1 from the cell surface, and that by using a prodrug, this can be encouraged to take 
place in the absence of the requirement for the uptake of cellular bacterial material. It 
remains to be established whether presentation via MR1 in recycling endosomal 
molecules, as opposed to the ER (the predominant route for 5-A-RU and 5-OP-RU), leads 
to qualitatively different MAIT cell responses. A simple prodrug like 10 could be used to 
investigate this possibility further. The fact that 10 would be presented without additional 
bacteria-derived signals, such as TLR agonists, would enable the MR1-antigen 
presentation axis to be studied in isolation.  
 
The overarching aim of this thesis, developed more in later chapters, was to determine 
the ability of MAIT cells to adjuvant T cell responses through ‘helper’ signals such as 
those able to be provided by CD4+ T and NKT cells. Before initiating the studies 
presented here, in vitro experiments conducted by our colleagues had shown that once 
activated in the presence of 5-A-RU, human MAIT cells can mature APCs in an MR1 
and CD40L dependent manner29. This important observation suggests that MAIT cells 
can potentially control adaptive responses. The studies presented in this chapter indicate 
that in vivo analyses to explore this further might proceed more efficiently with a 
stabilized compound. However, prodrug 10 did not activate MAIT cells to the same 
magnitude as 5-A-RU that had been reacted with exogenous MG to form 5-OP-RU prior 
to incubation. The utility of the prodrug may, therefore, be limited by the availability of 
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MG (or other relevant dicarbonyl compounds) to form relevant agonists. Whether this 
difference in activation will be mirrored in the ability of prodrug 10 to induce MAIT-
dependent activation of DCs compared to 5-A-RU + MG will be explored in the next 
chapter.   
 
A significant advantage of the prodrug design is that it could allow for further chemical 
modifications. In light of our experience in designing improved vaccines through ligation 
of antigenic peptides to immune adjuvants, such as to the NKT cell agonists α-
GalCer242,243, one possibility was to ligate peptides that will be released with 5-A-RU 
within the same APC upon cleavage by intracellular cathepsins. This is explored in the 
next chapter. Other possibilities, not explored in this thesis, include conjugation to TLR 
agonists or antibodies to target specific cell subtypes; each is described briefly below. 
 
TLR-signalling has been shown to be an important auxiliary signal in both MR1 
presentation and MAIT cell activation.  Co-culture with the TLR9 agonist, CpG, induced 
the upregulation of MR1 on B cells244,245. In another study, conducted in vivo, intranasal 
administration of the TLR2 agonist Pam2Cys with 5-OP-RU induces enhanced expansion 
of MAIT cells in the lung and results in enhanced protection against pulmonary infection 
of mice with Legionella longbeachae246,247. These studies provide grounds to conjugate 
5-A-RU with TLR agonists, as co-localising these molecules within the same APC (with 
subsequent cleavage) could subsequently boost MAIT cell activation. One limitation of 
this approach is the localisation of many TLR agonists on the cell surface, namely 
TLR1/2, TLR3, TLR4, TLR5 and TLR62,3. A 5-A-RU TLR conjugate, as demonstrated 
in this chapter, would require intracellular processing to release both molecules. 
Therefore, the released TLR agonist would fail to interact with its receptor located on the 
cell surface. In contrast,  TLR7/8 or TLR9 which recognise microbial nucleic acid motifs, 
are internally expressed, therefore agonists for these receptors would be a viable option 
for conjugation with 5-A-RU. 
  
Adding a targeting motif to a prodrug form of 5-A-RU could also allow for selective 
targeting of 5-A-RU to specific cell subtypes. This approach has been successful in 
targeting antigens to cells expressing Clec9A, where conjugation of Clec9A-specific 
antibodies with weakly immunogenic influenza or enterovirus antigens resulted in 
trafficking of the antigens to Clec9A+ DCs (cDC1 cells). As these cells have enhanced 
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capacity for cross-presentation, this led to induction of improved CD8+ T cell responses 
and was also shown to improve antibody affinity and titers248. In a similar approach, 5-
A-RU prodrugs could be conjugated to targeting antibodies towards specific APC 
subsets. In this way, interactions with MAIT cells between specific APC subsets could 
be studied in vivo, such as their ability to modulate their activation state through cytokines 
or cell-cell contact. This approach is highly relevant as the interactions between MAIT 
cells and different APC subsets is still unclear. 
  
In summary, this chapter provides novel characterisation on the instability of 5-A-RU and 
its mode of auto-oxidation. The instability could be overcome by tempering the oxygen-
sensitive 5-amino group with a cathepsin-labile linker group which not only completely 
stabilised 5-A-RU but also increased its potency in in vitro and in vivo settings. Analysis 
of the presentation of 5-A-RU prodrugs also supported previous evidence that 5-A-RU 
may be presented in a non-ER manner via the recycling endosome; as such the prodrugs 
could be used as novel tools for the exploration of MR1 presentation pathways. Moreover, 
this prodrug design has the potential for a multitude of further modifications to explore 




















Chapter 4:  Investigation on the adjuvant activity 







MAIT cells are well documented as potent anti-bacterial effector T cells, exhibiting 
specific cytotoxicity towards bacterially infected cells199,217. Moreover, mice deficient for 
MR1 and therefore MAIT cells display defects in their ability to control models of 
pulmonary infection by Klebsiella pneumoniae and Francisella tularensis26,187. Though 
current studies highlight the necessity of MAIT cells in these bacterial responses, the 
mechanism by which MAIT cells are able to confer protection in vivo is poorly 
understood. A major mechanism proposed by current literature is that MAIT cells may 
directly contribute to the clearance of pathogens via lysis of infected cells. Additionally, 
there is also some evidence to suggest that MAIT cells may also be influencing adaptive 
responses in these models. Compared to WT, MR1-/- mice infected with F. tularensis were 
significantly impaired in their ability to recruit IFNγ producing CD4+ and CD8+ T cells 
to the lung26. Moreover, in vitro and in vivo activated MAIT cells can produce pro-
inflammatory cytokines such as IFNγ, TNFα and IL-17, which are known to contribute 
to the development of adaptive responses23,25,216. Together these observations indicate 
that MAIT cells may indeed be able to influence adaptive immune responses, i.e. T and 
B cells. A recent study has established that MAIT cells can influence B cell activation 
directly. In a murine model for systemic lupus erythematosus, MAIT cells were required 
for germinal centre formation and the expansion of activated CD4+ T cells189. Moreover, 
antibody production by B cells in vitro was dependent on CD40/CD40L signalling 
provided by MAIT cells. This study indicates that MAIT cells are indeed able to influence 
adaptive responses in vivo and suggests that activation of MAIT cells could be combined 
with antigens to drive antigen-specific T and B cell responses. 
 
Currently, there is a high need for safe and efficacious adjuvants to augment vaccination 
strategies against microbial infection or against tumours249. Due to their abundance in 
humans, MAIT cells are an appealing target for the use as a cellular adjuvant in this role. 
T cells, and in particular CD8+ T cells, are critical mediators of protection across a 
plethora of pathologies. Tumour infiltrating CD8+ T cells are highly associated with 
positive outcomes in cancer, due to their ability to readily penetrate tissues and exhibit 
targeted destruction of malignant cells135–137. MAIT cells are also highly enriched within 
the mucosa. Therefore they are attractive targets as mucosal adjuvants for diseases that 
infect via mucosal interfaces such as HIV and Mycobacterium tuberculosis where the 
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generation of antigen-specific CD8+ T cells have been shown to confer protection from 
disease progression250–252.    
 
As mediators of the adaptive immune response, DCs provide essential signalling towards 
T cells to prime their effector functionality. In order to study the ability of MAIT cells to 
modulate such CD8+ T cell responses, the interactions between MAIT cells and DCs must 
first be properly defined. There is some evidence to suggest that MAIT cells can indeed 
influence the activation state of DCs. In an in vivo model of pulmonary infection with F. 
tularensis, differentiation of inflammatory monocytes within the lung was shown to 
require GM-CSF production dependent on MAIT cells27. As GM-CSF is an important 
developmental cytokine for DCs253,254, this is amongst the first evidence that they possess 
some ability to modulate DC responses. When human MAIT cells are co-cultured with 
immature monocytes and 5-OP-RU, they are able to induce CD40L-dependent maturation 
of the monocytes, as well as induce the release of bioactive IL-1229. This suggests that 
MAIT cells can enhance DC function, and could therefore potentially be exploited as 
cellular adjuvants to stimulate adaptive T cell responses. Such a cellular adjuvant role has 
been described for NKT cells, where in vivo administration of the potent NKT cell agonist, 
α-GalCer, leads to CD40L-dependent activation of DCs. When such administration is 
combined with protein or peptide antigens, this leads to expansion of  antigen-specific 
CD4+ and CD8+ T cells19,20,255. This potent adjuvant activity occurs in the absence of any 
other stimulation, such as through PRRs, and the T cell responses induced have been 
shown to be effective in driving antigen-specific immune responses in different disease 
models including malaria, influenza and cancer178–181. In line with observations in vivo,  
preliminary results in a human phase I clinical trial conducted by our lab, MELVAC, 
showed that DCs loaded with α-GalCer and peptides encoding immunogenic epitopes for 
NY-ESO-1 resulted in the expansion of antigen-specific T cells in 7 out of 8 patients184. 
However, the anti-tumour effects of NKT cell-based cancer vaccine strategies are still 
currently being investigated. 
 
One concern with using NKT cells as cellular adjuvants is the discrepancy in frequency 
in humans where they represent a substantially smaller population within circulating T 
cells (> 0.1%) compared to mice (~ 1%)22,177. It is unknown yet whether this significant 
difference in cell number will affect the outcomes of NKT cell-based immunotherapies 
and therefore require further investigation within the human setting. In contrast, MAIT 
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cells are highly abundant in humans, representing up to 10% of circulating T cells and 
are highly enriched across mucosal organs as well as the liver and secondary lymphoid 
organs23,25,200. Their high frequency and the emerging evidence that MAIT cells can 
influence DC responses suggest that the MAIT activating ligand, 5-OP-RU, may be a 
useful adjuvant in the design of novel vaccine strategies. Importantly, it is now 
established that human MAIT cells can activate DCs through CD40L signalling29, an 
important mechanism known to boost antigen-specific T cell responses. Thus far, no 
research has described whether this phenomenon can occur in an in vivo setting. Therefore, 
the aims of this chapter are to explore the capacity of using 5-A-RU, the precursor that 
binds with cellular sources of MG to form 5-OP-RU, to induce in vivo activation of DCs 
and whether they can adjuvant adaptive T cell responses to co-administered antigens.  
 
Our laboratory has shown that chemical conjugation of peptide antigens via a cathepsin-
cleavable prodrug version of α-GalCer leads to improved T cell activity as a result of 
enhanced co-delivery of the NKT cell agonist and peptide to the same APC242,243. Once 
separated by enzymatic cleavage, both α-GalCer and peptide are simultaneously released 
and presented on CD1d and MHC-I, respectively. This co-localisation of agonist and 
peptide results in the licensing of the APC with increased expression of co-stimulatory 
markers which enhances the engagement of antigen-loaded MHC-I to cognate T cells. In 
vivo administration of such α-GalCer conjugates results in decreased NKT activation, and 
an overall reduction in circulating IFNγ, relative to injection of unconjugated α-GalCer, 
but significantly enhances T cell function242,243. This was interpreted to suggest that 
conjugation encourages focused NKT cell-mediated adjuvant activity on relevant APCs 
involved in T cell immunity. As CD1d can be found expressed on a range of 
hematopoietic cell lineages and other cell types such as intestinal epithelial cells and liver 
hepatocytes256–258, unconjugated α-GalCer alone may be presented by an array of cells to 
induce the activation of NKT cells that do not possess the molecular machinery to process 
and present antigenic peptides to T cells efficiently. The fact that cathepsins are highly 
expressed by professional APCs also makes it more likely that α-GalCer conjugates will 
be specifically released in APCs capable of inducing antigen-specific T cell responses. In 
support of this, the capacity of the conjugate vaccines to stimulate CD8+ T cells was 




In addition to increasing potency, the advantage of synthetic vaccines is that the choice 
of the peptide is highly amendable, providing a useful platform to adapt different antigens 
easily, and hence target various diseases. The previous chapter described preparation of 
the 5-A-RU prodrug 10 (referred to as 5-A-RUL from here on). As had been noted, this 
linker provides an opportunity to append additional motifs such as peptides to 5-A-RU; 
therefore, this chapter also describes the application of 5-A-RU conjugated to model 






Current research on MAIT cells suggests that they have some capacity to modulate 
adaptive immune responses. Importantly, it is now established that human MAIT cells 
can activate DCs through CD40L signalling, an important mechanism known to boost 
antigen-specific T cell responses. Thus far, no research has described whether this 
phenomenon can occur in an in vivo setting. Moreover, in the previous chapter, the 
synthesis of a 5-A-RU prodrug has provided a potent MAIT cell agonist that enhances in 
vivo activity and will allow the attachment of peptides to drive co-localisation of adjuvant 
and antigen within a singular DC. Thus, this chapter aimed to assess the ability of MAIT 
cells to activate DCs to enhance adaptive T cell responses and whether conjugation of 5-
A-RU to peptides will improve this response, and could, therefore, be used as a synthetic 
vaccine strategy. 
 
Specific aims are: 
• Determine the ability of 5-A-RU +/- MG to induce MAIT cell and DC activation 
in secondary lymphoid tissues 
• Assess whether administration of 5-A-RU admixed with the antigen leads to 
generation of antigen specific CD4+ or CD8+ T cell responses 
• Determine the mechanism in which 5-A-RU is able to adjuvant T cell responses 
• Establish whether the prodrug of 5-A-RU induces DC activation 






 Intravenous injection of 5-A-RU activates murine MAIT 
cells across multiple tissues 
It has previously been reported that when mice are intranasally administered 5-OP-RU, 
MAIT cells localise within the lung and become highly activated246. However, MAIT cell 
populations can be found at varying frequencies in other tissues of specific relevance to 
initiating immunity, notably the lymph nodes, spleen and liver23 and capacity for MAIT 
agonists to activate cells at these sites in vivo has not been explored in any detail. 
Intravenous administration would be expected to deliver small molecules, like MAIT cell 
agonists, to sites such as the lung, liver, and spleen via the systemic circulation. This route 
of administration was therefore chosen to conduct an initial assessment of MAIT cell 
activation in lung spleen and liver, and importantly, because these organs also contain 
numerous well-defined APC populations, it was also possible to explore the downstream 
impact of MAIT cell activity on APC phenotype. Groups of mice were injected 
intravenously with either 5-A-RU or 5-OP-RU prepared immediately before injection by 
mixing 5-A-RU and MG in the same tube for 2 min. At 18 h after injection, the lung, liver 
and spleens were collected and the level of MAIT cell and DC activation was compared 
to vehicle (PBS)-injected controls.   
 
In all organs tested MAIT cells were identified by flow cytometry using MR1 tetramers 
loaded with 5-OP-RU and an antibody to TCR β, using a gating strategy that involved the 
exclusion of dead cells, monocytes (B220+) and myeloid cells (CD11b+) (Appendix B). 
In mice treated with 5-A-RU alone, upregulation of the early activation marker CD69 
was observed specifically on MAIT cells in spleen, liver and lung (Fig 4.1a & b), but this 
did not reach statistical significance in the lung. However, when 5-A-RU was pre-
incubated with MG to form 5-OP-RU prior to injection, significant activation of MAIT 
cells was seen across all these tissues, with the level of upregulation higher than observed 
in mice treated with 5-A-RU alone. This improved activity of 5-OP-RU over 5-A-RU had 
also been observed in vitro when examining human MAIT cells in chapter 3, and may 
suggest that there is low cellular availability of endogenous levels of MG to condense 






Figure 4.1. Intravenous injection of 5-A-RU leads to activation of murine MAIT 
cells. Mice (n=5) were administered PBS, 5-A-RU or 5-A-RU + MG i.v. After 18 h, 
lungs, livers and spleens were harvested and assessed for MAIT cell activation. (a) 
Representative flow cytometry plots depicting gating strategy for MAIT within the lung 
and upregulation of CD69 after treatment with 5-A-RU + MG. MAIT cells were identified 
as MR1-5-OP-RU tetramer+ from CD64- B220- TCRβ+ cells (b) Graphs depicting the 
mean fluorescence index (MFI) of CD69 gated on MAIT cells across indicated tissues. 
Graphs are depicted with the mean ± SEM. Statistical significance was determined by 
One-Way ANOVA with Tukey’s multiple comparisons test. Representative of three  
similar experiments.  
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 Intravenous injection of 5-A-RU leads to activation of DC 
subsets and is dependent on T cell signalling. 
Previous in vitro research on human MAIT cells has shown that upon activation with 
synthetic agonists, they are able to feedback onto DCs and induce maturation in an MR1-
and CD40L-dependent manner29. Having established that intravenously delivered 5-A-
RU can reach secondary lymphoid organs and robustly activate MAIT cells in mice, it 
was therefore investigated whether MAIT cells can induce maturation of DCs in vivo. 
Thus, the activation status of DCs from the lung, liver and spleen was examined by flow 
cytometry 18 h following i.v. injection with 5-A-RU +/- MG.  The DCs were divided into 
two subsets based on their expression of the X-C Motif Chemokine Receptor 1 (XCR1) 
(Appendix C). The cDC-1 subset, XCR1+, represents a population of Batf3+ DCs, that is 
recognised as an essential subset required in cross-presentation of exogenous antigens 
onto MHC-I65. Conversely, the cDC-2 subset (XCR1-), consist mainly of Irf4+DCs are 
primarily associated with high efficiency of MHC-II antigen presentation74,75.  For both 
cDC-1 and cDC-2 subsets, in all tissues, administration of 5-A-RU leads to an 
upregulation of the T cell co-stimulatory marker, CD86 (Fig 4.2). Interestingly, the use 
of MG was dispensable despite 5-A-RU + MG inducing a much higher level of MAIT 
cell activation within each of the tissues tested at the same time point.  
 
To effectively stimulate APCs, T cells must provide activatory signals such as ligation of 
CD40L with CD40 on the DC15–17. Cytokines such as IFN-γ and TNF have also been 
shown to enhance the magnitude of DC activation113. To interrogate whether the 
activation of DCs by administration of 5-A-RU was reliant on the presence of T cell 
signalling and pro-inflammatory cytokines, mice were pre-treated with blocking 
antibodies for CD40L, IFN-γ or TNF via i.p injection 24 h prior and the day of i.v. with 
5-A-RU. As shown in Figure 4.3, splenic DC activation in mice treated with 5-A-RU was 
reduced by the treatment of each of the blocking antibodies but not by their isotype 
controls. 
 
Together this data demonstrates that administration of 5-A-RU in vivo can lead to the 
maturation of DCs, which is in line with in vitro data using human cells.  This was 
observed in organs accessed by intravenous administration that are known to have 
reasonable quantities of MAIT cells and is dependent on CD40 signalling and provision 
of cytokines, presumed to be from the activated MAIT cells themselves. This data would 
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indicate that 5-A-RU could potentially be used as an adjuvant in conjunction with 





Figure 4.2. Intravenous administration of 5-A-RU induces activation of DCs in lung 
spleen and liver. Mice (n=5) were administered i.v. PBS, 5-A-RU or 5-A-RU + MG. 
After 18h, maturation was determined on DCs which were identified as CD11chi MHC-
IIhi cells from CD64- B220- cells. Graphs depict MFI of CD86 expression in each DC 
subset from treated mice. Data presented is representative of two independent 
experiments. Graphs are depicted with the mean ± SEM. Statistical significance was 
determined by One-Way ANOVA with Tukey’s multiple comparisons test. 
Representative of two independent experiments. 
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Figure 4.3. 5-A-RU dependent maturation of DCs is mediated by CD40L and pro-
inflammatory cytokines. Mice (n=5) were administered i.p. PBS or 500 µg of α-CD40L, 
α-IFNγ or α-TNFα or  their corresponding isotype control armenian hamster IgG, rat IgG1 
or human IgG, respectively, on d -1 and d 0. Mice were then administered i.v. PBS or 5-
A-RU on d 0 and 18 h later spleens were harvested and assessed for DC activation by 
flow cytometry. DCs were identified as CD11chi cells from CD64- B220- cells. Graphs 
depict MFI of CD86 expression in DC subset from treated mice. The same cohort of PBS 
treated mice were used as the control group between data sets. Data presented is 
representative of two independent experiments. Graphs are depicted with the mean ± 
SEM. Statistical significance was determined by One-Way ANOVA with Tukey’s 
multiple comparisons test. Representative of two independent experiments. 
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 Co-administration of 5-A-RU with antigen induces weak 
systemic CD8+ T cell responses  
It is known that DCs that receive CD4+ T cell help mediated by CD40L-signalling are 
licensed to induce effective downstream CD8+ antigen-specific T cells through enhanced 
expression of co-stimulatory molecules and production of important cytokines like IL-
12p7015,16. As 5-A-RU induces CD40L-dependent activation of DCs the next step was to 
examine its capacity to adjuvant peptide-specific T cell responses. 
 
To investigate the ability for 5-A-RU to enhance stimulation CD8+ T cell responses to 
antigen, an in vivo killing assay was used (VITAL assay225). The mice were 
prophylactically vaccinated with an admix of 5-A-RU and OVA protein and then seven 
days later, when the T cell response was expected to be strong, they were each 
intravenously challenged with fluorescent target cells prepared from splenocytes of 
syngeneic mice. Three different populations of target cells were used, each pulsed with a 
different dose of the H-2Kb-binding epitope, OVA257-264 (SIINFEKL), before injection. 
The populations were labelled with different concentrations of the fluorescent dye 
carboxyfluorescein succinimidyl ester (CFSE) so that each target cell population could 
be gated individually by flow cytometry-based on fluorescence intensity. A control target 
population was also injected that had not been pulsed with peptide and was stained with 
CellTrackerTM Orange (CTO). Mice that generated a cytotoxic CD8+ T cell response to 
the peptide target were expected to lyse peptide-loaded target cells, and leave the CTO 
labelled control population unaffected. Therefore, the proportion of specific lysis could 
be calculated by establishing the ratio of surviving cells in the CFSE-labelled target 
populations in blood relative to the CTO labelled control population. Mice that had not 
been vaccinated, but received vehicle (PBS), served as a negative control on this 
experiment, while mice injected with OVA mixed with the NKT cell agonist α-GalCer, 
which was expected to cause a strong CD8+ T cell response, served as a positive control. 
Example flow cytometry plots are depicted in Fig 4.4a. 
 
Using this method, up to 40 % specific lysis of peptide-pulsed target cells was observed 
in mice vaccinated with 5-A-RU and OVA (Fig 4.4b) showing that 5-A-RU can function 
as an immune adjuvant to support cross-priming of a CD8+ T cell response. Again, 
perhaps surprisingly, prior mixing of 5-A-RU with MG to form 5-OP-RU did not improve 
the response. It was also clear that the overall magnitude of T cell response was 
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significantly lower than observed in animals administered OVA and α-GalCer, although 
α-GalCer is generally regarded as a very potent adjuvant in mice.   
 
Given that the cytotoxic response was relatively weak in mice prophylactically vaccinated 
with 5-A-RU and OVA, the next step was to determine whether the responses induced 
could have functional relevance in a disease model. To explore this, mice were engrafted 
with B16-OVA, a derivative of the murine melanoma cell line B16-F10 which has been 
transduced to overexpress the OVA protein as a model of a tumour-associated antigen. 
After challenge with 5x105 B16-OVA cells, tumours were allowed to form over 5 d at 
which point they became palpable. At this point, mice were vaccinated with 5-A-RU + 
OVA, a vehicle control or OVA alone. An additional control group was vaccinated with 
an α-GalCer-OVA conjugate (α-GalCerOVA), which has previously been shown to induce 
potent activity against B16-OVA tumours243. While this positive control group exhibited 
marked anti-tumour activity, mice vaccinated with 5-A-RU + OVA failed to limit tumour 
growth (Fig 4.5a). This result indicated that MAIT cell activation with 5-A-RU failed to 
support the priming of a sufficiently powerful antigen-specific T cell response that could 
delay a fast-growing tumour.  
 
The induction of OVA-specific CD8+ T cells can be detected by flow cytometry using 
fluorescently conjugated SIINFEKL-H-2Kb pentamers. These molecules consist of five 
covalently linked H-2Kb molecules (a murine MHC-I molecule expressed in C57BL/6J 
mice) each bound to an eight amino acid peptide, SIINFEKL, a known CD8+ epitope of 
OVA (OVA257-264). Only CD8+ T cells with a TCR arrangement that binds SIINFEKL in 
the context of H-2Kb will be bound by the fluorescent pentamer. Using this assay, α-
GalCerOVA was shown to be a potent producer of SIINFEKL-specific CD8+ T cells, as 
expected from the anti-tumour activity observed (Fig 4.5b). In contrast, no significant 
SIINFEKL-specific CD8+ T cells could be detected in mice at 7 d post-vaccination with 
5-A-RU + OVA, thus, while cytotoxic activity could be detected by in vivo killing assay, 
which was conducted in the absence of any tumour, in this experiment, there was little 
evidence that 5-A-RU + OVA could induce a functional anti-tumour CD8+ T cell 
response. 
 
It could be reasoned that the weak CD8+ T cell response provided by 5-A-RU, as seen in 
the in vivo killing assay, is unable to overcome tumours once already grafted due to the 
 90 
immunosuppressive nature of tumour microenvironments. It was, therefore, possible that 
the T cell response generated with 5-A-RU may be sufficient to prevent initial 
engraftment of tumours at the peak of the immune response, 7 days after vaccination. To 
test this, mice were vaccinated prophylactically with 5-A-RU and OVA and challenged 
one week later subcutaneously in the flank with B16-OVA. Again, the positive control 
group were vaccinated with α-GalCer and OVA, and tumour growth in the treated animals 
was compared to growth in animals injected with vehicle only. This analysis showed that 
mice vaccinated with 5-A-RU +/- MG and OVA were not significantly protected from 
tumour challenge with B16-OVA (Fig 4.5c). The combination of 5-A-RU + OVA, 
therefore, could not induce a functional anti-tumour CD8+ T cell response, even when the 
ratio of T cells to tumour cells was high and solid immunosuppressive tumour lesions had 










Figure 4.4. Co-administration of 5-A-RU and OVA leads to expansion of OVA 
specific CD8+ T cells. Mice (n=5) were administered i.v. PBS, OVA or OVA in 
combination with 5-A-RU, 5-A-RU + MG or α-GalCer. After 7 d, mice were administered 
CFSE-stained splenocyte populations pulsed with either 0.5, 5 or 50nM of SIINFEKL 
peptide and equivalent peptide negative control population stained with CTO. Cytolytic 
activity was measured in the peripheral blood lymphocytes by flow cytometry. (a) 
Representative flow cytometry plots from treated mice depicting a proportional decrease 
in peptide-pulsed CFSE-stained target cells in αGalCer + OVA group. (b) Graphs are 
depicted with the mean ± SEM. Statistical significance was determined by Two-way 




Figure 4.5. Co-administration of 5-A-RU and OVA fail to protect against tumour 
challenge or expansion of endogenous OVA-specific CD8+ T cells.  (a) Mice (n=5) 
were s.c. challenged with 5x105 B16-OVA cells. At 5 d post challenge, mice were 
administered PBS, OVA, 5-A-RU + OVA or α-GalCer-OVA conjugate i.v. Tumour size 
was monitored and recorded every 2 d. (b) At 7 d post-vaccination mice were bled and 
the frequency of H-2Kb-SIINFEKL pentamer+ T cells was assessed by flow cytometry 
from B220- CD3+ cells. (c) Mice (n=5) were administered i.v. PBS, OVA or OVA in 
combination with 5-A-RU or α-GalCer. At 7 d post-vaccination, mice were challenged 
subcutaneously with 5x105 B16-OVA cells. Tumour size was monitored and recorded 
every two days. Graphs are depicted with the mean ± SEM. Representative of  at least 
two independent experiments 
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 Conjugation of 5-A-RU to OVA peptide enhances OVA-
specific CD8+ T cell responses 
Previous studies in our lab have demonstrated that targeting peptide antigen and adjuvant 
to the same APCs by conjugating the components together greatly enhances the 
generation of peptide-specific T cell responses242,243. In the case of α-GalCer-peptide 
conjugates, after enzymatic processing, these conjugate molecules are able to 
simultaneously present α-GalCer on CD1d and peptide on MHC-I. These APCs receive 
signals from iNKT cells to mature the DC through ‘helper’ signals which in turn enhances 
the presentation of MHC-I epitopes to naïve CD8+ T cells.  
 
It was, therefore, reasoned that T cell responses generated by co-administration of 5-A-
RU and antigen could be enhanced through chemical conjugation of antigenic peptides to 
the MAIT agonist precursor to facilitate improved uptake and presentation of both 
components within the same APC. As discussed in the previous chapter, the amino group 
on 5-A-RU, which condenses with α-dicarbonyl adducts to form MR1-binding ligands, 
provided a site for attachment of a widely used cathepsin-sensitive VC-PAB carbamate. 
Incubation with cathepsins or loading onto human PBMCs in vitro revealed that this ‘pro-
5-A-RU’ (hereby referred to as 5-A-RUL) stably released 5-A-RU which in turn could 
activate MAIT cells.  
 
Thus, a 5-A-RU-linker conjugate was constructed by attaching a bicyclo[6.1.0]non-4-yne 
(exo-BCN) moiety to the valine residue on the original 5-A-RUL. Any antigenic peptide 
could then be attached through strain-promoted alkyne-azide cyclo-addition (SPAAC) 
chemistry (Fig 4.6). To test this vaccine concept, the first peptide conjugated to this 
structure was KISQAVHAAHAEINEAGRE-SIINFEKLTEWT. All chemical conjugates 
were synthesised by Ferrier Research Institute This sequence encompassed both a CD4+ 
T cell epitope (OVA323-33; ISQAVHAAHAEINEAGR) and a CD8+ T cell epitope 
(OVA257-264; SIINFEKL) from OVA protein. Once cleaved, the linker collapses to release 
5-A-RU, which in turn condenses with cellular MG to form 5-OP-RU. In order to ensure 
proper release of the conjugated peptide, the antigenic sequence was preceded by a known 
protease cleavable sequence (FFRK). Based on our earlier studies with α-GalCer-peptide 
conjugates, this N-terminal extension is not always required, but in general, enhances 
processing and presentation regardless of antigenic sequence attached. 
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In the previous chapter, the protection of 5-A-RU by the VC-PAB linker enhanced its 
ability to activate MAIT cells. It was hypothesised that this was in part attributed to 
increased stability of 5-A-RU, allowing enhanced accumulation and specific release 
within APCs. In line with this hypothesis, this mechanism may also enhance MAIT-DC 
interactions. Therefore, the 5-A-RU OVA peptide construct (hereby referred to as 5-A-
RUOVA) and 5-A-RUL were first tested for their ability to activate DCs compared to the 
parent molecule 5-A-RU alone. As shown in Fig 4.7a, mice treated with 5-A-RUL or 5-
A-RUOVA conjugate both show significantly enhanced DC activation, as shown by 
enhanced expression of the co-stimulatory molecule CD86, when compared to 5-A-RU 
alone.   
 
An increase in the ability to activate DCs suggests that 5-A-RU conjugates may also 
enhance the immunogenic expression of antigen to prime antigen-specific CD8+ T cells. 
To determine the ability of 5-A-RUOVA conjugate to induce these responses, an in vivo 
killing assay was performed. For these experiments, co-administration of unconjugated 
KISQAVHAAHAEINEAGRE-SIINFEKLTEWT peptide (hereby denoted as OVA(P)) 
with 5-A-RU or 5-A-RUL was used to assess the need for conjugation. Administration of 
5-A-RU or 5-A-RUL admixed with OVA(P) induced a T cell response that achieved 
around 40% specific lysis of the injected target cells (Fig 4.7b). However, 5-A-RUOVA 
conjugate induced near 100% lysis of target cells, highlighting the importance of 
conjugation. Moreover, this response could be titrated to a substantially lower dose before 
losing activity in killing assay (Fig 4.7c). As 5-A-RUL and 5-A-RUOVA showed similar 
levels of DC activation, these results support the hypothesis that the co-localisation of 
antigen and adjuvant within the same DC greatly contributes to the subsequent level of 
CD8+ T cell response.  
 
To further interrogate the strength of the T cell response generated with 5-A-RU 
conjugates, anti-tumour activity was assessed in mice subcutaneously challenged with 
B16-OVA cells. At d 5, when tumours were palpable, mice were vaccinated with the 
conjugate, or with unconjugated components, and then tumour growth was measured 
every 2-3 d. Mice treated 5-A-RUOVA conjugate were the only group that showed a 
significant delay in tumour growth post-vaccination (Fig 4.8a). To investigate whether 
the immune response was correlated to the production of CD8+ T cells specific to 
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SIINFEKL, mice were bled at 7 d post-vaccination and analysed by flow cytometry. 
Reflective of the tumour delay, mice that received 5-A-RUOVA were the only group to 
show a significant expansion of SIINFEKL-specific CD8+ T cells (Fig 4.8b).  
 
As the 5-A-RUOVA conjugate induces DC activation to a higher degree than 5-A-RU, it 
was possible that this enhanced adjuvant activity induced an endogenous anti-tumour 
response that did not necessarily involve OVA. To rule this out, mice bearing B16-OVA 
tumours were vaccinated with 5-A-RUOVA or an irrelevant peptide conjugate, 5-A-RUGP33. 
This construct contains the CD8+ T cell epitope for another model antigen lymphocytic 
choriomenigitis virus glycoprotein, GP33 (KAVYNFATM). As shown, only mice treated 
with the 5-A-RUOVA conjugate generated a significant tumour growth delay to B16-OVA 
tumours (Fig 4.8c). This was reflective of the response seen in the blood where only 5-
A-RUOVA vaccinated mice showed an expansion of SIINFEKL-specific CD8+ T cells (Fig 
4.8d). 
 
Together these results demonstrate that the chemical conjugation of 5-A-RU to antigenic 




Figure 4.6. Structure of 5-A-RUOVA. Chemical structure depicts 5-A-RU (red) 





Figure 4.7. Conjugation of 5-A-RU to OVA peptide enhances immune adjuvant 
activity.  (a) Mice (n=5) were administered PBS, 5-A-RU, 5-A-RU-L or 5-A-RUOVA i.v. 
After 18h, splenic cDCs were assessed by flow cytometry for their expression of CD86. 
(b) Mice (n=5) were vaccinated with 18nmol of either 5-A-RUOVA or OVA(P) alone or in 
combination with 18nmol of 5-A-RU or 5-A-RUL. At 7 d post-vaccination, cytolytic 
activity to peptide-pulsed target cells was measured by the VITAL assay. (c) Titrating 
amounts of 5-A-RUOVA were administered to mice (n=3) and cytolytic activity to peptide-
pulsed target cells was measured by the VITAL assay. Graphs are depicted with the mean 
± SEM. Statistical significance was determined by One-Way ANOVA with Tukey’s 













Figure 4.8. 5-A-RU conjugates induce peptide specific protection from tumour 
challenge.  (a) Mice (n=5) were challenged s.c. with 5x105 B16-OVA cells. At 5 d post 
challenge, mice were administered 5-A-RUOVA, PBS, OVA alone or OVA in combination 
with 5-A-RU or 5-A-RUL i.v. Tumour growth was monitored and recorded every two 
days. (b) Seven days post-vaccination mice were bled and the frequency of H-2Kb-
SIINFEKL pentamer+ T cells was assessed by flow cytometry from B220- CD3+ cells. (c) 
Mice (n=3) were challenged s.c. with 5x105 B16-OVA cells. At 5 d post challenge, mice 
were administered PBS, 5-A-RUOVA or 5-A-RUGP33 i.v. Tumour growth was monitored 
and recorded every 2 d. (d) At 7 d post-vaccination, mice were bled and the frequency of 
H-2Kb-SIINFEKL pentamer+ T cells was assessed by flow cytometry. Graphs are 
depicted with the mean ± SEM. Statistical significance was determined by One-Way 
ANOVA with Tukey’s multiple comparisons test. Representative of at least two 
independent experiments. 
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 5-A-RU conjugated to an HPV peptide generates antigen-
specific CD8+ T cells and protects from TC-1 tumour challenge 
Thus far, OVA has been used as a model antigen to assess anti-tumour responses to 
vaccination with 5-A-RU conjugates. However, as this protein is not naturally expressed 
in tumours, 5-A-RU should be combined with a more clinically relevant antigen to 
evaluate whether this vaccine approach could be translated into humans. To test the 
general utility of the 5-A-RU conjugate platform, T cell responses to another antigen were 
assessed. Human papilloma virus (HPV) is an oncolytic virus that is a significant cause 
of cervical and head and neck cancer. Oncogenesis by this virus is mainly mediated 
through inappropriate expression of E6 and E7 within basal epithelial cells. To model this 
cancer in mouse studies, the TC-1 cell line was developed from a lung epithelial cancer 
cell line, genetically engineered to express E6 and E7 oncoproteins of HPV260.  
 
To investigate the ability of 5-A-RU to adjuvant immune responses to HPV-related 
oncoprotein, 5-A-RUL was conjugated to an H-2Db binding CD8+ T cell epitope from the 
HPV E7 protein: RAHYNIVTF (HPV(P)). Using an in vivo killing assay as previously 
described, mice treated with the 5-A-RU HPV conjugate (5-A-RUHPV) induced T cell 
responses capable of significant lysis of target cells compared to admixed 5-A-RU and 
peptide (Fig 4.9a). Furthermore, 5-A-RUHPV conferred protection to TC-1 tumour 
challenge when administered prophylactically (Fig 4.9b). Again using 5-A-RUGP33 as an 
irrelevant peptide control confirmed that the anti-tumour efficacy was antigen-dependent. 
Finally, 7 d post-vaccination, flow cytometric analysis using RAHYNIVTF-H-2Db 
pentamers revealed that mice vaccinated with 5-A-RUHPV conjugate showed significant 
expansion of HPV E7-specific CD8+ T cells (Fig 4.9c). 
 
Collectively, these results show that 5-A-RU is also capable of adjuvanting alternative 
peptides that hold more clinical relevance. The data presented is the first to suggest that 




Figure 4.9. Protection from TC-1 tumour challenge with a 5-A-RU HPV conjugate.  
(a) Mice (n=5) were administered i.v. PBS, 5-A-RU + HPV(P) or 5-A-RUHPV. At 7 d post-
vaccination, cytolytic activity to peptide-pulsed target cells was measured by the VITAL 
assay. (b) Mice (n=5) were administered PBS, HPV(P) +/- 5-A-RU, 5-A-RUGP33 or 5-A-
RUHPV i.v. At 7 d post-vaccination, mice were challenged s.c. with 1x105 TC-1 cells and 
tumour size was measured every 2 – 3 d. (c) Mice (n=5) were administered i.v. PBS or 5-
A-RUHPV At 7 d post-vaccination, mice were bled and the frequency of H-2Db-
RAHYNIVTF pentamer+ T cells was assessed by flow cytometry. Graphs are depicted 
with the mean ± SEM. Statistical significance was determined by One-Way ANOVA with 
Tukey’s multiple comparisons test. Representative of  at least two independent 
experiments.
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 The immune response to 5-A-RUOVA is dependent on 
Clec9A+ cross-presenting DCs 
The earlier results in this chapter demonstrated that 5-A-RU and 5-A-RU conjugates 
could effectively activate cDCs. With subsequent studies showing that 5-A-RUOVA 
conjugate vaccines also confers protection against tumours, the assumption had been that 
the mechanism of action was through priming of T cells by MAIT cell-licensed DCs. 
However, because the expression of MR1 is widespread, it was possible that other cell 
types may be contributing to the presentation of 5-A-RU derivatives and antigen during 
priming of the T cell response. Therefore, it was necessary to conclusively define the role 
of DCs in this vaccine response.  
 
To explore the necessity of the DC compartment, a conditional ablation model was used 
to deplete DCs in vivo based on the expression of the DC-associated marker CD11c. To 
do this, CD11c-DTR mice were used. These mice express a transgene containing the 
human diphtheria toxin receptor (DTR) sequence under the control of the CD11c 
promoter (Itgax)261. As mice are generally tolerant to low doses of diphtheria toxin, the 
more sensitive human DTR renders cells expressing CD11c susceptible to the cytotoxic 
effects of injected toxin, and they will be ablated. However, due to the limited expression 
of CD11c on more than just immune cells, multiple rounds of DT administration have 
been shown to be toxic to mice262. Therefore, bone marrow chimeras were established in 
which bone marrow was transferred from CD11c-DTR mice into irradiated C57Bl/6J 
(Wild-type; WT) mice to ensure the selective targeting of DT to only myeloid cells 
expressing CD11c. As controls, WT mice were reconstituted with WT bone marrow to 
assess any immunological effects of transferring bone marrow. After reconstitution with 
bone marrow from either WT or CD11c-DTR mice, the chimeras were rested for 6 weeks 
and then were dosed with either DT or PBS 2 d and 1 d before vaccination with 5-A-
RUOVA conjugate. Treatment with DT showed specific ablation of cells harbouring 
CD11c (Fig 4.10a). Seven days post-vaccination, mice who had their DCs depleted 
showed complete ablation of the CD8+ T cell response as measured by in vivo killing 
assay (Fig 4.10b). These results show that indeed CD11c+ cells, presumably DCs, are the 
major contributor in the generation of a CD8+ T cell response to 5-A-RUOVA. 
 
Cross-presentation of exogenous antigens onto MHC-I molecules is an important 
mechanism by which the immune system generates CD8+ T cell responses to many 
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infections.While CD11c+ cells have the capacity to cross-present antigen to some extent, 
not all do so to an equal degree. Additionally, not all cells expressing CD11c are DCs. 
CD11c may also be expressed on a number of other myeloid cells such as macrophages 
and inflammatory monocytes, and therefore the previous experiment cannot completely 
inform the critical cell type involved in response to 5-A-RUOVA.  
 
The C-Type Lectin Domain Family 9A (Clec9A) mediates antigen uptake in DCs and is 
specifically co-expressed on the CD8+ XCR1+ subset65,263. Importantly, these DCs, which 
are commonly referred to as cDC167,224, represent the major class of DCs with a 
heightened propensity for cross-presentation. Given that the 5-A-RUOVA conjugate 
contains a long peptide which is provided to cells exogenously through vaccination, it 
was hypothesised that this conjugate would require cross-presentation involving the 
cDC1 subset. To examine this, Clec9A-DTR mice that allow for depletion of the Clec9A 
expressing cells with administration of DT were used. The Clec9A-DTR mice were 
administered i.p. PBS or DT 2 d and 1 d before vaccination with 5-A-RUOVA conjugate 
and induction of T cell responses were assessed by in vivo killing assay. Mice treated with 
DT showed selective depletion of CD8+ CD11c+ cells, a general phenotype of cDC1 cells 
in the spleen (Fig 4.10c). Moreover, mice lacking Clec9A+ cells completely lost the 
ability to generate peptide-specific responses when administered 5-A-RUOVA conjugate 
(Fig 4.10d). Collectively, these experiments confirm the role of cDC1s and highlight the 




Figure 4.10 Immune response mediated by 5-A-RUOVA is dependent on cross-
presenting DCs. Mice (n=5) were irradiated and 24 h later injected with donor bone 
marrow from either WT mice or CD11c-DTR mice. Six weeks post-reconstitution some 
mice were treated i.p. with PBS or DT at days -2 and -1 before they were administered 
i.v. with PBS or 5-A-RUOVA on d 0. (a) Flow plots depicting depletion of CD11chi cells 
after DT regime. CD11chi cells were gated from B220- cells. (b) At 7 d post-vaccination, 
cytolytic activity to peptide-pulsed target cells was measured by the VITAL assay. (c) 
WT or Clec9A-DTR mice (n=5) were administered PBS or DT i.p at days -2 and -1 and 
were administered i.v. PBS or 5-A-RUOVA on d 0. Flow plot depicts depletion of CD8α+ 
DCs after DT regime. (d) At 7 d post-vaccination, cytolytic activity to peptide-pulsed 
target cells was measured by the VITAL assay. Graphs are depicted with the mean ± 
SEM. Statistical significance was determined by Two-way ANOVA with Tukey’s 
multiple comparisons test. Representative of  at least two independent experiments. 
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 The immune response to the 5-A-RU conjugate remains 
intact in MR1-/- mice but absent in CD1-/- mice 
Thus far, 5-A-RU has proven to be an effective adjuvant that stimulates MAIT cells,  
activates DCs, and drives immune responses to antigen. Moreover, conjugation of antigen 
to 5-A-RU significantly increases its ability to facilitate activation of DCs, leading to 
enhanced CD8+ T cell responses.  
 
However, to confirm the hypothesis that the adaptive immune responses enhanced by 5-
A-RU are indeed dependent on MAIT cells, this vaccination strategy must be tested in 
mice deficient for MR1, which lack MAIT cells. To test the dependence of MR1, WT or 
MR1-/- mice were given B16-OVA tumours and treated therapeutically at d 5 with either 
PBS or 5-A-RUOVA conjugate. Surprisingly, there was no significance in the delay of 
tumour growth between mice treated with 5-A-RUOVA in either strain (Fig 4.11a). This 
was reflected in the immune response seen in the blood at seven days post-vaccination 
(Fig 4.11b), where there was no significant difference in the frequency of 5-A-RUOVA 
conjugate-induced SIINFEKL-pentamer positive CD8+ T cells between WT or MR1-/- 
mice.  
 
To investigate whether absence of MAIT cells had an impact further upstream of the T 
cell response, WT, MR1-/- and CD1-/- were treated with PBS or 5-A-RUOVA, and DCs 
were assessed for activation. In line with the tumour responses, mice lacking MR1 did 
not show any significant difference in their ability to activate DCs when treated with 5-
A-RUOVA (Fig  4.11c). The induction of T cell response to the conjugate was, therefore, 
dependent on a mechanism that surprisingly did not involve MAIT cells.  
 
Given the role of T cell-mediated signals in the DC activation observed in response to 5-
A-RU in vivo (Fig 4.2), and that DC activation occurred in such a short timeframe in these 
experiments (within a day), it was reasoned that another innate-like T cell population 
might be involved. To investigate this, CD1-deficient mice were used, which lack NKT 
cells. It is important to note that the murine CD1 locus only contains CD1d1 and CD1d2; 
therefore, CD1-/- mice lack CD1d-restricted NKT cells. Surprisingly, the observed 
activation of DCs induced by 5-A-RUOVA and ability to generate antigen-specific T cell 
responses towards peptide-loaded target cells was abolished in CD1 deficient mice (Fig 
4.11c & e). These data together suggest that CD1d-restricted NKT cells may be playing 
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the key role in the immune response to 5-A-RU-peptide conjugates. To assess this, 
activation of NKT cells in this model was investigated by flow cytometry gating on 
CD1d-α-GalCer tetramers (which function similarly to pentameric molecules mentioned 
above). To assess the activation of NKT cells, expression of the c-type lectin receptor 
NK1.1, an important functional co-receptor found on NK and NKT cells highly associated 
with IFNγ production in NKT cells, was evaluated172,264.  During activation, NKT cells 
rapidly down regulate this receptor as a mechanism of immune regulation. In mice 
vaccinated with 5-A-RUOVA, NKT cells showed a marked down-regulation of NK1.1 on 
gated NKT cells after 18 h; similar downregulation was seen in α-GalCer treated control 
mice, as a comparator (Fig 4.11d). Thus, administration of 5-A-RUOVA clearly induces 
activation of NKT cells. 
 
These surprising findings indicate an alternative mode of action of these vaccines that do 
not involve the canonical MR1-MAIT activation pathway. However, to establish whether 
the conjugate vaccine construct itself was somehow activating NKT cells, the next step 
was to examine whether the parent molecule 5-A-RU was acting through the same 
mechanism. To this end, WT, CD1-/- and MR1-/- mice were administered PBS or 5-A-RU. 
To further assess the role of NKT cells, an additional mouse strain lacking NKT cells was 
used. In Jα18-/- mice the gene for TCRα joining region 18 (TRAJ18) is deleted so that the 
canonical “invariant” TCR expressed by mouse NKT cells (Vα14-Jα18) cannot be 
formed265. Using the two NKT cell-deficient strains (CD1-/- mice and Jα18-/- mice), it 
could be investigated whether the immune response to 5-A-RUOVA was dependent on 
NKT cells themselves, or to CD1d presentation of 5-A-RU (or some derivative) to another 
CD1d-restricted T cell population. As had been seen with the conjugate, in both WT and 
MR1-/- mice DC activation was observed after the administration of 5-A-RU. (Fig 4.12a). 
Activation of NKT cells was also observed (Fig 4.12c), as indicated by down regulation 
of NK1.1 and upregulation of PD-1 and CD69. In contrast, mice lacking CD1, or 
specifically lacking Vα14-Jα18 NKT cells, were unable to induce DC activation in 
response to 5-A-RU. This loss in activity was not due to any loss in MAIT cell activation, 
as in both CD1-/- mice and Jα18-/- mice the MAIT cells all equally upregulated PD-1 or 
CD69 in response to 5-A-RU (Fig 4.12b). 
 
Collectively, these results show that the immune responses seen in the earlier experiments 
with 5-A-RU + antigen, or 5-A-RU-peptide conjugates, were unlikely to have involved 
MR1-restricted MAIT cells, despite showing a marked activation of these cells. These 
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compounds can, however, induce adjuvant activity that is dependent on CD1d-restricted 






Figure 4.11. Immune response induced by 5-A-RUOVA is dependent on CD1 but not 
MR1. WT or MR1-/- mice (n=3) were s.c. challenged with 5x105 B16-OVA cells. After 
5 d, mice were administered i.v. PBS or 5-A-RUOVA. Tumour growth was monitored and 
measured every 2-3 d. (b) After 7 d, mice were bled and the frequency of H-2Kb- 
SIINFEKL pentamer + T cells was assessed by flow cytometry. (c)  WT, MR1-/- or CD1-
/- mice (n=3) were administered i.v. PBS or 5-A-RUOVA. After 18 h, spleens were 
harvested and DCs were assessed by flow cytometry from MHC-IIhi CD11chi  B220- 
CD64- cells for expression of CD86. (d) Mice (n=3) were administered i.v. PBS, 5-A-
RUOVA or α-GalCer. After 18 h, spleens were harvested and NKT cells were assessed by 
flow cytometry as CD1d-α-GalCer tetramer+ B220- TCRβ+ cells. MFI of NK1.1 was 
calculated on NKT cells. (e) Mice (n=5) were administered PBS, OVA(P) or 5-A-RUOVA 
i.v. At 7 d post-vaccination, cytolytic activity to peptide-pulsed target cells was measured 
by the VITAL assay. Graphs are depicted with the mean ± SEM. Statistical significance 
was determined by Two-way ANOVA with Tukey’s multiple comparisons test. 




Figure 4.12 5-A-RU mediated DC maturation is dependent on the presence and 
activation of NKT cells. WT, MR1-/-, CD1-/- or Jα18-/- mice (n=5) were administered i.v. 
with PBS or 5-A-RU. After 18 h, spleens were harvested and assessed by flow cytometry. 
(a) Expression of CD86 was measured on cDCs. (b) Activation of MAIT cells was 
assessed by the expression of CD69 or PD-1. (c) Activation of NKT cells was assessed 
by expression of CD69, PD-1 or NK1.1. Graphs are depicted with the mean ± SEM. 
Statistical significance was determined by One-way ANOVA with Tukey’s multiple 
comparisons test. Experiments a and b were from one experiment and c was 
representative of two independent experiments. 
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 Fractionation and filtration of 5-A-RU reveals its NKT and 
DC activity is dependent on an unknown micro-particle 
contaminant  
The observation that NKT cells were required for DC activation, and hence the adjuvant 
activity of 5-A-RU or 5-A-RU-conjugates,  suggests that the 5-A-RU-based compounds 
used in the previous  experiments may contain some NKT-activating contaminant, or that 
the 5-A-RU itself forms a CD1d-binding ligand able to activate NKT cells directly. In 
order to assess the former, Dr Regan Anderson (Ferrier Research Institute) used LCMS 
in an attempt to identify any α-GalCer that may be contaminating the 5-A-RU 
preparations. However, no evidence could be found to suggest that this was the case (data 
not shown). To further interrogate this hypothesis, 5-A-RU was subjected to preparative 
HPLC, a method employed in chemistry in order to isolate compounds based on their size 
and physicochemical properties. This method would allow isolation of 5-A-RU and 
exclusion of any material with alternative molecular masses or physicochemical 
properties (Fig 4.13). After this process, 5-A-RU could be correctly identified in an early 
soluble fraction and was isolated for study (Appendix A). In the previous chapter, 5-A-
RU was shown to be labile to auto-oxidation. Thus, to establish whether fractionation had 
affected the integrity of 5-A-RU as an active ligand, this ‘fractionated’ 5-A-RU was then 
tested for its ability to activate human MAIT cells. As shown in Fig 4.14a, fractionation 
of 5-A-RU did not affect its ability to activate human MAIT cells when compared to the 
same batch which had not undergone fractionation. Interestingly, when this fractionated 
5-A-RU was injected intravenously into mice, it was unable to activate splenic DCs or 
NKT cells (Fig 4.14b and c).   
 
Given that the laboratory that produced 5-A-RU used for these studies has a long-standing 
history of synthesis of α-GalCer, including analogues or peptide-conjugate forms of α-
GalCer, it was speculated that the contaminating product could be derived from 
particulate matter such as silica from preparative steps to which trace amounts of varying 
CD1d-binding ligands may have adhered, and which would not be detectable by LCMS. 
Therefore, 5-A-RU was filtered by centrifugation through a tube with a 0.1µM pore filter 
in order to investigate whether particulate matter contributes to the responses seen. When 
tested on human PBMCs, filtered 5-A-RU did not show any deficiency in the ability to 
activate MAIT cells (Fig 4.15a). However, in a similar fashion to fractionated 5-A-RU, 





Figure 4.13. Schematic depicting preparative HPLC to fractionate 5-A-RU. Isolation 
was performed using a Phenomenex Gemini C18 reverse-phased column. A 500µl 
sample 5-A-RU at 13mgmL-1 was loaded onto the column for isolation. Elution was 
performed by the addition of a mobile phase to the column as follows: 0 – 5 min, 95% 
water + 5% methanol, 5 – 15 min, 95% water + 5% - 100% methanol (linear gradient), 
15 – 20 min, 100% methanol, 20 – 40 min, 90% methanol + 10% isopropanol. All 
solvents contained 0.05% trifluoroacetic acid. The solvents were applied to the column 
at a flow rate of 5mL/min. UltraViolet light at 214nm was utilised to identify compounds 
by spectroscopy. Fraction 1 containing 5-A-RU was detected and eluted between 2 min 




Figure 4.14. Fractionation of 5-A-RU leads to loss in DC and NKT activity. 5-A-RU 
was fractionated by preparative HPLC.  (a) 5-A-RU or 5-A-RU fractionated from the 
same stock was incubated at titrating concentrations with human PBMCs. After 18h, 
MAIT cells from the PBMCs were analysed by flow cytometry for activation. MAIT cells 
were identified as CD19- CD3+ Vα7.2+ CD161hi cells and activation was assessed by 
expression of CD137 on MAIT cells. Mice (n=5) were vaccinated i.v. with PBS, 5-A-RU 
or fractionated 5-A-RU. After 18h, spleens were harvested and (b) expression of CD86 
was measured on cDCs or (c) expression of NK1.1, PD-1 or CD69 was measured on NKT 
cells. Graphs are depicted with the mean ± SEM. Statistical significance was determined 





Figure 4.15. Filtration of 5-A-RU results in loss in DC and NKT cell activity. 5-A-
RU was filtered through a 0.1µM pore filter by centrifugation  (a) 5-A-RU or filtered 
5-A-RU from the same stock was incubated at titrating concentrations with human 
PBMCs. After 18h, MAIT cells from the PBMCs were analysed by flow cytometry for 
activation by expression of CD137. Mice (n=5) were vaccinated i.v. with PBS, 5-A-RU 
or fractionated 5-A-RU. After 18h, spleens were harvested and (b) expression of CD86 
was measured on cDCs or (c) expression of NK1.1, PD-1 or CD69 was measured on NKT 
cells. Graphs are depicted with the mean ± SEM. Statistical significance was determined 
by One-way ANOVA with Tukey’s multiple comparisons test. Data was obtained from a 
single experiment. 
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 CD1d-indendepent maturation of lung DC populations can 
be achieved when 5-A-RU is admixed with MG 
It was possible during the extensive work researching the adjuvant activity of 5-A-RU 
and 5-A-RU conjugate vaccines that the contaminating NKT cell activity was obscuring 
any MR1-dependent activity provided by MAIT cells. When 5-A-RU was filtered or 
fractionated, and therefore devoid of NKT activity, the manipulated material could not 
induce activation of DCs in the spleen, despite retaining its ability to activate MAIT cells. 
However, the size of the population of MAIT cells in the spleen is small (< 0.1% of all T 
cells), which may be insufficient to induce DC activation. As the lung contains one of the 
highest proportions of MAIT cells in mice, it was therefore decided to re-evaluate the 
potential for MAIT cells within the lung to activate DCs.  
 
Importantly, in Fig 4.1, it was shown that the addition of MG to 5-A-RU to form 5-OP-
RU prior to injection greatly enhanced the activation of MAIT cells, most notably in the 
lung. Thus, for these experiments, WT or CD1-/- mice were administered purified 5-A-
RU with or without prior mixing with MG. In the lungs of 5-A-RU + MG treated mice, 
there was a significant upregulation of CD86 on both cDC-1 and cDC-2 (Fig 4.16a). 
Critically, this response was independent of CD1d as CD1-/- mice showed a similar 
response. While 5-A-RU induced a small increase in CD86 by the DC subsets, this did 
not reach statistical significance. Interestingly, mice that received 5-A-RU + MG did not 
show any significant increase in DC activation within the spleen or the liver despite 
having shown potent MAIT activation in the same tissues (Fig 4.16b). Overall, this data 
indicates that activation of MAIT cells can promote DC activation within the lungs and 
that this is independent of NKT cells. However, only when 5-A-RU was first converted 
to 5-OP-RU by the addition of MG was this apparent, suggesting that availability of 
sufficient ligand is a limiting step. Further characterisation of this response and analysis 





Figure 4.16. 5-A-RU + MG induces CD1d-independent activation of lung DCs.  (a) 
WT or CD1-/- mice (n=5) were administered PBS, purified 5-A-RU or purified 5-A-RU 
+ MG i.v. After 18 h, lungs were harvested and stained for flow cytometry. MFI was 
calculated for CD86 on lung cDC-1 and cDC-2. (b) Mice (n=5) were administered PBS 
or 5-A-RU + MG i.v. After 18 h, spleens and livers were harvested and stained for flow 
cytometry. MFI was calculated for CD86 on lung cDC-1 and cDC-2. Graphs are depicted 
with the mean ± SEM. Statistical significance was determined by Two-Way ANOVA 
with Tukey’s multiple comparisons test for (a) and a One-Way ANOVA with Tukey’s 





Previous research conducted on human MAIT cells in vitro has revealed that similar to 
other innate-like T cells19,20,255,266, they are able to provide stimulation to APCs that 
present 5-OP-RU on MR129. Upon activation, provision of CD40L by MAIT cells drives 
the differentiation and activation of immature monocyte-derived DCs to produce IL-
12p70 in an MR1-dependent manner29. This chapter aimed to assess whether MAIT cells 
could provide these helper signals towards DCs in vivo in order to determine whether 
MAIT cells could be harnessed as adjuvants for the development of new vaccines and 
immunotherapies. In the studies presented at the beginning of this chapter, the 5-A-RU 
material used was shown to be able to activate DCs in a CD40L-dependent manner and 
that co-administration of 5-A-RU with OVA could indeed adjuvant weak CD8+ T cell 
responses. Furthermore, the development of 5-A-RU-peptide conjugates not only 
enhanced DC activation but drove peptide-specific responses that could delay tumour 
growth. Unfortunately, analysis in MR1-/- mice revealed that the 5-A-RU-mediated 
responses generated with these materials were not dependent on MAIT cells. In fact, i.v. 
administration of 5-A-RU and 5-A-RU-peptide conjugate lead to CD1d-dependent 
activation of NKT cells. However, it was possible to remove the NKT cell-activating 
component within 5-A-RU by changes to the preparative method. When this was 
conducted, and 5-A-RU was converted to 5-OP-RU before injection, activation of MAIT 
cells was observed in vivo that lead activation of DCs within the lung where MAIT cells 
are numerically rich. Interestingly, this DC activation was only observed in the lung but 
not the spleen or liver where MAIT cells could be seen activated at the same time point. 
These observations point to the possibility that MAIT cells may indeed be able to adjuvant 
T cell responses; however, confounding NKT activation within the 5-A-RU compounds 
obscured any MAIT cell-based activity.  
 
The first hypothesis was the possibility that 5-A-RU, or some derivate thereof, was 
possibly binding to CD1d in order to activate NKT cells. Although CD1d molecules 
exhibit some level of promiscuity in what antigens they bind, in contrast to other MHC-I 
molecules and MR1, the CD1d antigen-binding pocket is exceptionally hydrophobic and 
lack hydrogen-bonding sites267,268. The hydrophobic and large internal A’ and F’ pockets 
which typically bind large lipids such as α-GalCer would therefore be unfit to bind a small 
polar molecule such as 5-A-RU. However, in an attempt to reconcile whether 5-A-RU 
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was the causal agent which induced NKT and DC activation, preparative HPLC was 
performed on 5-A-RU in order to isolate 5-A-RU from other possible compounds with 
alternative physicochemical properties. This was necessary as 5-A-RU was prepared as a 
crude mix from the reduction of nitrouracil by sodium dithionite which underwent no 
purification prior to in vivo use. This meant that 5-A-RU which would eventually be 
injected into mice would have trace amounts of non-5-A-RU by-products such as 
sulfonated derivatives (described in Chapter 3). Analysis of the 5-A-RU fractionated by 
HPLC revealed little defect in its ability to activate human MAIT cells and was 
subsequently injected i.v. into mice to assess NKT and DC activation. As shown, 
compared to 5-A-RU which underwent no purification, fractionated 5-A-RU (without 
being admixed with MG) completely lost the ability to activate NKT cells and DCs. This 
result suggests that MAIT cell activation induced by 5-A-RU alone itself was unable to 
adjuvant T cell responses, and there was some contaminating element causing NKT and 
DC activation. 
 
Our laboratory’s long-standing collaboration with the Ferrier Research Institute has 
resulted in the synthesis of large amounts of α-GalCer and various lipid analogues over 
the years. Although stringent cleaning and quality control protocols are in place to prevent 
cross-contamination between compounds, it was hypothesised that a steady accumulation 
of trace amounts of lipids could be the source of NKT activity in 5-A-RU preparations. 
One potential source of these lipids could be from the argon chambers used to store 
chemical compounds. These chambers are closed systems that fill with argon to displace 
oxygen in order to prevent oxidation of compounds. It is possible that during the 
displacement of oxygen, trace amounts of the compounds being stored may become 
lodged within the gas pumps and chamber; this could be a source of contamination when 
a subsequent compound is stored, with the flux in air and argon causing the contaminant 
to be dislodged. Methods to investigate this possibility are currently under investigation. 
Coincidentally, during the investigation of NKT-based activity generated by 5-A-RU and 
5-A-RU conjugates, a new laboratory was built to replace the laboratory in which α-
GalCer-related compounds had been generated. A strong piece of evidence that the source 
of NKT-activity in these 5-A-RU-based compounds is from contamination is the 
observation that all subsequent 5-A-RU batches produced in the new lab lacked any 
detectable NKT cell activating properties. However, no such further synthesis of 5-A-
RUOVA has been carried out to substantiate these observations further.  
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It is widely known that α-GalCer is a highly potent activator of NKT cells and is able to 
activate NKT cells at very low concentrations in vitro and in vivo. In our experience, i.v. 
administration of α-GalCer at a dose as low as 2ng (~2.5pmol) per mouse still resulted in 
NKT-dependent activation of DCs259. Surprisingly, despite the observations on activation 
of NKT cells by 5-A-RU, analysis by LCMS on the original 5-A-RU and 5-A-RUOVA 
compounds revealed no detectable levels of α-GalCer (data not shown, performed by 
Regan Anderson). However, other analogues or α-GalCer derivatives were not 
investigated in this manner, and it is possible that the NKT activity could be accounted 
for by co-operation of other potential agonists at minute concentrations. 
 
It is important to note that the NKT-activating observations made in these experiments 
were also seen in a separate collaborator’s laboratory who also work on NKT cells (Salio, 
personal communication). In their hands, i.v. administration of 5-A-RU also resulted in 
the activation of DCs which was abrogated in both β2m-/- (which lack MHC-I restricted 
T cells) and CD1-/- mice. Importantly, the 5-A-RU used in these experiments was 
synthesised in another chemistry laboratory. These similar NKT-dependent findings from 
two separately generated 5-A-RU batches indicates either that contamination with NKT-
activating compounds is not an isolated problem, or that the mechanism involved is not 
contamination of a “foreign” compound, but rather is a consequence of compounds or 
processes used normally in the manufacture of 5-A-RU. It is paramount that further 
investigation is carried out to understand and identify the source of NKT cell activity as 
it is possible that in other laboratories similar activities are being induced using 
compounds they expect to be devoid of this activity.  
 
Interestingly, when 5-A-RU was filtered through a 0.1µM filter before injection into mice, 
no loss in human MAIT cell activation was observed, but the filtrate failed to activate 
DCs or NKT cells in vivo. Importantly, filtration of 5-A-RU in a collaborator’s lab 
matched the observations seen in this thesis (Salio, personal communication). These data 
support the hypothesis that particulate matter is inducing NKT cell activity, and hence is 
responsible for the adjuvant activity of unfiltered 5-A-RU. There are some bodies of 
research detailing the ability of nanoparticles (NP) to modulate immune responses. When 
murine bone marrow-derived DCs (BMDCs) were incubated with carbon black NPs, 
upregulation of CD86 and enhanced allogenic mixed lymphocyte reaction were 
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observed269. Similar results were seen when BMDCs were incubated with TiO2 NPs, 
which increased expression of CD86, CD80 and MHC-II, and induced release of TNFα, 
indicative of activation270. Additionally, silica NPs showed similar results in vitro, which 
was reported to be mediated by activation of the NLRP3 inflammasome in BMDCs271. 
Together, these studies indicate that particulate matter has the ability to influence DC 
activation status, which may contribute to downstream T cell responses. The fact that 
silica NPs activated DCs is of particular interest, as silica is a common material used in 
the stationary phase of HPLC columns. It could be speculated that some silica material 
was contaminating preparations of 5-A-RU and causing the observed activation of DCs 
in vivo. The initial 5-A-RU preparations were not purified by HPLC prior to use, but the 
compounds used in manufacture were exposed to silica. The hypothesis that particles 
contributed to the NKT cell responses is hard to align with the published work on NPs, 
which was mostly conducted on isolated BMDCs in vitro and the role of specific cell 
subtypes were not investigated in the in vivo models. However, a recent publication may 
provide one explanation, where ER stress was shown to induce activation of NKT cells 
by inducing presentation of stimulatory self-lipids. In the reported study, a small inhibitor 
of ER Ca2+ ATPase, thapsigargan, induced ER stress when incubated with BMDCs272. 
As a consequence, the lipid composition of the BMDCs was altered, and when co-
cultured with NKT cells, induced their activation in a CD1d-dependent manner. 
Numerous studies detail the ability of NPs, including silica, to induce ER stress273–276. 
Thus, it would be necessary in future work to understand the nature of the particulate 
matter if it is modulating cellular metabolism such through ER-stress.  
 
A known feature of lipids is their proclivity to form large hydrophobic aggregates in polar 
solvents. Preparation of 5-A-RU for use in vivo is carried out in aqueous solution and is 
further diluted in PBS in order to be injected into mice. Therefore, it is possible that trace 
amounts of aggregates containing NKT activity could be present in these preparations. It 
is therefore possible that it was these lipid aggregates that were removed by filtration (and 
fractionation), but further work is needed to confirm this. Another possibility is that NKT 
cell-activating compounds adhere to the filter. However, lipids like α-GalCer were not 
expected to adhere to the polyvinyl fluoride filters used, and experiments by a laboratory 
colleague have confirmed that soluble α-GalCer will pass through. Nonetheless, α-GalCer 
aggregates can form in aqueous solution, and can be filtered out if of sufficient size 
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(Authier-Hall personal communication). Further work is required to examine the size and 
character of the material collected by filtration from the early 5-A-RU preparations.   
 
Loss in NKT cell-based activity of 5-A-RU after filtration suggests a microparticle 
contaminant. Transmission electron microscopy (TEM) of the filter membrane could aid 
in visually identifying microparticles and combined with scanning electron microscopy 
(SEM), and Energy Dispersive X-Ray Spectroscopy (EDS) could identify the elemental 
composition of the microparticles (i.e. organic/ inorganic material). EDS is of particular 
interest as it could confirm the presence of inorganic elements such as silica within the 5-
A-RU preparations. Furthermore, identification of organic elements would support the 
notion that the particle may be CD1d-binding ligands. To further scrutinise this possibility, 
an attempt to form crystal structures with CD1d could be employed in order to identify 
the structure of the contaminant by X-ray crystallography. However, crystallization 
requires highly pure samples in order to achieve high resolution, and it is currently 
unknown whether NKT cell-based activity from these 5-A-RU preparations is derived 
from a single compound. 
 
One of the final experiments in this chapter was an attempt to establish whether “clean” 
5-A-RU does have any activity in the absence of NKT cells by injecting WT or CD1-/- 
mice with 5-A-RU +/- MG. Interestingly, within the lungs of CD1-/- mice, both cDC-1 
and cDC-2 populations showed increased expression of CD86, indicative of activation. 
This observation highlights how the early experimental results examining MAIT cell 
activity with the initial 5-A-RU preparations were obscured by the NKT cell activating 
contaminant. In addition, the earlier studies showed that prior mixing with MG was 
dispensable for inducing DC activation despite the inclusion of this step being responsible 
for a much higher level of MAIT cell activation. In fact, due to the apparent lack of 
requirement of MG in this system, further experiments did not include the use of MG and, 
therefore, may have failed to identify true MR1-dependent responses. Moreover, the 
studies of 5-A-RUOVA have to be now reconsidered as newly synthesised ‘clean’ 5-A-RU 
was not a strong adjuvant on its own. Due to time constraints, investigation on whether 
‘clean’ 5-A-RUOVA would still result in some generation of antigen-specific responses 
could not be investigated. However, in CD1-/- mice that lacked NKT cells but not MAIT 
cells this compound failed to induce DC activation  or produce a cytotoxic CD8+ T cell 
response suggesting that MAIT cells were unlikely able to adjuvant antigen-specific 
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responses when activated with by 5-A-RUOVA. The requirement to form 5-OP-RU before 
injection to achieve DC activation within the lung suggests that the limiting step in using 
5-A-RU as an adjuvant in vivo is in formation of the adduct with cellular MG. This would 
indicate that perhaps a 5-OP-RU-peptide conjugate would more likely drive DC 
maturation and the initiation of peptide-specific T cell responses. Chemical strategies to 
do this are currently being explored. 
 
In light of the confounding impact of contaminants in 5-A-RU and related products used 
in this chapter, the next chapter will detail the use of newly synthesised and ‘clean’ 5-A-


























Chapter 5:  MAIT cells stimulate the activation of 






It has now been established that i.v. injection with 5-A-RU +/- MG could lead to 
significant activation of MAIT cells at systemic sites, namely the lung, liver and spleen.  
In the previous chapter, improvements in chemical synthesis and preparation of 5-A-RU 
resulted in a ‘clean’ product devoid of the NKT cell activity that had been seen in earlier 
preparations. Furthermore, with this new material, mice treated with 5-A-RU alone did 
not show clear evidence of DC maturation, but when mixed before injection with MG to 
form 5-OP-RU, induced significant maturation of lung DC populations in a CD1d-
independent manner. The lack of DC maturation with 5-A-RU alone was assumed to be 
due to its lower potential to activate MAIT cells when compared to injection with the 
fully-formed agonist, potentially because the availability of MG was limiting in vivo. 
Because synthetically prepared 5-OP-RU was not yet available to the laboratory, further 
studies on the impact of MAIT cell activation in vivo were conducted with 5-A-RU mixed 
with MG to form 5-OP-RU. 
 
The original hypothesis that MAIT cells can adjuvant T cell responses through the 
maturation of DCs remained untested due to the confounding contamination issue. It was, 
therefore, necessary to explore this again with the new, purified 5-A-RU in combination 
with MG. Thus, this chapter describes experiments aimed to address the remaining 
questions posed by the previous chapter about the extent to which MAIT cells and DC 





This thesis aimed to determine whether MAIT cells activated with freshly prepared 5-
OP-RU were able to act as cellular adjuvants to induce maturation of DCs and enhance 
their ability to generate adaptive T cell responses. Unfortunately, in the last chapter, the 
true influence of MAIT cells on T cell responses was obscured by an unknown NKT cell 
activating contaminant. Improvements in quality control have yielded ‘clean’ 5-A-RU 
that can mediate DC maturation within the lung in a CD1d-independent manner. 
Therefore, the overall aim of this chapter was to critically analyse the role of MAIT cells 
in this response and whether the influence of activated MAIT cells is sufficient to help 
drive T cell responses. 
 
Specifically, this chapter will address: 
• The impact of activating MR1-restricted MAIT cells in the lung following i.v. 
with 5-A-RU + MG 
• The impact of activating MAIT cells in vivo on DCs and other immune cell 
populations 
• The ability of MAIT cells to act as cellular adjuvants to stimulate T cell responses 




 Maturation of murine MAIT cells in vivo leads to maturation 
of DCs in the lung but not the liver or spleen 
In the previous chapter, it was shown that 5-A-RU could be filtered to eliminate any NKT-
mediated activity in vivo while maintaining MAIT cell activity. With the new ‘clean’ 5-
A-RU, it was also shown that when first admixed with MG, 5-A-RU could indeed activate 
DCs within the lung in a CD1d-independent manner but not within the liver or the spleen.  
 
In order to confirm that this DC maturation was mediated through MAIT cells, 5-A-RU 
+ MG was administered to C57Bl/6J and MR1-/- mice, which do not harbour MAIT cells. 
To improve the analysis on the maturation of DCs in this model, other co-stimulatory 
markers, CD80, CD40 and PD-L1 were added to the flow cytometry panel. After 
administration of the MAIT cell agonist, both cDC-1 and cDC-2 populations in the lung 
showed increased expression of CD40, CD80, CD86 and PDL-1, which was not seen in 
MR1-deficient animals (Fig 5.1), confirming the role of MAIT cells in this response. 
 
In the steady-state migratory DC populations traffic from the lung to the mediastinal 
lymph node as part of homeostatic immune-surveillance277. During infection, the number 
of migratory DCs carrying antigen entering the lung draining lymph node greatly 
increases, contributing towards the priming of CD8+ T cell responses277–279. Therefore, it 
was next examined whether DCs migrate to the mediastinal lymph node in a similar 
manner when lung resident MAIT cells were activated with 5-A-RU + MG. Migratory 
DCs that enter the lymph node can be identified by their increased expression of MHC-
II, due to immunogenic interactions in the periphery upon antigen encounter59. Therefore, 
to discriminate between migratory and residential DCs in the lymph node, expression of 
CD11c accompanied by high MHC-II expression was used as a marker of migratory DC 
while intermediate MHC-II expression was used to identify resident DCs. Analyses 
conducted 18 h after administration of the MAIT agonist showed an increase in migratory 
cDC1 and cDC2s infiltrating the mediastinal lymph nodes of treated wild-type mice, as 
seen by the increased number and frequency of MHC-IIhiCD11cint cells (Fig 5.2a & c). 
This migration was not observed in MR1-deficient mice, so was dependent on activation 
of MAIT cells. In addition to this increased frequency, which was also observed in the 
lung, the migratory DCs showed increased expression in maturation marker CD86 (Fig 
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2c). In contrast, the resident cDC1 and cDC2 populations did not exhibit any increase in 
maturation (Fig 5.2b).  
 
In summary, these results demonstrate that MAIT cells are poised to interact with DCs in 
the lung resulting in their maturation and migration into the draining LN. It is also now 
clear that MAIT cells are also unable to interact with DCs in the liver and the spleen in a 
similar manner which may be reflective of differences in population frequency or tissue-







Figure 5.1. MR1-dependent maturation of lung resident DCs. WT or MR1-/- mice 
(n=5) were administered i.v. PBS or 5-A-RU + MG. After 18 h, lungs were harvested 
and stained for flow cytometry. MFI was calculated for CD86, CD80, CD40 and PDL-1 
on lung cDC-1 and cDC-2. Data presented is representative of two independent 
experiments. Graphs are depicted with the mean ± SEM. Statistical significance was 




Figure 5.2. Activated MAIT cells mediate accumulation of activated migratory DCs 
within the mediastinal lymph node. WT or MR1-/- mice (n=5) were administered i.v.  
PBS or 5-A-RU + MG. After 18 h, mediastinal lymph nodes were harvested and stained 
for flow cytometry. (a) Resident (res) DC and migratory (mig) DC populations were gated 
according to their CD11c and MHCII expression from CD64- B220- cells. MFI was 
calculated for CD86, CD80, CD40 and PDL-1 on lung cDC-1 and cDC-2 and cell number 
enumerated from either resident (b) or migratory DCs (c). Data presented is representative 
of two independent experiments. Graphs are depicted with the mean ± SEM. Statistical 
significance was determined by Two-Way ANOVA with Tukey’s multiple comparisons 
test. 
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 Activation of MAIT cells leads to infiltration of other 
myeloid cells in the lung 
One of the hallmarks of early inflammation is the influx, activation and differentiation of 
innate-immune cells to the site of infection through the production of local inflammatory 
cytokines and chemokines. Indeed, MAIT cells have already been shown to be able to 
produce GM-CSF in response to pulmonary bacterial infection, which leads to the 
infiltration and differentiation of inflammatory monocytes27. When assessing DC 
maturation in response to 5-OP-RU in the previous experiments, it was notable that 
infiltration of other inflammatory populations was observed. Therefore, to analyse these 
cells in more detail a previously published gating strategy was used to allow for the 
detection of neutrophils, eosinophils and inflammatory monocytes280 (Fig 5.3a). When 
mice were administered 5-A-RU + MG, after 18 h there was an increase in the number 
and frequency of Ly6C+ inflammatory monocytes, neutrophils and eosinophils (although 
the frequency of eosinophils did not reach statistical significance) which was not present 
in MR1-/- mice (Fig 5.3b & c). Therefore, this data demonstrates that MAIT cells are able 
to influence the infiltration or expansion of myeloid populations within the lungs. 
 
Previous research has shown that the presence of MAIT cells during infection is important 
in the generation of pro-inflammatory cytokines that conferred protection26,187. Moreover, 
upon ex vivo stimulation, MAITs are potent producers of cytokines23,25; however, their 
ability to influence cytokine responses upon in vivo administration of 5-OP-RU has not 
been defined. Importantly, as the relationship between expression of specific cytokines 
has been correlated with the influx of defined cell populations, analysis on the cytokine 
pattern post 5-OP-RU injection in vivo could help to inform possible new cell interactions 
with MAIT cells. To address this, serum from mice was obtained 6 h after i.v. with 5-A-
RU + MG. Pam2Cys, a potent TLR2 agonist, was utilised as a positive control due to its 
potent properties in inducing systemic cytokine release. In order to analyse the cytokines, 
a 23-plex cytokine bead array was used. Within this kit, specific antibodies towards each 
of the 23 cytokines are coated onto beads with known fluorescent indexes. Therefore, this 
method allows for the simultaneous capture and differentiation of all 23 selected 
cytokines within the analyte and quantification by measuring their unique fluorescence 
intensity. Of the cytokines analysed (Appendix D) an increase in circulating IL-5 and 
granulocyte-colony stimulating factor (G-CSF) was observed after administration of 5-
A-RU + MG (Fig 5.4).  
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Collectively, these results demonstrate that activated MAIT cells can influence the lung 
immune microenvironment through recruitment, expansion or activation of other myeloid 
populations. Whether MAIT cells are directly producing cytokines such as G-CSF and 
IL-5 in response to 5-A-RU + MG or are mediating cross-activation of other immune 





Figure 5.3. Activated MAIT cells results in increased myeloid populations in the 
lung.  (a) Representative flow cytometry gating strategy to detect monocytes, eosinophils 
and neutrophils. Cells were gated first for singlets, live cells and were CD45.2+. Mice 
(n=5) were injected with PBS or 5-A-RU + MG. After 18 h lungs were harvested and 
assessed by flow cytometry. The total number of Ly6C+ monocytes, neutrophils and 
eosinophils were enumerated  from the lung (b) and the frequency as a percentage of live 
CD45.2+ cells calculated (c). Data presented is representative of two independent 
experiments. Graphs are depicted with the mean ± SEM. Statistical significance was 




Figure 5.4. MR1-dependent increase in systemic G-CSF and IL-5. Mice (n=5) were 
administered i.v. PBS, 5-A-RU + MG or Pam2Cys and bled after 6 h for serum. Serum 
was analysed by Bioplex. Data presented is representative of a single experiment. Graphs 
are depicted with the mean ± SEM. Statistical significance was determined by Two-Way 
ANOVA with Tukey’s multiple comparisons test. 
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 MAIT cell-mediated maturation of DCs is insufficient to 
help drive T cell responses 
The results so far have indicated that MAIT cells have the capacity to induce the 
maturation and migration of lung DCs and influence other lung-resident myeloid 
populations. These data indicated that MAIT cells could potentially be able to drive the 
formation of adaptive T cell responses if co-administered with antigen. Therefore, to test 
this hypothesis, mice were administered 5-A-RU + MG i.v. in combination with OVA 
and one week later, the expansion of OVA-specific CD8+ T cells within the lungs and 
spleen was assessed using an OVA257-64 (SIINFEKL)-loaded H-2Kb pentamer. As a 
positive control, OVA was injected with the TLR2 agonist Pam2Cys, which as expected, 
led to increased numbers of OVA-specific CD8+ T cells in lung and spleen relative to 
vehicle-treated controls. In contrast, co-administration of OVA with 5-A-RU + MG did 
not increase levels of OVA-specific CD8+ T cells (Fig 5.5a). 
 
This data suggests that MAIT cell activation with 5-OP-RU is not sufficient to adjuvant 
the induction of CD8+ T cell responses to soluble antigens. To further interrogate this in 
a more sensitive system, mice were administered a small population of CD8+ T cells from 
OT-I mice. These mice express transgenic TCRs specific for OVA257-264 , a CD8+ T cell 
epitope that binds to H-2Kb. With this method, flow cytometry could be used to identify 
the expansion of this OVA-specific population over time. The OT-I strain and C57BL/6J 
hosts used in this experiment were also congenic for CD45, with OT-I mice expressing 
the CD45.1 isoform, and C57BL/6 mice the CD45.2 isoform; the transgenic OVA-
specific CD8+ T cells could, therefore, be identified through the use of antibodies for the 
TCR rearrangement used in the transgene (Vα2) and expression of CD45.1.  
 
After receiving donor cells intravenously, mice were administered 5-A-RU + MG + 
OVA, or α-GalCer + OVA as a positive control which is known to induce a significant T 
cell response19. The expansion of OVA-specific T cells was followed over 10 d in the 
blood (Fig 5.5b). As expected, administration of OVA with α-GalCer lead to a significant 
expansion of the OT-I population. In contrast, no increase in OT-I cell numbers was 
observed following administration of OVA and 5-A-RU/MG. The MAIT cell-mediated 
maturation of DCs in the lung is therefore insufficient to help drive conventional CD8+ T 





Figure 5.5. MAIT cells are insufficient to drive T cell responses to OVA.  (a) Mice  
(n=3) were administered i.v. PBS, OVA or OVA combined with either 5-A-RU + MG or 
Pam2Cys. After seven days, lungs and spleens were harvested for flow cytometry. Graph 
depicts the frequency of OVA-specific CD8+ T cells by staining with an H-2Kb-
SIINFEKL pentamer from CD45+ CD64- B220- CD3+ CD8+ cells. (b) Mice (n=5) were 
adoptively transferred CD8+ OT-I cells and after 24 h intravenously administered PBS, 
OVA or OVA combined with either 5-A-RU + MG or αGalCer. At d 4,7 and 10, mice 
were bled and the number of OT-I CD8+ T cell was assessed by flow cytometry. OT-I 
cells were defined as B220- CD3+ CD45.1+ CD8+ Vα2+ cells. Data presented is 
representative of two independent experiments. Graphs are depicted with the mean ± 
SEM.  
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 Activation of MAIT cells leads to specific IL-12 production 
in lung DCs 
The heterodimeric cytokine IL-12p70, formed by covalently linked p35 and p40 subunits, 
is an essential polarizing signal that drives the differentiation of NK cells, Th1 cells and 
importantly the generation of CTLs281. Production of IL-12 by DCs, specifically cDC1s, 
are critical in the formation of adaptive CD8+ T cell responses. Given MAIT cells can 
induce DC maturation but do not appear to be able to adjuvant peptide-specific T cell 
responses it was next investigated whether MAIT cells would be able to provide 
appropriate stimuli to DCs in order to produce bioactive IL-12p70. To this end, C57BL/6 
or MR1-deficient mice were treated with 5-A-RU + MG, or Pam2Cys as a positive control, 
and bled after 6h to examine IL-12 within the circulation. No IL-12p70 or the IL-12p40 
subunit could be found in either mouse strain treated with 5-A-RU + MG (Fig 5.6a), 
whereas Pam2Cys induced significant levels. It could be reasoned that due to the lack of 
DC maturation seen at sites other than the lung, that perhaps IL-12 was produced only 
within the lungs and did not reach systemic circulation, and perhaps was sequestered 
within the local tissue environment. To explore this possibility, IL-12p40eYFP mice were 
used which contain a knock-in IL-12p40 allele linked to an enhanced yellow fluorescent 
protein (eYFP), so that cells expressing IL-12p40 will also produce eYFP. This can be 
detected by flow cytometry, allowing identification of tissue-specific IL-12 production in 
situ. These mice were injected i.v. with either 5-A-RU + MG or α-GalCer which has been 
shown in vivo to be a potent inducer of IL-12 production by DCs. The cDC2 population 
of these mice showed no significant upregulation of IL-12p40 in any of the treatment 
groups (data not shown), consistent with reports detailing that IL-12 is prominently 
produced by cDC1s282. Within the lungs, administration of 5-A-RU + MG led to a 
significant increase in IL-12p40 production, even more so than α-GalCer (Fig 5.6b). In 
line with the lack of DC maturation in the liver or spleen, 5-A-RU + MG  did not induce 
significant production of IL-12p40 at these sites, whereas significant levels were seen in 
mice treated with α-GalCer. Together these results align with the earlier findings that 
MAIT cell-mediated priming of DCs within the tissues investigated were restricted to the 
lung.    
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Figure 5.6. Tissue-specific induction of IL-12 by MAIT cells.  (a) Mice (n=5) were 
injected with 5-A-RU + MG or Pam2Cys i.v. and bled after 6 h for serum. Serum was 
analysed by bioplex to assess IL-12p40 and IL-12p70. (b) IL-12p40eYFP mice (n=3) were 
injected with 5-A-RU + MG or αGalCer i.v. Lungs, livers and spleen were harvested 
after 18 h and eYFP expression was assessed by flow cytometry on cDC-1 cells. Data 
presented in (a) is from a single experiment and (b) is representative of two independent 
experiments. Graphs are depicted with the mean ± SEM. For (a) Statistical significance 
was determined by Two-Way ANOVA with Tukey’s multiple comparisons test and (b) 
was determined by One-Way ANOVA with Tukey’s multiple comparisons test. 
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 CD40L is upregulated on activated MAIT cells but may be 
dispensable in MR1-dependent maturation of DCs 
Ligation of CD40 on human and murine DCs results in increased expression of MHC 
molecules and co-stimulatory molecules and enhances production of bioactive IL-
1215,16,18. This licensing of DCs is particularly important in the priming of CD8+ T cells 
to induce functional CTL. Stimulation of the CD40 on DCs can be accomplished by 
CD40L+ T helper cells, typically CD4+ T cells, although innate-like T cells such as NKT 
cells can also efficiently perform this role15,16,283. Because MAIT cells can express 
CD40L and have been shown to activate human DCs in a CD40-dependent fashion in 
vitro29, it was possible that the lack of T cell response to co-administration of antigen with 
the MAIT agonist in earlier experiments could be caused in a failure of MAIT cells to 
interact with DCs via CD40-CD40L interactions in vivo.  
 
To test this, it was first necessary to establish whether MAIT cells in vivo upregulate 
CD40L in response to stimulation. Mice were administered PBS or 5-A-RU + MG, and 
the levels of CD40L were measured after 3 h. In line with in vitro findings for human 
MAIT cells29, lung resident MAIT cells indeed upregulated CD40L in response to 5-A-
RU + MG (Fig 5.7a). To assess the role of CD40L-CD40 engagement in MAIT-cell 
mediated DC maturation, mice were administered a CD40L-blocking monoclonal 
antibody (αCD40L) 1 d before, and the day of, i.v. administration with 5-A-RU + MG. 
To show that the blocking strategy worked, the same regimen of antibody treatment was 
used in combination with i.v. administration of α-GalCer, as NKT cell-mediated DC 
maturation is known to involve CD40-signalling. After 18 h, NKT cell-mediated 
maturation of DCs was observed in the lung of α-GalCer-treated mice, with upregulation 
of CD86, CD80 and CD40 and PD-L1. Interestingly, upregulation of some, but not all, 
of these markers was blocked in animals treated with αCD40L, notably CD40 (on cDC1) 
and CD86 (on cDC1 and cDC2). In contrast, MAIT-cell-mediated maturation of DCs was 
not blocked by αCD40L antibody, except CD40 upregulation on cDC2 (Fig 5.7b). 
Although not definitive, these results would indicate that CD40L may not be a primary 
mechanism in which MAIT cells induce DC maturation and may be why 5-OP-RU is 
unable to induce T cell responses in combination with antigen.  
  
 137 
Figure 5.7. Upon activation MAIT cells upregulate CD40L but is dispensable in the 
maturation of DCs.  (a) Mice (n=5) were administered i.v. PBS or 5-A-RU + MG. After 
3 h lungs were harvested and MAIT cells were assessed for upregulation of CD40L and 
MFI was calculated by flow cytometry (b) Mice (n=5) were administered 
intraperitoneally αCD40L antibody or Armenian Hamster IgG as control the day before 
and the day of i.v. with PBS, 5-A-RU + MG or αGalCer. After 18 h, lungs were harvested 
and stained for flow cytometry and MFI was calculated for CD86, CD80, CD40 and PDL-
1 on lung cDC-1 or cDC-2. Average of PBS MFI for each marker is represented by the 
dotted line. Graphs are depicted with the mean ± SEM. Statistical significance for (a) was 




 Role of type I interferon signalling in the response to 5-A-
RU + MG 
As CD40-CD40L ligation did not appear to be critical in the MAIT-dependent DC 
maturation seen, it was possible that MAIT cells mediated DC maturation through a 
contact independent manner mediated by cytokines. Type I IFN are known as activatory 
cytokines that can drive the maturation and differentiation of DCs through binding to the 
IFN α/β receptor (IFNAR) on the cell surface.90,284,285. Thus, it was determined whether 
type I IFNs signalling played a role in MAIT cell-mediated DC maturation in the lungs.  
 
One way to examine whether type I IFNs was involved in MAIT cell-mediated DC 
maturation was to look for expression of markers regulated by IFN regulatory factors. 
Bone marrow stromal Ag 2 (BST-2), a transmembrane protein that prevents virus release 
from infected cells, is one such marker. Importantly, the BST-2 promotor contains an IFN 
regulatory factor binding site, and as a consequence BST2 expression upregulated upon 
many different immune cell-types after exposure to type I IFNs, including DCs286. 
Therefore, expression of BST-2 was examined on DCs after administration of 5-A-RU + 
MG. As a positive control for this experiment, the TLR3 agonist, poly I:C, was used as 
TLR3 is highly expressed on pDCs, a cell-type that produces marked amounts of type I 
IFNs upon stimulation. Interestingly, mice treated with 5-A-RU + MG showed an 
increased expression of BST-2 on lung cDC2, and a trend towards increased expression 
on cDC1 that did not reach significance (Fig 5.8a). Expression of BST-2 on these DCs 
indicates the exposure to type I IFNs in this model. One possibility is that MAIT cells 
could be directly reacting to 5-OP-RU loaded on MR1 on pDCs, which are potent 
producers of type I IFN. Therefore, the maturation status of pDCs was assessed in the 
lungs by gating on CD11c+ B220+ cells that express the pDC-associated marker SiglecH+ 
cells (after excluding CD64+ macrophages) and examining CD86 expression. There was 
a minor but significant increase in pDC maturation in response to 5-A-RU + MG (Fig 
5.8b). These results collectively suggest that type I IFNs are involved in MAIT cell-
mediated maturation of cDCs, and that this may be stimulating IFN production by 
activating pDCs.  
 
To assess the extent in which Type I IFNs are involved in driving DC maturation, mice 
were treated with an antibody which blocks IFNAR on d -1 and d 0 in order to prevent 
binding of IFNα or β. On d0, mice were also treated with 5-A-RU + MG, and after 18 h, 
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the level of DC maturation was measured. Again, Poly I:C was used as a positive control 
as a known inducer of type I IFN, which could be significantly blocked by αIFNAR pre-
treatment (Fig 5.9). In contrast, type I IFN signalling seemed to be dispensable in mice 
treated with 5-A-RU + MG. With the exception for minor decreases in CD40 expression 
and PDL-1 expression in DC-2, the DC maturation by 5-A-RU + MG was largely 
unaffected by αIFNAR treatment. Collectively, this data shows that in vivo administration 
of 5-A-RU + MG does result in some type I IFN signalling. However, these signals were 






Figure 5.8. BST-2 upregulation of DCs and maturation of pDCs. Mice (n=5) were 
administered i.v. PBS or 5-A-RU + MG. After 18 h, lungs were harvested and stained 
for flow cytometry. (a) MFI for BST-2 was calculated on cDC-1 and cDC-2 and CD86 
was measured on pDCs identified as CD11c+ SiglecH+ cells from B220+ CD64- cells. 
Data presented is from a single experiment. Graphs are depicted with the mean ± SEM. 




Figure 5.9. Type I IFN signalling is not crucial in MAIT-dependent DC maturation 
in the lung. Mice (n=5) were administered intraperitoneally αIFNAR antibody or Rat 
IgG as control on d -1 and d0. On d0 mice were administered PBS, 5-A-RU + MG or 
Poly I:C i.v. After 18 h, lungs were harvested and stained for flow cytometry and MFI 
was calculated for CD86, CD80, CD40 and PDL-1 on lung cDC-1 or cDC-2. Data 
presented is from a single experiment. Graphs are depicted with the mean ± SEM. 
Statistical significance was determined by Two-Way ANOVA with Tukey’s multiple 
comparisons test.  
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 Co-administration of a TLR agonist with 5-A-RU + MG helps 
drive CD8+ T cell responses 
Previous studies conducted on human DCs in vitro showed that signals from activated 
MAIT cells co-operate with stimuli via pathogen-derived pattern recognition receptors to 
induce release IL-12p70, the bioactive form of IL-1229. To determine if a similar 
cooperative activity was required to improve DC function and support T cell responses 
in vivo, OVA and 5-A-RU + MG was injected with low doses of the TLR2 agonist 
Pam2Cys. As seen in Fig 5.10a, combining MAIT cell activation with TLR stimulation-
induced increased expression of maturation markers CD86, CD40 and PDL-1 on lung 
DCs, observed 18 h after the administration of the agonists. Using this combination of 
agonists with administration of OVA protein also resulted in enhanced induction of an 
OVA257-64-specific CD8+ T cell response compared to when OVA was injected with 5-A-
RU/MG or Pam2Cys alone. These responses were observed without transfer of OT-I cells, 
so represent activated cells from the endogenous T cell repertoire. The enhanced 
responses in lung and liver after 7 d were statistically significant, whereas the slight 
improvement in spleen did not reach significance. Critically, the impact of including 5-
A-RU + MG was abrogated in MR1-deficient animals, highlighting the role of MAIT 
cells in the response (Fig 5.10b). Therefore, given the correct additional signals, MAIT 




Figure 5.10. MAIT cells can co-operate with TLR signalling to induce T cell 
responses to OVA.  (a) Mice (n=3) were administered i.v. PBS, 5-A-RU + MG, 375ng 
of Pam2Cys or combined 5-A-RU + MG and Pam2Cys. After 18 h, lungs were harvested 
and stained for flow cytometry and MFI was calculated for CD86, CD40 and PD-L1 on 
all cDCs. (b)  WT and MR1-/- mice (n=5) were administered i.v. PBS, OVA or OVA 
combined with either 5-A-RU + MG, 375ng of Pam2Cys or a combination of 5-A-RU + 
MG and Pam2Cys. After 7 d, lungs and livers were harvested for flow cytometry. Graph 
depicts the frequency of OVA-specific CD8+ T cells by staining with an H-2Kb-
SIINFEKL pentamer as in Fig 6a. Data presented is representative of two independent 
experiments. Graphs are depicted with the mean ± SEM. Statistical significance was 





In the previous chapter, it was established that 5-A-RU alone was insufficient to induce 
maturation of DCs, but could do so if mixed with MG prior to injection to form the active 
ligand 5-OP-RU. Here, when looking at lung tissue, i.v. injection with 5-OP-RU lead to 
significant upregulation of co-stimulatory molecules in both cDC-1 and cDC-2 
populations (with the exception of CD86 on cDC-2). Importantly, this response was 
completely dependent on MR1, confirming that MAIT cells were responsible for the 
cross-talk with DCs in vivo. Interestingly, this DC maturation was only seen in the lung, 
but not in the liver nor the spleen. This result may be reflective of differences in the 
frequency of MAIT cells between the tissues tested. A previous report showed that lung 
MAIT cells were the most frequent tissue population in C57BL/6 mice, accounting for 
~3% of lung T cells, whereas MAIT cells in the liver and spleen represent only ~0.5% 
and ~0.06% of T cells, respectively23. The number of MAIT cells available to feedback 
onto DCs may, therefore, be a critical determinant in the observed response. However, 
the frequency of MAIT cells in our colony of C57BL/6 mice differs from this report, with 
both the lung and the liver having similar frequencies of around 0.5% of T cells 
(Appendix B). This would suggest that some tissue-specific functionality of MAIT cells 
exists that may affect their propensity to interact with DCs. A published microarray 
analysis of mouse MAIT cells, which included unsupervised clustering, showed that 
across the lung, liver and spleen, MAIT cells have distinct transcriptional profiles198, 
supporting the notion that MAIT cells show tissue-specific functionality. The genes that 
would distinguish cells with capacity for DC maturation would require further 
investigation. The dataset from the microarray study is publicly available and could be 
further analysed to assess any baseline differences between different MAIT cell 
populations in genes associated with DC cross-talk such as co-stimulatory receptors, 
cytokines and adhesion molecules. One limitation of this analysis would be that these 
tissue-specific differences in functionality may only become apparent when MAIT cells 
become activated, influenced by their tissue microenvironment.  
 
Transport of antigen to draining lymph nodes is an important mechanism in the generation 
of adaptive immune responses. Tissue-resident DCs that acquire antigens and receive 
signals to migrate, upregulate key chemokine receptors such as CCR7 in order co-localise 
and interact with naïve T cells within lymph nodes59. Alternatively, molecules can also 
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directly drain into the lymph nodes independent of cellular uptake. In mice treated with 
5-A-RU + MG there was a marked increase of migratory DC in the mLN, which was 
MR1 dependent. Furthermore, these migratory DCs had a higher maturation status than 
resident DCs, indicating that MAIT cells within the LN were not interacting with and 
activating resident DCs but rather maturation occurred through lung-resident MAIT cells 
that resulted in the trafficking of DCs to the LN. A limitation of these observations, 
however, is the inability to distinguish between resident and migratory DCs with high 
specificity in this model. It is possible that DCs within the lymph node did indeed become 
activated and as a result, upregulated MHC-II and merged with migratory DCs in the flow 
cytometry gate. Indeed, there was decrease of the number of resident DCs (although 
statistically insignificant) in mice treated with 5-A-RU + MG, and activated MAIT cells 
were observed in the mLN after i.v. injection at the same time point (data not shown). 
Fluorescently-labelled antigens have been used in order to study DCs draining to afferent 
lymph nodes which clearly distinguishes migratory versus resident populations287–289. If 
the population of migratory DCs observed is solely derived from lung tissue a similar 
approach with a fluorescently labelled 5-OP-RU would allow accurate identification. 
Such a compound was not available for the studies here. However, due to 5-OP-RU being 
a small molecule, attachment of a fluorescent molecule may heavily impact on its 
biodistribution and the cells which preferentially endocytose it. Alternatively, pertussis 
toxin could be used to inhibit G protein-coupled migration of DCs into lymph nodes290 to 
determine the relative contributions of lung vs mLN resident MAITs in this response. 
 
After injection with 5-A-RU + MG, an increase in the number and frequency of Ly6C+ 
monocytes could be seen. In vivo infection of mice with F. tularensis revealed that GM-
CSF production by MAIT cells can drive the differentiation of inflammatory monocytes 
which may contribute to the recruitment of CD4+ T cells in this model27. A number of 
other in vivo studies confirm that inflammatory monocytes readily contribute to the 
recruitment of CD4+ T cell responses during microbial infections291–294. Therefore, it is 
possible that activation of MAIT cells by 5-A-RU + MG could be used to direct the 
expansion of antigen-specific CD4+ T cells through the recruitment of inflammatory 
monocytes. Unfortunately, the induction CD4+ T cell responses were not directly 
measured in this chapter; however, this possibility is currently under investigation.  
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Analysis of serum cytokines also revealed an increase in the levels of IL-5 and G-CSF, 
which was followed by an infiltration of eosinophils and neutrophils into the lung tissue. 
During the course of helminth infections, eosinophils are recruited to the site of infection 
through Th2-associated cytokines such as IL-4 and IL-13 and the chemokine eotaxin 
where they are subsequently activated by IL-5. NKT cells can also induce eosinophilia 
after intranasal administration of α-GalCer295. In this model, NKT cells could recruit 
eosinophils in an IL-4 and IL-13 dependent manner and directly activate them through 
the production of IL-5. Current literature suggests that MAIT cells are not producers of 
these Th2 cytokines, evident in their limited expression of GATA3190. Production of high 
levels of IL-13 has been observed in MAIT cells, although only after multiple rounds of 
stimulation in vitro296. In the current study, there was no evidence of increased levels of 
eotaxin, IL-4 or IL-13 in the serum of mice treated with 5-A-RU + MG. However, 
analysis of cytokines in serum may have limited sensitivity as the observed MAIT cell-
mediated responses appear to be isolated to the lung. Therefore, to further these findings 
analysis of bronchoalveolar lavage (BAL) fluid may reveal some significant differences 
in cytokine levels after treatment as it would provide a more concentrated and 
representative sample of the local inflammatory environment.  
 
Neutrophils are key anti-microbial effector cells of the innate immune system that can 
eliminate bacteria through phagocytosis, the release of anti-microbial proteins 
(degranulation), or production of neutrophil extracellular traps (NETs)297. In addition to 
these direct anti-microbial functions, neutrophils can also exhibit anti-inflammatory 
properties. In response to α-GalCer, neutrophils rapidly migrate to sites of NKT-mediated 
inflammation and directly inhibit their function through cell-cell contact298. A recently 
published paper described this function in human MAIT cells, where neutrophils 
suppressed MAIT cell function through a process that involved cell-cell contact and was 
dependent on H2O2299. Additionally, the authors showed that TNF-production by MAIT 
cells in vitro mediated neutrophil death. A negative feedback loop was proposed in which 
MAIT cells and neutrophils suppress one another in order to resolve inflammation. 
Neutrophils also promote tissue repair through the release of IL-22 and promotion of cell 
proliferation300. It is unknown in this current study whether activation of MAIT cells led 
to significant lung pathology, although no overt changes were observed. It could be 
hypothesised that neutrophils may be reacting to a chemokine/cytokine gradient as a 
result of MAIT-mediated inflammation. For example, IL-17, known to be highly 
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expressed by MAIT cells, induces G-CSF, CXCL1, CXCL2 and CXCL5 production in 
mouse fibroblasts and epithelial cells which are known to promote the recruitment of 
neutrophils301–303. 
 
Having established that MAIT cells were able to induce inflammation within the lung and 
drive the maturation and migration of DCs, it remained possible that MAIT cells could 
function as cellular adjuvants to help induce adaptive immune response to antigens. 
However, when mice were co-administered 5-A-RU + MG and OVA protein, there was 
no expanded pool of OVA-specific CD8+ T cells detected in the lung or the spleen after 
7 d. Furthermore, increasing the sensitivity of detecting a response by adoptively 
transferring a cohort of naïve transgenic OVA-specific CD8+ T cells before “vaccination” 
also yielded no results. This result was surprising considering high levels of co-
stimulatory markers present on the cDC-1 population within the lung.  
 
It is well established that the CD40-CD40L signalling axis is critically important in 
driving effective T cell responses. When DCs lack CD40, they are unable to prime CD4+ 
and CD8+ T cells even when they have high expression of MHC and co-stimulatory 
markers CD80/8618. Importantly, ligation of CD40L to CD40 is critical in ‘licensing’ DCs 
to produce IL-12 and effectively engage with naïve CD8+ T cells15,18,157. Indeed, it was 
found that lung MAIT cells were also able to upregulate CD40L in response to injection 
with 5-A-RU + MG. However, blockade of CD40L did not show any effect on 
upregulation of any of the co-stimulatory markers in mice treated with 5-A-RU + MG, 
suggesting a possible fault in the ability of MAIT cells to engage CD40L with CD40 on 
DCs or that this was not the mechanism by which MAITs promoted DC maturation. The 
clear limitation of these observations is that only CD86 and CD40 expression was 
significantly down regulated by CD40L blockade in α-GalCer treated mice, a treatment 
that is known to enhance T cell responses via CD40-signalling, and therefore acted as the 
positive control. In order to definitively assess the role of CD40L in this model, it would 
be relevant to examine the effect of CD40L blockade further upstream of the response, 
such as in the ability to produce IL-12 (which is known to be modulated by CD40-
signalling). To improve upon the antibody blocking method used, detection of CD40L 
expression by flow cytometry could be used to confirm blockade of this molecule, as 
blockade would obscure binding of fluorescently labelled CD40L (of the same clone). 
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Alternatively, use of CD40L deficient mice would overcome antibody blocking 
challenges.  
 
As DC maturation by MAIT cells did not seem to require CD40L signalling, this 
prompted an investigation in whether MAIT cell-mediated maturation was mediated by 
soluble factors such as cytokines which are also known to be key drivers of DC 
maturation. Type I interferons, i.e. IFNα/β, are known to drive DC maturation285. There 
was some indication that type I IFN signalling was induced by administration of 5-A-RU 
+ MG as cDC-1s showed a modest upregulation of the type I IFN-inducible marker BST-
2. Plasmacytoid DCs are one of the main producers of these IFNs, and after treatment 
with 5-A-RU + MG showed a marginal level of maturation. This observation aligns with 
results seen in vitro showing, that human MAIT cells could activate pDCs in an MR1-
dependent manner29. However, when mice were treated with IFNAR blocking antibody 
then treated with 5-A-RU + MG, the state of DC maturation was largely unaffected 
(except for minor decreases in CD40). Therefore, there is evidence for type I IFN 
signalling in this model; however, it appears dispensable in the maturation of DCs. 
 
One of the key pro-inflammatory cytokines involved in priming T cell responses is 
bioactive IL-12p70, constituting a heterodimer complex of IL-12p40 and IL-12p35. 
Analysis of serum cytokines after i.v. injection with 5-A-RU + MG showed no signs of 
circulating IL-12p40 or IL-12p70. This result is perhaps unsurprising since activated DCs 
could only be found within the lungs in this model which may constrain the amounts of 
IL-12 that make it into the systemic circulation. Therefore, it was important to assess 
direct production of IL-12 by the DCs themselves; however, intracellular staining for IL-
12 is notoriously difficult. The use of IL-12p40eYFP reporter mice revealed that indeed IL-
12p40 production could only been seen in DCs within the lung. However, production of 
IL-12p40 is not directly indicative of the formation of IL-12p70 as it must combine with 
IL-12p35 to form bioactive IL-12. In fact, evidence in the literature suggests that 
homodimers of IL-12p40 have an inhibitory role, suppressing Th1 and Th17 responses 
through competitive binding of the IL-12 receptor304–306, which may explain the lack of 
T cell expansion despite the presence of IL-12p40 producing DCs. Moreover, several 
studies have detailed the use of IL-12p40 homodimers as inhibitors of mouse models of 
inflammation307,308. Therefore, without direct measurement of IL-12p35 production in 
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DCs as a response to MAIT cell activation in vivo, it cannot be ruled out that MAIT cell-
DC interactions result in the generation of inhibitory homodimers of IL-12p40.  
 
It is also important to note that MAIT cells have been shown to induce IL-12p70 by DCs 
only when 5-OP-RU was combined with TLR agonists. When DCs were loaded with 5-
OP-RU and then co-cultured with human MAIT cells, significant levels of IL-12p40 
could be detected but not IL-12p70. However, when the TLR4 agonist, 
lipopolysaccharide (LPS), or the TL7/8 agonist, resiquimod (R848), were added to these 
co-cultures, the DCs were able to produce significant amounts of IL-12p70 in an MR1-
dependent manner. This data demonstrates that MAIT cells activated by 5-OP-RU on 
DCs alone are unable to produce IL-12p35 to form bioactive IL-12p70. This may explain 
the inability of 5-A-RU + MG to adjuvant CD8+ T cell responses when combined with 
OVA in vivo, as IL-12p70 is a critical cytokine in CD8+ T cell priming. This is an 
interesting finding as NKT cells can  induce IL-12p70 production by α-GalCer 
stimulation alone without TLR signalling. Perhaps one of the discrepancies between these 
two cell types is the ability to produce IFNγ in response to TCR stimulation, a cytokine 
which is known to regulate the expression of IL-12p35 specifically. At steady-state, the 
majority of NKT cells in the B6 mouse are NKT1 cells expressing T-bet and high amounts 
of IFNγ. In contrast, the majority of MAIT cells are MAIT17, expressing high levels of 
RORγt and IL-17. Thus, the over-representation of the MAIT17 subtype in B6 mice may 
result in failure to produce sufficient IFNγ in order to induce IL-12p35 in DCs. This 
further emphasizes the need to experimentally determine whether after injection with 5-
A-RU + MG if lung resident DCs produce IL-12p35 as it may be a limiting factor in the 
formation of IL-12p70 to prime antigen-specific CD8+ T cells.   
 
To assess whether TLR stimulation would enhance MAIT cell-mediated DC functionality 
similar to the described in vitro studies above, 5-A-RU + MG was administered in 
combination with the TLR2 agonist, Pam2Cys. This combinations strategy resulted in 
enhanced maturation of DCs, which could not be achieved with either stimulus (at the 
doses used) alone. Importantly, when these stimuli were administered with OVA, 
expanded populations of endogenous OVA-specific CD8+ T cells were observed in both 
the liver and the lung, in an MR1-dependent manner. Therefore, while the action of MAIT 
cells alone is insufficient to drive an appropriate level of maturation of the DCs, additional 
stimuli can overcome this deficit. It is assumed that this increased activity is through the 
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action of the TLR agonist on DC, although it is also possible that TLR stimulation directly 
augments MAIT cell functionality through TLRs on the cells themselves, perhaps through 
promoting the enhanced expression of CD40L or release of cytokines. Indeed, activated 
CD4+ T cells can express TLR2 and produce higher levels of IFNγ when stimulated by 
bacterial lipopeptide309. Furthermore, it possible that TLR stimulation is enhancing T-bet 
expression in MAIT cells, resulting in increased IFNγ production. A recently published 
study modelling pulmonary infection with Legionella longbeachae shows that MAIT 
cells activated by bacterial infection but not 5-OP-RU alone were able to stimulate T-bet 
expression in MAIT cells221. This would suggest that in this model, TLR stimulation in 
combination with 5-A-RU + MG may be modulating MAIT cells towards a more Th1 
and IFNγ producing phenotype which would favour CD8+ T cell priming through 
enhanced IL-12p70 production. It has also been shown that TLR stimulation induces 
MR1 presentation by APCs in vitro, which in turn enhances MAIT cell activation238,245. 
A combination of these activities is entirely possible. At the doses used, TLR stimulation 
with Pam2Cys alone induced only a limited level DC maturation. When combined with 
MAIT cell activation, this MyD88-dependent expression of transcription factors such as 
NFκB100,310 may co-operate with as yet undefined MAIT cell-mediated signals to DC to 
enhance activation status. Of relevance here, it has been shown that lung MAIT cells can 
be induced to proliferate after intranasally administered 5-OP-RU, but this requires co-
administration of the TLR agonists Pam2Cys, CpG, or Poly I:C246. Like the observations 
here, in this model signals mediated via TLRs may be altering MAIT cell functionality 
directly, or through enhancing the capacity of APCs to stimulate MAIT cell activation 
and proliferation. This collective body of evidence highlights the importance of TLR co-
operation in MAIT cell responses; however, the full extent and manner in which these 
co-operative activities affect adaptive immunity is not completely understood. The data 
here suggest signals mediated via TLR2 in particular can co-operate with MAIT cells to 
have impact on T cell responses. Whether other TLRs or indeed other forms of pattern 
recognition, can mediate similar cooperative activities remains to be established.  
 
Similar co-operative properties have been shown between NKT cells and TLR ligands, 
where a combination of α-GalCer with a variety of different TLR ligands was shown to 
greatly enhance T cell responses to soluble antigens21. This was interpreted to reflect 
improved DC activity but, as above, the NKT cells could potentially respond to TLR 
stimulation directly via TLRs they express themselves. Indeed, it is known that NKT cells 
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express TLR4, and therefore can react directly to LPS. In experimental models of contact 
hypersensitivity, LPS has been shown to activate NKT cells in a TCR-independent 
manner to produce IL-4, which in turn activates B-1 cells to produce IgM and the 
recruitment of T cells311–314. Additionally, CD1-/- mice, which have no NKT cells,  show 
defects in the ability to produce IFNγ, IL-12 and TNFα when administered LPS314. 
Together, these data suggest that NKT cells are major mediators in innate immune 
responses to TLR stimulation. It is possible that MAIT cells may be acting cooperatively 
with TLR stimulation in a similar manner.  
 
In summary, this chapter details evidence for a novel role of MAIT cells within the lungs. 
Marked activation of lung resident DCs could be seen after i.v. injection with 5-A-RU + 
MG, which also resulted in the accumulation of activated DCs within the mLN. 
Activation of MAIT cells in vivo also resulted in the appearance of multiple myeloid 
populations within the lung tissue, revealing new roles for MAIT cells in modulating 
immune responses. MAIT cells alone were unable to provide sufficient help to drive 
adaptive CD8+ T cell responses; however, in combination with TLR signalling could 
facilitate the expansion of antigen-specific CD8+ T cells. There is still much investigation 
required in order to understand the exact mechanisms by which MAIT cells interact with 
DCs. However, this is the first evidence to support the concept that MAIT cells can act 
as cellular adjuvants, and provides a novel platform to explore the use of MAIT cell 
agonists in the design of novel immunotherapies. 
  
 152




 Complications in the synthesis and use of 5-A-RU 
 
Since the identification of the MAIT cell agonists, 5-OP-RU, 5-OE-RU and 5-MOP-RU 
and their precursor, 5-A-RU, numerous studies have detailed their use both in vitro and 
in vivo in order to investigate MR1 presentation and MAIT cell biology. Unfortunately, 
at the outset of this thesis efficient synthesis of the most potent known MAIT agonist, 5-
OP-RU, was not yet achievable due to its unstable nature and proclivity to rapidly cyclise 
to inactive lumazines210. To circumvent these obstacles, the MAIT agonist precursor, 5-
A-RU, which could be synthesised more readily, was used in this thesis to assess the 
influence MAIT cells have on adaptive immunity. Use of this precursor was initially 
regarded as an attractive approach, as 5-A-RU alone was also shown to be sufficient to 
drive MAIT cell activation due to availability of dicarbonyls as a byproduct of eukaryotic 
metabolism to condense with 5-A-RU to form MR1-antigens in situ. However, 5-A-RU 
also has stability issues, which were investigated in detail in this thesis. 
 
 Overcoming the instability of 5-A-RU 
As had been noted earlier by other groups, 5-A-RU is prone to oxidation; however, the 
extent and consequences of this instability on MAIT cell activation had been 
understudied231,236. In one study, 5-A-RU was shown to degrade to unidentified products 
as early as 21 h when left at ambient temperature and exposed to light. However, the data 
in this thesis clearly shows that the propensity of 5-A-RU to undergo oxidative 
degradation was previously highly underestimated. In fact, loss of 5-A-RU occurs as early 
as a few minutes after exposure to oxygen in dilute aqueous solutions typically used in 
biological studies. Furthermore, incubation of these downstream oxidized products with 
human PBMCs revealed that they were unable to activate human MAIT cells. These 
findings are particularly relevant for immunologists who wish to use 5-A-RU, as this 
tendency to swiftly undergo oxidation occurs much faster than previously shown and 
could hamper reproducibility of biological studies. Thus, care should be taken when 
handling and storing 5-A-RU, and dilution to aqueous solutions should be minimized 
prior to use. 
 
To circumvent these problems, 5-A-RU was conjugated to a cathepsin-cleavable VC-
PAB linker to form a prodrug which greatly enhanced stability, even at room temperature. 
This stability was clearly demonstrated when the compound was exposed to air in 
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aqueous solution for up to 21 days without any signs of degradation. Stability of 5-A-RU 
has previously been achieved through preparation as an HCl salt which significantly 
improved shelf life231. However, the prodrug formulation used in this thesis has a 
significant additional advantage in that it was able to induce increased MAIT cell 
activation compared to native 5-A-RU. This was evident when 5-A-RUL (compound 10) 
was compared to 5-A-RU in in vitro cultures with human MAIT cells, and when the 
activation of lung-resident MAIT cells was evaluated after intravenous administration 
into mice. It is possible that this increased MAIT cell activity could be attributed to the 
increased stability of 5-A-RUL, and hence prolonged availability of the agonist precursor 
(after enzymatic release). The increased stability of the prodrug could be due to the 
electron-withdrawing properties of the VC-PAB linker, with the prodrug form preventing 
nucleophilic attack by chemical species such as oxygen. The linker may, therefore, confer 
protection of 5-A-RU en route to APCs in cell culture, or within systemic circulation after 
intravenous administration, where it may otherwise be susceptible to reactive species. 
This protection would, therefore, lead to an increase in intracellular concentrations of 5-
A-RU which confers the enhanced MAIT cell activatory properties of 5-A-RUL.   
 
With the rise of research on MAIT cells, the synthesis and use of activatory compounds 
such as the MR1 ligand precursor 5-A-RU are becoming more widespread; however, not 
all laboratories have access to chemists able to produce such compounds. Therefore, with 
access being a limiting factor, a prodrug that can be shipped at room temperature without 
compromising integrity is a welcome advance to the field. However, despite the increased 
activity of the prodrug over native 5-A-RU, it was not as potent as 5-OP-RU, although 
the latter had to be prepared fresh for each experiment by combining 5-A-RU with MG. 
This, therefore, suggests that conversion of the prodrug to active agonist is not maximized, 
which could be due to either slow turnover into 5-A-RU or limiting MG. To overcome 
this disadvantage, a 5-OP-RU prodrug could be developed. Generation of a prodrug from 
5-A-RU was achievable as the 5-amino group provided an accessible reactive site to 
attach the VC-PAB linker, and also conveniently impeded oxidative degradation, thereby 
enhancing stability. However, condensation of 5-A-RU with MG to form 5-OP-RU leads 
to loss of this amino group and consequently the original attachment site for the VC-PAB 
linker. To stabilise 5-OP-RU it would be necessary to impede its cyclisation into the 
weaker MR1 ligand, RL-7-Me. Furthermore, linkers that take advantage of release under 
acidic conditions such as within endosomes would be advantageous to ensure the 
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selective release of 5-OP-RU in proximity with MR1 molecules. The prospect of 
alternative linker chemistries that could fulfil these criteria is currently being explored 
through our collaboration with the Ferrier Research Institute. 
 
 A confounding NKT cell-activating factor in 5-A-RU and 5-
A-RU conjugates 
The assessment of 5-A-RU and peptide conjugate derivatives in vivo revealed a unique 
problem. While administration of 5-A-RU or 5-A-RUOVA to mice induced activation of 
splenic DCs, and the conjugate induced peptide-specific responses, both of these 
activities were dependent on CD1d-restricted NKT cells which obscured the contribution 
of MAIT cells. It was initially thought to be possible that MAIT cells were somehow 
cross-activating NKT cells, which were then providing the majority of the DC stimulation. 
As similar findings were made in a collaborator’s laboratory, where the source of 5-A-
RU was different, we were confident in this initial hypothesis. However, fractionation 
and filtration of 5-A-RU in later experiments revealed that a microparticle contaminant 
was the cause of NKT-cell activation, which could be removed while retaining the MAIT 
cell-activating properties. It was presumed that a similar contaminating element was the 
cause of NKT cell activity within 5-A-RUOVA; however, this could not be definitively 
assessed due to lack of sufficient material. A similar filtration method employed during 
the investigation of 5-A-RU may also prove difficult as 5-A-RUOVA is non-polar and tend 
to form aggregates that could prevent filtration. 
 
Unfortunately, the nature of this NKT cell-activating property could not be identified by 
the means explored in this thesis. As discussed, the possibility of 5-A-RU forming a CD1d 
ligand is likely to be low due to the physical constraints of the hydrophobic CD1d-binding 
pocket267,268. However, the possibility of this should still be explored by trying to form 
crystal structures of 5-A-RU with CD1d. An alternative explanation is that the 
manufacturing process for 5-A-RU  itself introduced a contaminant that activates NKT 
cells directly or indirectly. A direct NKT cell-activating contaminant could be identified 
with the use of lipid digesting enzymes. A range of glycosphingolipids are known to dock 
CD1d and activate NKT cells315. As an example, with α-GalCer, the ceramide group binds 
to the CD1d groove through insertion of the phytosphingosine and acyl chain within the 
F’ and A’ pocket, respectively267,316,317. The enzyme imiglucerase, an analogue of the 
human β-glucocerebrosidase, cleaves sugars such as galactose from ceramides318,319 that 
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are required to contact the NKT TCR and could be used to treat 5-A-RU preparations. 
Thus, elimination of NKT activity by imiglucerase would suggest a direct NKT cell-
activating ligand contaminant. Alternatively, as discussed, an indirectly NKT cell-
activating compound such as particulate matter could be activating DCs through an 
undefined mechanism. The chemical composition of the contaminants (i.e. inorganic or 
organic) could be analysed by a combination of microscopy methods such as TEM, SEM 
and EDS. It is important to reiterate that these NKT cell-activating properties were 
observed in 5-A-RU prepared from two separate laboratories, both of which manufacture 
lipid compounds. This would favour the former hypothesis that a direct NKT cell agonist 
is the contaminant. Moreover, in both labs, inconsistencies have been noted between 
batches of 5-A-RU in their ability to activate NKT cells and drive DC activation. These 
observations would, therefore, again favour the presence of a contaminant over an innate 
property of 5-A-RU to activate NKT cells. 
 
The fact that an NKT cell activation was seen in two laboratories and could be filtered 
out is particularly relevant as the manufacture and use of 5-A-RU, and its derivatives are 
increasingly being used in the growing MAIT cell field. If the introduction of an NKT 
cell contaminating element can occur simply from the manufacturing process, this may 
be a systemic problem that is occurring in other laboratories that produce 5-A-RU. 
Therefore, it is possible that NKT cell activity could be contributing to the biological 
phenomenon observed when using 5-A-RU. It would, therefore, be of great interest to 
test other sources of 5-A-RU for NKT cell activity and whether this activity could be 
ameliorated by filtration.  
 
New protocols have been established from the observations in this thesis in order to 
ensure that new 5-A-RU preparations are devoid of NKT cell activity. Using flow 
cytometry, lack of NKT activation can be confirmed by analysis of the spleen 18 hours 
after i.v. administration into mice. To eliminate any NKT activity, filtration of 5-A-RU 
stocks can be easily achieved by centrifugation through a 0.1µM filter. Subsequently, the 
ability of filtered 5-A-RU to activate MAIT cells can then be confirmed by testing a range 
of concentrations on human PBMCs in vitro. 
 
 Access of endosomal MR1 by a 5-A-RU prodrug 
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The canonical mode of presentation of antigen via MHC-I occurs firstly within the ER 
where appropriate binding of peptides ultimately results in translocation of MHC/peptide 
complexes to the cell surface for presentation towards T cells38. In addition to this, MHC-
I molecules are continually internalised from the cell surface and are either targeted for 
destruction or may recycle to the cell surface after an exchange of antigen320. Recent 
studies have revealed that MR1 molecules follow similar pathways to MHC-I recycling 
where antigen can be captured in endosomes containing MR1 that has been recycled from 
the cell surface205,213–215. However, the biological implications of endosomal loading of 
MR1 versus the loading of MR1 within the ER in terms of downstream MAIT cell 
activation are currently unknown.  
 
In this thesis, it was demonstrated that the 5-A-RU prodrug is almost exclusively loaded 
within recycling endosomes. Pre-saturating MR1 with Ac6-FP in THP cell lines revealed 
that 5-A-RUL was loaded in a separate compartment to 5-A-RU. Inhibiting endosomal 
acidification with bafilomycin and linking MR1 molecules to the cell surface with GPI 
anchors then confirmed that 5-A-RUL was being loaded within recycling endosomes (Fig 
6.1). For MHC-I molecules, recycling from the cell surface represents an important 
mechanism to encounter antigens for cross-presentation321,322. In the case of MR1, 
accessing recycled MR1 molecules is likely a mechanism to directly sample microbial 
antigen within endocytic compartments. However, both soluble antigens such as 5-OP-
RU and bacteria utilise ER-derived and recycled MR1 to present to MAIT cells. The 
necessity of 5-A-RU prodrug to load almost exclusively onto recycled MR1 molecules 
means it can be used to study the implications of endosomal loading of MR1 in isolation 
and eliminates confounding factors such as the pattern recognition likely to be triggered 
with whole bacteria that can potentially affect rate and level on MR1 presentation and 
induce co-stimulatory molecules238,245. It is also possible that access to recycled MR1 
within endosomes confers the enhanced ability of 5-A-RUL to activate MAIT cells when 
compared to 5-A-RU. It could be speculated that perhaps antigen presentation on MR1 
within the recycling endosome results in altered spatiotemporal cell surface presentation 





Figure 6.1 MR1 presentation of the 5-A-RU prodrug. Loading of endogenous soluble 
ligands leads to accumulation of MR1 on the cell surface which eventually leads to 
internalization into endosomes. Vesicles containing 5-A-RUL fuses with incoming 
endosomes containing MR1. Subsequent lysosomal fusion of these late endosomes results 
in release of antigen from MR1. Endosomal cathepsins release 5-A-RU from the linker 
chemistry allowing condensation with MG to form 5-OP-RU. Antigen exchange can then 
occur onto MR1 allowing translocation and re-expression on the cell surface towards 
MAIT cells. Anchoring of MR1 molecules to the cell surface with GPI molecules inhibits 





 MAIT cells as cellular adjuvants to help induce T 
cell responses 
 
Dendritic cells are a key subset involved in bridging the innate and adaptive immune 
responses. After the acquisition of antigen, the activation state of DCs is critically 
important to efficiently present these antigens in an immunogenic manner to naïve T and 
B cells8–10. Therefore, the study of adjuvants that can influence DC maturation is of high 
importance in the development of novel immunotherapies. After implementing strategies 
to eliminate NKT cell-activating contaminants, MR1-dependent and CD1d-independent 
DC activation within the lung could be achieved when 5-A-RU was first converted to 5-
OP-RU by mixing with MG prior to i.v. administration to mice. However, priming of 
CD8+ T cells could only be achieved when an antigen (in this case OVA) was 
administered with 5-A-RU + MG and the TLR2 agonist, Pam2Cys. Extra signals were 
therefore required for T cell priming, but at this stage, it remains unclear what these 
signals are.   
 
An important observation made in previous in vitro studies was that 5-OP-RU could drive 
IL-12p40 production by DCs but required co-operation with TLR signalling to drive 
bioactive IL-12p70 expression29. The capacity to prime T cells in vivo when TLR 
stimulation accompanied MAIT cell activation may, therefore, be a result of enhanced 
IL-12p70 production in DCs; however, this was not directly investigated. It is interesting 
to speculate about other ways in which Pam2Cys may help T cell priming. It is possible 
that the signalling provided by MAIT cells to DCs via CD40L may not reach the required 
threshold in order for the DCs to prime T cells. Indeed, the level of co-stimulatory 
markers expressed on DCs by the administration of 5-A-RU + MG could be significantly 
increased by co-administering a low dose of Pam2Cys. Therefore, direct stimulation of 
MAIT cells by TLR agonists (via TLR on the MAIT cells) may improve their capacity to 
enhance co-stimulation via CD40L or production of IFNγ to enhance IL-12p35 
production by DCs. The possibility of TLR signalling occurring on both MAIT cells and 
DCs should be investigated in future. A conditional knockout system such as Itgax-cre 
Myd88-flox that have the TLR adapter protein MyD88 knocked out in CD11c-expressing 
cells could be used to determine the contribution of TLR stimulation, such as with 
Pam2Cys, on DCs engaged in the priming of CD8+ T cells. Conversely, Cd3e-cre Myd88-
flox, where MyD88 is knocked out in CD3e expressing cells, may be a useful tool to 
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determine the role of direct TLR signalling on MAIT cells; however, this method may be 
confounded by TLR signalling acting on naïve CD8+ T cells themselves323. The choice 
of TLR ligand should also be considered in future experiments. In this thesis, only 
Pam2Cys was explored. However, other TLR ligands have been described to enhance 
MAIT cell responses such as CpG and Poly I:C246 which should be compared for their 
ability to enhance MR1-dependent DCs responses. Further, to explore whether MAIT 
cells fail to provide sufficient CD40L to DCs could be investigated in future experiments 
by co-administration of agonistic CD40.  
 
The data from this thesis has presented clear new evidence that MAIT cells are able to 
influence the maturation state of DCs in vivo and when in combination with TLR agonists 
can drive antigen-specific CD8+ T cell responses (Fig 6.2). In vivo research to date has 
shown that MAIT cells contribute to clearance of bacterial infection187,247,324, which was 
thought to be mainly attributed to their ability to lyse infected cells216,217. This thesis 
provides another mechanism where bacteria provide both 5-OP-RU and TLR signalling 
to initiate MAIT-DC cross talk. This immunogenic interaction would enhance the 
presentation of bacterial derived antigens to generate antigen-specific T cell responses, 
therefore providing another mechanism MAIT cells may confer protection. A weakness 
in this thesis is that only the ability for MAIT cells to augment CD8+ T cells was explored 
and not CD4+ T cell responses.  Future experiments should aim to determine whether 
MAIT cells activated by 5-A-RU + MG are sufficient to drive CD4+ T cells responses or 
differentiation of CD4+ T cells to TFH cells. Priming of antigen-specific CD8+ T cells 
when 5-A-RU + MG is co-administered with Pam2Cys may be in part due to an enhanced 
CD4+ T cell responses. Further, an enhanced CD4+ TFH response may contribute to the 
development of B cell responses which should be investigated in future. This possibility 
could be investigated by CD4 depletion by antibody or I-Aα-/- mice (MHC-II deficient).  
 
The expansion of antigen-specific CD8+ T cells could be identified when 5-A-RU + MG 
was co-administered with Pam2Cys and OVA; however, their functionalities were not 
explored. Subcutaneous tumour models could be employed to characterise the ability of 
these CD8+ T cells to infiltrate and lyse their target cells. Their ability to produce pro-
inflammatory cytokines and express chemokine receptors should be measured and 
compared to other adjuvants for other innate-like T cells, such as α-GalCer, to determine 
whether targeting MAIT cells confer any significant advantage. More clinically relevant 
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antigens should also be used to examine further the ability of MAIT cells to act as 
adjuvants. The use of the HPV antigens E6/E7 could be explored here as pre-existing 
mucosal orthotopic models of the TC-1 cell line are available325. With these models, the 
use of MAIT cells as mucosal vaccines could be investigated. Further, targeting MAIT 
cells to stimulate responses against human self-antigens such as tyrosinase-related protein 
2 (TRP-2), melanA and glycoprotein 100 (gp100)326–330 should be investigated. Such 
antigens which are involved in differentiation of melanocytes are targets for 
immunotherapies for melanoma; however, are subject to tolerance mechanisms and 
require auxiliary signals such as adjuvants in order to prime CD8+ T cells towards them. 
Thus, assessing the ability of MAIT cells to adjuvant such antigens would be informative 
in the translation of MAIT cell-based therapies into clinical studies. As previously 
described in studies utilising α-GalCer as an adjuvant, human PBMCs cultures could be 
employed to study whether MAIT cells can adjuvant T cells responses in human cells 
which can be tracked using pentamers that target specific TCRs243. 
 
Collectively, the data in this thesis suggests that MAIT cells could be harnessed 
therapeutically in order to generate such antigen-specific responses. It is well established 
that NKT cells are able to adjuvant potent antigen-specific adaptive responses in vivo18–
20,178–181, however, there is limited evidence for their ability to provide the same efficacy 
in the clinic which may in part be due to their decreased frequency in humans22,182. As 
MAIT cells are highly enriched within humans, up to 10% of circulating T cells, the data 
in this thesis suggest that MAIT cells could be a suitable candidate for vaccine 
development for use in the clinic.  
 
Development of mucosal vaccines is of particular interest due to the high numbers of 
MAIT cells at mucosal tissues such as the lung. It has been shown in numerous studies 
that the mucosal based vaccinations are favourable in the generation of protective 
immunity against mucosal pathogens such as HIV, herpes virus, influenza virus and 
Mycobacterium tuberculosis331–334. In the case of HIV, the virus infects primarily through 
genito-urinary or genito-rectal mucosal surfaces335. Non-progression in patients with HIV 
is highly correlated with HIV-specific CD8+ T cells252. However, previous vaccine 
strategies that utilised systemic delivery of vaccines failed to elicit HIV-specific 
immunity at mucosal surfaces which is thought to contribute to failure in protection336. 
Thus, the favourable positioning of MAIT cells at these mucosal surfaces provides an 
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opportunity to investigate whether they can be targeted in mucosal vaccine strategies as 
adjuvants. Such targeting of MAIT cells via mucosal vaccination could also prove 
beneficial for mucosal tumours such as in head and neck, lung and genital cancers. In a 
orthotopic murine model of head and neck cancer, it was shown that intranasal 
vaccination was far more efficient than intramuscular or subcutaneous administration at 
inducing effective antigen-specific CD8+ T cell. Moreover, this route of immunization 
specifically stimulated mucosal integrins CD103 and CD49a on CD8+ T cells which 
conferred enhanced tumour infiltration337. Similar benefits have been described in gastric, 
colorectal and bladder models of cancer where mucosal based vaccination strategies 
showed improved anti-tumour responses compared to subcutaneous administration337–340. 
Therefore, in future, it may be of interest to compare the functionality of antigen-specific 
T cells derived from MAIT cell-based vaccine strategies and whether they better mucosal 
homing properties. Moreover, alternative routes of administration should be explored to 






Figure 6.2 MAIT cells enhance DC functionality in order to prime CD8+ T cells. 
MAIT cells are activated by antigen loaded MR1 molecules on the DC. (1) TLR 
signalling on MAIT cells or DCs, or both, results in enhanced activation of the DC. (2) 
Consequently, DCs upregulate co-stimulatory markers such as CD86/80 that interact with 
naïve CD8+ T cells, (3) ultimately leading to their proliferation. 
.  
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 A role for MAIT cells in Th2 immunity? 
 
The study of MAIT cells in Th2 responses is limited, primarily due to the lack of reported 
GATA3 expression in MAIT cells and the fact that they do not readily produce Th2 
cytokines such as IL-4 and IL-13. In addition to the findings that MAIT cells were 
influencing DC maturation in the lung, flow cytometric analysis of other cell populations 
as well as analysis of serum cytokines after injection with 5-A-RU + MG revealed MAIT 
cells were also influencing other immunological events. An MR1-dependent increase of 
the Th2 cytokine, IL-5, and G-CSF could be seen in the serum of treated mice. Moreover,  
a marked increase in eosinophils and neutrophils, known to be associated with Th2 
responses, could be seen in the lungs.  
 
Given the infiltration of eosinophils into the lungs seen in this model, it’s interesting to 
consider the possible role that MAIT cells may play in the inflammatory response to 
helminth infections which are known to provoke strong Th2 responses including 
eosinophilia. Helminths feed on bacteria, and some studies have reported helminths may 
act as vectors for pathogenic strains of bacteria which survive internally within the 
helminth341–343. Some strains found in these studies include bacteria that are known to 
express the riboflavin operon, which can result in the formation of MAIT antigens. It’s 
intriguing to postulate that during helminth infection, MAIT cells may be reacting to these 
antigens and support the recruitment and activation of eosinophils. It is unclear whether 
an increase in eosinophilia within the lung after MAIT cell activation would confer 
protection against helminth infections due to conflicting evidence in the literature 
(reviewed here344). The increase of neutrophils would also suggest further roles of MAIT 
cells in Th2 immunity as neutrophils are heavily implicated in helminth infections where 
they are rapidly recruited, activated and mediate protection as well as tissue 
remodelling345–347. 
 
Inappropriate activation and recruitment of eosinophils is also a hallmark of asthma348. 
An increase in circulating IL-5 and eosinophils into the lung suggests that MAIT cells 
may have a role in the pathogenesis of asthma, although the functionality of these 
eosinophils is unknown in this model. Clear evidence for a role of MAIT cells in asthma 
is yet to be established. In one study, increased levels of IFNγ-producing MAIT cells in 
the blood at 1 year of age correlated with decreased risk of asthma at age 7349. In another 
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study circulating IL-17 producing MAIT cells were associated with increased asthma 
severity in children350.  Together these studies would suggest that the MAIT1 subset 
provides a protective role while MAIT17 is associated with pathology; however, no such 
experimental data exists to substantiate a causal link. Moreover, there is no evidence yet 
that the association between MAIT cells and asthma could be attributed by an ability to 
influence Th2 immune responses. 
 
It is unclear from the work in this thesis whether MAIT cells are directly exhibiting Th2 
cell properties or if their activation results in cross-activation and recruitment of innate 
cells such as eosinophils and neutrophils. The contributions of MAIT cells in infection 
models that evoke Th2 immune responses could be explored with MR1-/- mice. The 
nematode Nippostrongylus brasiliensis infects rodents and enters the lungs during their 
L3 developmental stage where they induce strong eosinophilia351. Thus, in this model, 
the role of MAIT cells in protection against N. brasiliensis could be determined by 
enumerating the number of eosinophils or live worms in the lung when infected in MR1-
/- compared to WT.  
 
Fluorescent cytokine reporter mice could be used to explore the possibility that MAIT 
cells are directly producing Th2 cytokines. The IL-5 tdTomato352 or the 4C13R353 reporter 
mouse could be used to assess if MAIT cells are expressing IL-5 or IL-4 and IL-13, 
respectively. Moreover, a larger-scaled cytometric analysis including a wide array of 
markers could be conducted in order to identify as many cell types as possible, including 
activation markers or other markers of cellular function such as the release of cytokines. 
During Th2 inflammation an array of immune cell types may be involved such as mast 
cells, granulocytes and innate lymphoid cells which may be contributing to observations 
made here. Technologies such as high dimensional spectral flow cytometry, or mass 
cytometry (CyTOF), would be useful tools in this analysis, as upwards of 35 markers can 





In conclusion, this thesis has shown that the synthetic MAIT cell agonist precursor 5-A-
RU, like the agonist 5-OP-RU itself, is unstable. The precursor is very sensitive to 
oxidation and rapidly forms products that fail to form agonists that can activate MAIT 
cells. Modification of 5-A-RU by chemical conjugation of a cathepsin-labile linker to 
form a prodrug enhanced stability, conferred enhanced MAIT cell activation, and enabled 
attachment of peptide antigens (and other moieties of choice). Unlike unmodified 5-A-
RU, the agonists formed from the prodrug were loaded onto MR1 primarily in recycling 
endosomes rather than the ER. Despite these attributes, the prodrug was unable to achieve 
the level of MAIT cell activity induced by admixing 5-A-RU with MG to form 5-OP-RU 
before use, although this latter process was hard to control. Although manufacturing 
issues that lead to NKT cell activation confounded initial in vivo investigations with 
MAIT cell agonists in this thesis, later studies showed that administration of 5-OP-RU 
could activate DC in the lungs. However, co-administration of soluble antigen with 5-
OP-RU was insufficient to drive antigen-specific CD8+ T cell responses, suggesting 
further signals to the DC were required. Indeed, when antigen and 5-OP-RU were 
administered in concert with TLR2 stimulation, antigen-specific CD8+ T cell responses 
were induced. Moreover, activation of MAIT cells resulted in the appearance of 
additional immune subsets in the lung, including eosinophils, macrophages and 
neutrophils, which point towards a broader role for MAIT cells in inflammatory disease 
settings.  Collectively, the data in this thesis detail a role for MAIT cells in influencing 
innate and adaptive immunity, and suggest that, with the supply of appropriate signals, 










Figure A. Isolation of 5-A-RU by HPLC. Isolation was performed using a Phenomenex 
Gemini C18 reverse-phased column. A 500µl sample 5-A-RU at 13mgmL-1 was loaded 
onto the column for isolation. Elution was performed by the addition of a mobile phase 
to the column as follows: 0 – 5 min, 95% water + 5% methanol, 5 – 15 min, 95% water 
+ 5% - 100% methanol (linear gradient), 15 – 20 min, 100% methanol, 20 – 40 min, 90% 
methanol + 10% isopropanol. All solvents contained 0.05% trifluoroacetic acid. The 
solvents were applied to the column at a flow rate of 5mL/min. UltraViolet light at 214nm 
was utilised to identify compounds by spectroscopy. Fraction 1 containing 5-A-RU was 






Figure B. In vivo gating strategy and tissue distribution of MAIT cells. Representative 
flow cytometry gating strategy for MAIT cells in the lungs of mice. When analysing the 
liver and the spleen, the same gating strategy was used and yielded similar results. Graph 
shows frequency of MAIT cells across the specified tissues where MAIT cells are gated 






Figure C. In vivo gating strategy for cDCs. Representative flow cytometry gating 
strategy for cDCs in the lungs of mice. When analysing the liver and the spleen, the same 






Figure D. Serum cytokines 6 h post i.v. WT or MR1-/-- mice (n=5) were injected with 
5-A-RU + MG or Pam2Cys i.v. and bled after 6 h for serum. Serum was analysed by 
bioplex to assess cytokine production. Data representative from a single experiment. 
Numbers represent the fold change relative to control for each cytokine after 
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Frequency and function of innate-like T cells in patients with cancer 
Principal Investigator: Dr Robert Weinkove. (Robert.Weinkove@ccdhb.org.nz /04 385 5999 via 
hospital switchboard)  
CONSENT FORM FOR PARTICIPANTS 
Following signature and return to the research team this form will be stored in a secure place for ten 
years. 
Name of participant:………………………………………….. 
1. I have read the Information Sheet for this study and understand the aims of this research 
project. 
2. I have had enough time to talk with other people of my choice about participating in the 
study.   
3. I confirm that I meet the criteria for participation which are explained in the Information 
Sheet. 
4. All my questions about the project have been answered to my satisfaction, and I 
understand that I am free to request more information at any stage.  
5. I know that my participation in the project is entirely voluntary, and that I am free to 
withdraw from the project at any time without disadvantage. 
6. I know that as a participant I will undergo a blood test as part of this study, giving 
approximately 25ml of blood.  
7. I understand that non-identifiable information may be shared with other researchers for 
future analyses of innate-like T cells. 
8. I know that the questionnaire will ask some health questions. If I feel hesitant or 
uncomfortable I may decline to answer any particular question(s), and /or may withdraw 
from the project without disadvantage of any kind. 
9. I agree to the investigators reviewing my medical records in order to link the stage, type 
and outcome of any malignancy with innate-like T cell numbers and function. I 
understand this information will be kept confidential. 
10. I understand the nature and size of the risks of discomfort or harm which are explained in 
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11. I know that when the project is completed all personal identifying information will be 
removed from the paper records and electronic files which represent the data from the 
project, and that these will be securely stured and kept for ten years.  
12. I understand that results of this study may be published and available in the University of 
Otago Library and that I will not be identifiable in study reports. 
13. I know that there is no remuneration offered for this study, and that no commercial use 
will be made of the data.  
14. I understand that the blood samples will be transported to and stored securely at the 
Malaghan Institute of Medical Research, and that the researchers will dispose of my 
samples when they are no longer necessary for this research project, unless I have 
provided separate written consent for future research. 
15. I would like a karakia prior to destruction of by blood cell samples: Yes / No 
16. Optional: I agree to be contacted by the researchers to ask whether I would like to donate 
future blood samples for this study: Yes / No 
Signature of participant:  Date: 
   
   
Signature and name of witness 
(optional): 
 Date: 
   




If you would like a summary of the results of this study, or if you agree to be contacted by the 
researchers to ask about donating future blood samples, please provide at least one contact method 
below. 
 
 Telephone:  ______________________________________ 
 OR Email:  ______________________________________ 












Future Unspecified Research – Innate-like T cells and cancer 
Principal Investigator: Dr Robert Weinkove. (Robert.Weinkove@ccdhb.org.nz /04 
385 5999 via hospital switchboard)  
INFORMATION SHEET FOR PARTICIPANTS 
What is future unspecified research? 
You have been asked to take part in a study of innate-like T cells in patients with 
cancer and in healthy volunteers. That study involves donating blood to allow for 
laboratory investigation of immune cell number and function. Normally, all of the 
cells, whether used for the research or not, would be destroyed at the end of the above 
research project. 
However, it is possible that leftover cells that you have donated may be useful for 
future research projects (‘future unspecified research’). Therefore, we are asking 
whether you would like to donate any remaining cells to the Malaghan Institute of 
Medical Research for this purpose. 
This information sheet explains why we are asking you to donate remaining cells for 
future research, and what would happen if you choose to participate.  Agreeing to 
donate remaining cells is voluntary – you do not have to agree to this in order to take 
part in the main study. 
As with the main study, this requires the storage of leftover blood products (human 
tissue). We acknowledge that there may be cultural issues with storing tissue for 
extended periods of time. As such, we encourage you to include your family/whānau 
in discussions for all stages of the research.  
What will happen to my cells if I agree to this, and how will they be disposed of? 
As a of the main study, your blood cells will already be cryopreserved (frozen) at the 
Malaghan Institute of Medical Research in Wellington. If you were to agree to this, 
the blood cells will be stored indefinitely in a very low temperature freezer at the 
Malaghan Institute of Medical Research, even after the current research project ends. 
At some time in the future your blood cells may be thawed and studied for future 
research projects a the Malaghan Institute. If you specifically agree to this in the 
consent form, your cells may be sent to other New Zealand researchers. Your blood 
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If you donate your remaining cells for future research, they will be destroyed at the 
earliest of the following: when there are insufficient cells left for future research, 
when the researchers think that your cells are not likely to be useful for future 
research, when there is no longer enough storage capacity to keep your cells, OR if 
you ask for them to be destroyed. If you have indicated that you would like a karakia 
performed prior to cell disposal on the consent form for the main study, this will be 
honoured at this point. Remaining cells are safely disposed of via incineration. Due to 
the addition of chemicals for storage and analysis, we are unable to return cells to 
you.  
What research might be done with my cells? 
There are many different ways in which the cells could be used and we cannot be 
specific about what tests might be done on them, but it is likely to be related to the 
further development of vaccines for the treatment of cancer and infectious diseases. 
Your cells will not be used for germline (hereditary) genetic analyses. Any research 
that is carried out on your blood cells will be approved by an accredited Ethics 
Committee, to ensure that it is in agreement with the original consent that you 
provided. 
How will my information be used? 
The results of any future unspecified research may be published in scientific journals 
and will therefore be made available to everyone. Even if your cells have been used, 
you will not be identified in any published material. Because information is freely 
shared by the international scientific community, and because sometimes 
collaborating with a commercial enterprise is the best way to progress a new 
technique, it is not possible to rule out the possibility that information derived from 
research on your blood cells will ultimately result in financial gain to someone. 
Any questions? 
If you have any questions now or in the future, please feel free to contact: 
Dr Robert Weinkove   Telephone: 04 385 5999 (via hospital switchboard) 
This study has been approved by the University of Otago Human Ethics Committee 
(Health). If you have any concerns about the ethical conduct of the research you may 
contact the Committee through the Human Ethics Committee Administrator (phone 
+64 3 479 8256 or email gary.witte@otago.ac.nz). Any issues you raise will be 






Appendix F – Chemistry methodology 
 
Methods for chemical analysis are from: The chemical synthesis, stability and activity of 
MAIT cell prodrug agonists that access MR1 recycling endosomes. (2020) ACS Chem. 
Bio. Doi: 10.1021/acschembio.9b00902. 
LCMS 
Method A: Analytical HPLC was performed on an Agilent 1260 HPLC with an Agilent 
6130 single quadrupole mass spectroscopic detector using ESI. A Phenomenex 
SynergiTM Fusion-RP C18 column (2.5 µM, 3x50 mm) was installed, heated to 35 °C, 
with 10 mM aq NH4OAc (pH 6.0) used as eluent A and MeOH as eluant B (flow = 0.5 
mL/min). The following gradient method was used: T0 (min) = 100:0 A:B, T1.5 = 100:0 
A:B, T1.51 = 90:10 A:B, T3.5 = 70:30 A:B, T4 = 100:0 A:B, T7 = 100:0 A:B. Peaks 
were detected by UV absorbance, primarily at 254 nm, and identified with the inline MS 
detector. 
Method B: As above in Method A with the following modifications: Eluent = 10 mM aq 
NH4OAc (pH 6.3) (isocratic), 20 °C.  
Method C: Analytical HPLC was performed on an Agilent 1260 HPLC with an Agilent 
6130 single quadrupole mass spectroscopic detector using ESI. An Agilent Poroshell 120 
EC-C18 column (2.7 µM, 3x50 mm) was installed, heated to 40 °C, with water (+0.1% 
formic acid) used as eluent A and MeOH as eluant B (flow = 0.5 mL/min). The following 
gradient method was used: T0 (min) = 70:30 A:B, T8 = 0:100 A:B, T9 = 0:100 A:B, T10 
= 70:30 A:B, T12 = 70:30 A:B. Peaks were detected by UV absorbance, primarily at 254 
nm, and identified with the inline MS detector.  
Method D: A Phenomenex SynergiTM Fusion-RP C18 column (2.5 µM, 3x50 mm) was 
installed, heated to 40 °C, with water (+0.1% formic acid) used as eluent A and MeOH 
as eluant B (flow = 0.5 mL/min). The following gradient method was used: T0 (min) = 
100:0 A:B, T4 = 100:0 A:B, T7 = 70:30 A:B, T8 = 100:0 A:B, T10 = 100:0 A:B. Peaks 
were detected by UV absorbance, primarily at 254 nm, and identified with the inline MS 
detector. 
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Method E: A Phenomenex Kinetex C18 column (100 Å, 2.6 µM, 3x50 mm) was installed, 
heated to 40 °C, with water (+0.1% formic acid) used as eluent A and MeOH as eluant B 
(flow = 0.5 mL/min). The following gradient method was used: T0 (min) = 95:5 A:B, T8 
= 0:100 A:B, T12 = 0:100 A:B, T13 = 95:5 A:B, T15 = 95:5 A:B. Detection was by 
selected ion monitoring (SIM) MS. The traces shown in Fig 8 of the main article represent 
the combined SIM chromatograms for prodrug substrate, expected cleavage product and 
internal standard (IS). Conversion was determined by comparing the ratio of substrate:IS 
at a given time point to the ratio at t=0.  
5-A-RU degradation studies 
For analysis of 5-A-RU prepared by hydrogenolysis of nitrouracil, an aliquot was 
removed by syringe and diluted 60-fold with deoxygenated water and analysed 
immediately by LCMS (Method A). A second aliquot was diluted similarly and the 
solution (30 µL) was gently agitated in air over 8 min. The solution was transferred to a 
capped HPLC vial and analysed by LCMS (Method A) at the timepoints indicated.  
For analysis of 5-A-RU prepared by dithionite reduction of nitrouracil  and aliquot of 5-
A-RU was diluted 130-fold with deoxygenated water in an Ar-filled HPLC vial and 
analysed immediately by LCMS (Method B). A second aliquot was diluted similarly and 
the solution (240 µL) was gently agitated in air over 3 min. The solution was transferred 
to a capped HPLC vial and analysed by LCMS (Method B) at the timepoints indicated in 
Figure 3 of the main article.  
Prodrug degradation studies 
In aqueous media: Prodrug 10 was dissolved in 1:4 DMSO/water to 0.2 mg/mL. 
Carbamate 12 was dissolved in water to 0.2 mg/mL. 100 µL samples were shaken in 
uncapped vials on an automatic shaker for 24 h, then capped and stored at rt protected 
from light. Aliquots were analyzed by LCMS (Method C for 10, Method D for 12) at the 
timepoints indicated. 
In DMSO: Prodrug 10 was dissolved in neat DMSO to 0.2 mg/mL, and stored either at 
rt protected from light, or at -20 °C. Aliquots were analyzed by LCMS (Method C) at the 
timepoints indicated. 
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Cathepsin B assay 
Cathepsin B assays were conducted in NH4OAc buffer: NH4OAc (50 mM, pH 5.3) + 
EDTA (2.5 mM) + dithiothreitol (2.5 mM). Phytosphingosine was used as in internal 
standard for LCMS analysis. A stock solution of phytosphingosine in DMSO (190 µM) 
was pre-mixed with NH4OAc buffer to a final phytosphingosine concentration of 6.3 µM. 
The prodrug substrate (190 µM in DMSO) was added to the pre-mixed buffer solution to 
give a final substrate concentration of 12.7 µM. Cathepsin B from human liver (Sigma) 
was diluted to 1 unit/mL in NH4OAc buffer and added to the reaction mixture to give a 
final cathepsin B concentration of 0.27 units/mL. For the control reaction (without 
enzyme) the same volume of buffer was added. The reaction mixtures were then 
incubated at 37 °C. Aliquots of 10 µL were taken from the reactions and analysed by 
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